

HOSPITAL BASED CANCER REGISTRY

(Partially supported by the National Cancer Registry Programme,
Indian Council of Medical Research)



ANNUAL REPORT

2015

MALABAR CANCER CENTRE

THALASSERY, KANNUR DISTRICT, KERALA

(An autonomous centre under Government of Kerala)



MALABAR CANCER CENTRE

(An autonomous centre under Government of Kerala)

[Partially supported by the National Cancer Registry Programme, ICMR]

**ANNUAL REPORT
2015**

ACKNOWLEDGEMENT

The Hospital Based Cancer Registry of Malabar Cancer Centre expresses its sincere thanks and gratitude to the following Institutions/Departments/Individuals for supporting and promoting the activities of the Registry.

1. Dr. SatheesanBalasubramanian, Director, Malabar Cancer Centre
2. National Cancer Registry Programme, Indian Council of Medical Research, Banglore
3. Medical Records Division, MCC, Thalassery
4. Department of Radiation Oncology
5. Department of Clinical Hematology & Medical Oncology
6. Department of Pathology
7. Department of Surgical Oncology



FROM DIRECTOR'S DESK

(7.3%), Mouth(6.6%) Thyroid (4.3%), Rectum(3.7%), Lung (3.6%), NHL (3.4%), Corpus Uteri (3.1%) and Tongue(2.9%).

Based on different methods of diagnosis, microscopically diagnosed was 89% in males and 91.8% in females and 80.7% had histology of primary in males and 86.6% in females. According to Broad group of treatment among males 38.8% received treatment only at RI and among females it was 41%. The clinical extent of disease (Prior & treatment at RI) was regional in 15.31% in males and 16.2% in females. Head and neck cancer is the leading cancer in 2015 also while considering system wise. The details of system wise report is as follows. Head and neck (904, 66.6% in males and 33.4% in females). The second was digestive organs (761, 63.7% in males and 36.3% in females). The third was Breast (540, 1.7% in males and 98.3% in females), The fourth leading was Respiratory system (504, 87.3% in males and 12.7% in females), The fifth leading was hematological and RE (409, 62.6% in males and 37.4% in females). The sixth leading was Gynecological system (336), the seventh leading was Male Genital Organ (101). The eighth leading was Urinary tract (93, 87.1% in males and 12.9% in females). The ninth leading was skin (64, 65.6% in males and 34.4% in females) and the tenth leading was CNS(61, 68.9% in males and 31.1% in females). In respiratory system cancer patients 43.7% were chronic smokers. In Head and Neck cancer patients 16.9% were chronic alcoholic and 23.6% had chronic panchewing habit. Among hereditary cancers, 34.8 % of colon cancer patients had family history of cancer.

The ten leading cancers irrespective of sex were recorded as Breast(13.75%), Lung(12.81%), Mouth (7.21%), Stomach(4.51%), NHL (4.48%), Tongue(4.25%), Rectum (3.85%), Cervix(3.44%), Oesophagus(3.26%) and Ovary (3.26%) respectively. Among 36 (0-14 years) childhood cancers the leading cancers were Leukemia(61%). Among 3926 patients 2733(69.6%) were new cases and 1193(30.4%) were old cases.

This report shows the type of cancers and its nature in this regions and hope this report will help treating oncologist, researcher and health authorities for further planning on control of the disease .I may take the opportunity to congratulate the entire team of the Department of Cancer Registry and Epidemiology for their sincere work. The support of Director ICMR-NCRP and the staff was tremendous and sincere gratitude is expressed here.

SATHEESAN.B
DIRECTOR

It's a pleasure to watch the young team of Cancer Registry and epidemiology make progressive strides in their responsibility. The 2015 HBCR report is an excellent example of the dedication and sense of purpose exhibited by the Department of Cancer Registry and Epidemiology. It is our sixth annual report after established the Hospital Based Cancer Registry (HBCR) in 2010 . For the development of Epidemiological and intervention strategies in the community, the role of Cancer Registry is unparalleled. Apart from HBCR, Malabar Cancer Centre established a Population Based Cancer registry also in 2014 in the three districts Kannur and Kasaragod of Kerala state and Mahe district of Union territory of Puducherry and published its first report in 2017. Now it has a large population based cancer registry named Malabar Population Based Cancer Registry (MPBCR). The efforts to expand the registry to other five northern districts is already started.

The highlights of the HBCR Annual Report for the year 2015 are as follows. A total of 3926 new cancer patients were registered at Malabar Cancer Centre(MCC) in the year 2015. Among them 2162(55.1%) were males and 1764 (44.9%) were females. Total proportion of tobacco related cancer (TRC) relative to all sites is 51.4% and 17.2% among males and females respectively. TRC with respect to all sites Lung cancer predominates (20.4%) among males, whereas in females, it was mouth (6.6%). TRC with respect to specific site, among male it is Lung(39.6%) and among females it is mouth cancer (38.6%). Comparing with previous years there is not much differences in leading sites of cancers in both sexes. Lung is the leading site in male followed by mouth. The number and proportion of leading cancers in males is as follows. Lung (20.4%), Mouth (7.7%), Stomach(6.2%), Tongue(5.4%), NHL (5.4%), Larynx(4.9%), Rectum(4%), Oesophagus(3.7%), Prostate(3.7%) and Hypopharynx(3.5%) .In females leading site is breast followed by cervix uteri. Number of cases and proportion of leading cancers in females as follows. Breast (30.1%), Cervix uteri(7.7%), Ovary

It is a matter of great pride for us to be, a part of the national cancer registry network from this year and also to present before you the 6th edition of Hospital Based Cancer Registry (HBCR) report of Malabar Cancer Centre.

Purpose of this HBCR has been to assess and evaluate cancer patient care in our hospital. Information about types of cancer and types of treatment has helped us in planning the facilities required. The establishment of HBCR is historically rooted in the belief that individual patients are better served through registry. The data of HBCR may be used for administrative and patient purposes. For administrative purposes, HBCR may measure utilization of facilities. This report will hopefully serve as a guide to the treating oncologist, researchers and health administrator's to look into various aspects in cancer patient management in our institution.

In fact HBCR which is today, one of the leading database and analytical tools on cancer, owes its existence to Dr.Satheesan Balasubramanian, Director, who continues to motivate the team to enhance our knowledge. He has extended not only his full support and vital resources to the cancer registry, but also gave us prompt guidance, ensuring that the HBCR is an accurate presentation of the centre's data.

I, express my heartfelt thanks to the Director and staff of National centre for disease information and research, Bengaluru for always rendering their timely help and support.

I also thank the various departments at MCC, involved in patient care for clarifying doubts and helping us bring forth quality data.

Finally the cancer registry and Medical records team, deserve special appreciation for the efforts they have put in for streamlining records, collection, and analysis of data and preparation of this report.

Sincerely,

Dr.Saina Sunilkumar

H.O.D (I/C) Department of cancer registry
and epidemiology



TABLE OF CONTENTS

Sl. No	Contents	Page No
I	INTRODUCTION	
1	Malabar Cancer Centre	07
2	Organizations	07
3	Departments & Divisions	09
4	Faculty	11
5	Department of Cancer Registry	13
6	Hospital Based Cancer Registry	14
7	National Cancer Registry Programme	16
8	Patterns of Patient Registration	18
9	Summary of Results	19
10	Magnitude of Total Cancers	19
11	Tobacco Related Cancers	20
12	Childhood Cancers	22
13	Leading Site of Cancers	23
II	Diagnostic, Clinical & Demographic Details	
1	Diagnostic Information	26
2	Clinical Information	26
3	Demographic Information	29
III	Detailed Information –NCRP-ICMR Diagnostic, Clinical and Demographic	
1	Diagnostic Information	32
2	Clinical Information	38
3	Demographic Information	50
IV	Detailed Information-MCC-Habits, Systemwise and Staging	
1	New/Old cases	60
2	Ten Leading Cancers- System wise	60
3	Alcohol Habits & System wise cancers	61
4	Panchewing Habits & System wise cancers	61
5	Smoking Habits & System wise cancers	61
6	Family History/Hereditary Cancers	62
7	Staging	63
8	Comparison of Performance Status	65
V	Ten Leading Cancers- Irrespective of Sex	
1	Breast	66
2	Lung	71

3.	Mouth	75
4	Stomach	80
5	NHL	84
6	Tongue	89
7	Rectum	93
8	Cervix Uteri	98
9	Oesophagus	103
10	Ovary etc.	107
VI	Type of Childhood Cancers	111
VIII	Multiple Cancers	113
X	Abbreviations	122
XI	References	122

INTRODUCTION

MCC- A Comprehensive Cancer Centre in Northern Kerala

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighboring parts of Karnataka and Tamilnadu states and Union Territory of Pondicherry(Mahe). The centre, situated in a beautiful hill top in Koderi in Thalassery Municipality 5km away from town established in 2001. The main objective of the Centre is not only to provide comprehensive cancer care but also to develop as a Research and Training Centre of International standards.

The institution is a tertiary cancer centre which renders its service to society with equal thrust on clinical and translational research, Education and Clinical oncological services. MCC is being developed as a postgraduate institute of oncology. The institution is in the process of developing and establishing a unique Clinical Research department to coordinate clinical research activities. It is our immense pleasure to disclose the research association MCC has with School of Health Sciences, Kannur

University, Centre for Electronic Materials Technology, Thrissur and P.S.Vaidhyarathnam Ayurveda College, Kottakkal, HTIC-Chennai, National cancer Grid which are expected to bring in revolutionary changes in the management of cancer. Malabar Cancer Centre has been recognized as Research Institute by Kerala University of Health Science.

The control and management of the Society are vested in the Governing Body consisting of 23 members with the Hon'ble Chief Minister of Kerala as the Chairman, Hon'ble Minister for Health as Vice Chairman and Hon'ble Minister for Power as Alternate Vice-Chairman. The routine activities and functions of the Centre are supervised by the Executive Committee, with the Secretary, Department of Health and Family Welfare, Government of Kerala, being the Chairman of the Committee. The members in the Governing Body and Executive Committee are functioning by virtue of their official positions. The institute has grown to have highly sophisticated facilities to provide cancer care. The hospital has very well trained staff, rendering cancer care to the needy.

ORGANISATION

Governing Body (GB): The Governing Body of the Society consists of 23 members.

1	Chairman	Chief Minister of Kerala
2	Vice-Chairman	Minister for Health & FW, Kerala
3	Alternate Vice-Chairman	Minister for Electricity, Kerala
4	Member	Secretary, Department of Finance, Kerala
5	Member	Secretary, Department of Power, Kerala
6	Member	District Medical Officer, Kannur
7	Member	Secretary, Department of Health & FW, Kerala
8	Member	An eminent Medical Scientist

9	Member	Secretary, Department of Science, Technology & Environment
10	Member	One nominee of the Ministry of Health, Government of India
11	Member	Principal, Medical College, Kozhikode
12	Member	Secretary- Planning & Economic Affairs Department, Kerala
13	Member	Director- Rajiv Gandhi Centre for Bio technology, Trivandrum
14	Member	Director of Medical Education, Directorate of Medical Education, Trivandrum
15	Member & Secretary to GB	Director, Malabar Cancer Centre, Thalassery
16	Member	M.L.A. of the Thalassery constituency
17	Member	President, District Panchayat, Kannur District
18	Member	Chairman, Thalassery Municipality, Thalassery
19	Member	A public man from North Malabar region (to be nominated by Government of Kerala)
20	Member	One Head of the department nominated from Malabar Cancer centre, Thalassery by the Government.
21	Member	One nominee of the Charitable Society established for rehabilitation and financial assistance for poor cancer patients
22	Member	Principal/Chief Executive Officer of Medical College, Pariyaram
23	Member	Director, Regional Cancer Centre, Trivandrum

EXECUTIVE COMMITTEE

Executive Committee (EC): The Executive Committee shall be composed of;

1	Secretary, Department of Health & Family Welfare, Government of Kerala	Chairman
2	Secretary, Department of Power, Government of Kerala	Member
3	Secretary, Department of Finance, Government of Kerala	Member
4	Chairman, Thalassery Municipality	Member
5	A public man from North Malabar to be nominated by Government of Kerala	Member
6	Secretary, Department of Planning, Government of Kerala	Member
7	Director, Regional Cancer Centre, Trivandrum	Member
8	The Director, Malabar Cancer Centre, Thalassery	Member/Convener

DEPARTMENTS & DIVISION

Sl No	Name of the Department	Divisions under the Department
1	Department of Radiation Oncology	<ul style="list-style-type: none"> ▶ Radiation Oncology Division ▶ Radiation Physics Division
2	Department of Imageology	<ul style="list-style-type: none"> ▶ For administrative purpose, this Department presently will be under Department of Radiation Oncology
3	Department of Clinical Hematology and Medical Oncology	<ul style="list-style-type: none"> ▶ Clinical Hematology Division ▶ Medical Oncology Division ▶ Division of Medicine ▶ Division of Pediatrics/Pediatric Oncology
4	Department of Respiratory Medicine and Critical Care	<ul style="list-style-type: none"> ▶ For administrative purpose, this Department presently will be under Department of Clinical Hematology and Medical Oncology
5	Department of Surgical Oncology	<ul style="list-style-type: none"> ▶ Surgical Oncology Division ▶ Division of Rehabilitation Physiotherapy, Speech and Swallowing therapy ▶ Division of Gynaecology/Gynaecologic Oncology ▶ Clinical Nutrition and Dietetics
6	Department of Clinical Laboratory Services and Translational Research	<ul style="list-style-type: none"> ▶ Oncopathology Division ▶ Molecular Oncology Division ▶ Biochemistry Division ▶ Microbiology Division ▶ Blood Bank and Transfusion Medicine Division ▶ Genetics Division (including Cytogenetics)
7	Department of Cancer Registry and Epidemiology	<ul style="list-style-type: none"> ▶ Cancer Registry and Epidemiology Division ▶ Medical Records Division ▶ Health Information Technology Division (Presently under Director) ▶ Clinical Research and Biostatistics Division (Presently under Director)
8	Department of Community Oncology	<ul style="list-style-type: none"> ▶ Community Oncology Division ▶ Tobacco Cessation Division
9	Department of Onco Anesthesiology	<ul style="list-style-type: none"> ▶ Onco Anesthesiology Division
10	Department of Cancer Palliative Medicine	<ul style="list-style-type: none"> ▶ Psycho-Oncology and Clinical Psychology Division ▶ Home Care Services Division.
11	Department of Dentistry and Rehabilitation	<ul style="list-style-type: none"> ▶ Dentistry and Rehabilitation
12	Department of Engineering and Maintenance	<ul style="list-style-type: none"> ▶ Engineering & Maintenance

13	Department of General Administration	<ul style="list-style-type: none"> ▶ General Administration Division ▶ Hospital Administration ▶ Academic Division & Library and Information Science ▶ Public Relations and Clinical Services Division ▶ Accounts Division ▶ Purchase/Store Division & Pharmacy ▶ Human Resources and Establishment Division ▶ Security Division
14	Department of Oncology Nursing	<ul style="list-style-type: none"> ▶ Nursing Services Division

FACULTY

SI No	Name	Designation
Department of Surgical Oncology		
1	Dr.Satheesan.B	Professor, Director
2	Dr.Sajith Babu. T.P	Associate professor
3	Dr.Sampada Dessai	Associate professor
4	Dr. Adarsh D	Assistant professor
5	Dr.Nizamudeen.M.P	Lecturer
6	Dr. Dipin J	Assistant professor
7	Dr. Santhosh Kumar	Assistant Professor
Department of Clinical Hematology and Medical Oncology		
1	Dr. Chandran.K.Nair	Professor & HOD
2	Dr.Vineetha Raghavan	Assistant Professor
3	Dr. Manu Prasad	Senior Lecturer
4	Dr.Praveen Shenoy	Senior Lecturer
5	Dr. Jithin T K	Assistant Professor
6	Dr. Anju Radhakrishna Kurup	Lecturer
Department of Radiation Oncology		
1	Dr.Geetha.M	Associate Professor and HOD
2	Dr. Vinin.N.V	Assistant Professor
3	Dr.Joneetha Jones	Assistant Professor
4	Dr. Greeshma.K.E	Assistant Professor
5	Dr.Sanudev Sadanandan	Assistant Professor
6	Dr.Kiran.P	Assistant Professor
7	Dr. Shohaib	Assistant Professor
8	Dr. Jyothsna Jayaraj	Senior Lecturer
9	Dr. Senthilnathan	Additional Professor, Nuclear Medicine
10	Smt. Suja C A	Lecturer, Radiation Physics
11	Smt. Silpa Ajayakumar	Lecturer, Radiation Physics
12	Smt. Resmi.K. Bharathan	Lecturer, Radiation Physics
13	Smt. Soumya N M	Lecturer, Radiation Physics
Department of Onco-Anesthesiology		
1	Dr.Nived.K	Associate Professor
2	Dr.Nikhil Mohan	Lecturer
Department of Clinical Laboratory Services and Translational Research		
1	Dr. Sangeetha. K.Nayanar	Professor
2	Dr.Sithara Arvind	Assistant Professor
3	Dr. Ashwathy Krishnan	Assistant Professor

4	Dr.Kandathil Joseph Philip	Assistant Professor
5	Dr. Noushad	Assistant Professor
6	Dr.Mohandoss.M	Assistant Professor,Blood Bank and Transfusion Medicine Division
7	Dr. Sajini Samuel	Assistant Professor , Microbiology
8	Dr. Parthiban. R	Associate Professor , Microbiology
9	Dr. Gurfran Ahmed	Visiting Consultant, Microbiology
10	Dr. Deepak Roshan.V.G	Lecturer, Division of Genetics and Cytogenetics
11	Dr. Shanju Shankar	Assistant Professor, Biochemistry Division
Department of Imageology		
1	Dr.Satheesh Babu T.V	Associate Professor
2	Dr.Sarath.K.E	Lecturer
Department of Cancer Palliative Medicine		
1	Dr.Biji.M.S	Assistant Professor
Department of Community Oncology		
1	Dr.Neethu.A.P	Lecturer
2	Dr.Phinse M Philip	Lecturer
Department of Cancer Registry and Epidemiology		
1	Dr.Saina Sunil Kumar	Lecturer
2	Smt. Bindu T	Lecturer in Biostatistics
3	Sri. Ratheesan K	Lecturer in Biostatistics
4	Sri. Subhradev Sen	Lecturer in Biostatistics, Clinical Research and Biostatistics Division
Department of Dentistry and Rehabilitation		
1	Dr. Pramod Sankar.S	Associate Professor

DEPARTMENT OF CANCER REGISTRY AND EPIDEMIOLOGY

Department of Cancer Registry and Epidemiology was established in the year 2010 and started Hospital Based Cancer Registry partially supported by National Cancer Registry Programme (ICMR), Bangalore. This is the Fifth Annual report of Hospital Based Cancer Registry. Funded project of NCRP/ICMR, Patterns of Care & Survival Studies in Breast, Cervix & Head & Neck cancers started in 2014. Also launched Malabar Population Based Cancer Registry on 1st January 2014 in the districts of Kannur, Kasaragod & Mahe (Two States- Kerala & Pondicherry) with the help of 8 field staffs – 4 social Investigators and 4 Data Collectors. There are three divisions under Department of cancer registry & Epidemiology.

Cancer Registry Division	
Dr. Saina Sunilkumar	Lecturer, HOD in charge
Smt. Bindu T	Lecturer in Biostatistics
Sri. Ratheesan.K	Lecturer in Biostatistics
Sri. Prachith K S	Coding Clerk
Smt. Sheena.E	Data Entry Operator
Smt. Subina K	Data Entry Operator
Smt. Nithya C.V	Coding Clerk
Field Staff (Malabar Population Based Cancer Registry)	
Smt. Deepthi.K	Social Investigator
Sri. Nijin. P	Social Investigator
Sri. Micheal Babu N B	Social Investigator
Sri. Vineesh A V	Social Investigator
Miss.Rejisha.R	Data Collector
Sri. Muhammed Shafeer C K	Data Collector
Smt. Vipina K P	Data Collector
Smt. Reshma	Data Collector
Medical Records Division	
Sri. Jayadev.G	Medical Records Officer
Miss. Indulekha M R	Medical Records Assistant
Miss. Nameetha S	Medical Records Attender

Cancer Registration [HBCR & PBCR]

Cancer Registration is the process of systematically and continuously collecting information on malignant neoplasm reported. Broadly there are two types of cancer registries – Hospital Based (HBCR) and Population Based (PBCR). Cancer patterns vary not only throughout the world but also between different population Groups within the same country. Epidemiologic studies based on these help in knowing what are happening and what can be done about it. Cancer registries provide the needed information to undertake such investigations.

HOSPITAL BASED CANCER REGISTRY

Hospital based cancer registries collect information of cancers reported in a given hospital, regardless of where that person with cancer resides. Hospital based registries help in assessing cancer patient care in a given hospital and aid in hospital administration including the individual hospital's cancer control programmes. Hospital registries help in planning and monitoring survival studies and clinical trials. Hospital registries contribute cases to the population based cancer registry in the area.

The cancer registry is an essential part of any rational programme of cancer control. Its data can be used in a wide variety of areas of cancer control ranging from etiological research, through primary and secondary prevention to health-care planning and patient care, so benefiting both the individual and society. The main objective of the cancer registry is to collect and classify information on all cancer cases in order to produce statistics on the occurrence of cancer in a defined population and to provide a framework for assessing and controlling the impact of cancer on the community. The collection of information on cancer cases and the production of cancer statistics are only justified, however, if use is made of the data collected. Cancer registry information may be used in a multitude of areas, and the value of the data increases if comparability over time is maintained. Cancer epidemiologists use their knowledge of the distribution of cancer in human populations to search for determinants of the disease.

The primary purpose of Hospital Based Cancer Registries is to contribute to patient care by providing readily accessible information on the patients with cancer, the treatment received and its results. The data is also used for clinical research and for epidemiological purposes. Hospital based cancer registries are concerned with recording of information on the cancer patients seen in a particular hospital (Isabel dos Santos Silva et al, 1999). Within the hospital, a registry is often considered to be an integral part of the hospital's cancer programme or health care delivery system.

FUNCTIONING OF HBCR

The data abstraction and entry are done using the hospital files. The demographic data are collected and entered into the computer at the time of new patient registration at MCC and transfer to the core- pro forma of the National Cancer Registry Programme (NCRP) of Indian Council of Medical Research (ICMR). The data transfer of the ICMR Core pro forma- first part (demographic details) and second part (diagnostic treatment and follow up details) is entered using the ICMR software after retrieving case sheets from the MCC Medical Records division. All variables in the core pro forma except age and various dates are directly selected. The selection box contains all the codes along with their descriptions for each variable. Hence, this helps to avoid mistakes beyond the range of values for each variable. The selection box corresponding to the variable topography and morphology contains the third edition of international classification of diseases for oncology (ICD-O-3) and the international classification of diseases (ICD-10).

DATA PROCESSING ANALYSIS

After abstraction, coding and data entry the data were sent to the coordinating unit of the NCRP of ICMR, Bangalore in an electronic format and the data was subjected to various range, consistency, unlikely combinations, and duplicate checks. Necessary corrections are done based on the error list of the cases sent by the coordinating unit and this report is generated.

ACTIVITIES

Ongoing Projects:

1. Hospital Based Cancer Registry(HBCR)
2. Population Based Cancer Registry (PBCR)
3. Patterns of Care & Survival Studies
4. Lifestyle and Cancer


NATIONAL CANCER REGISTRY PROGRAMME

(INDIAN COUNCIL OF MEDICAL RESEARCH)

The Indian Council of Medical Research initiated a network of cancer registries across the country under the National Cancer Registry Programme (NCRP) in December 1981. This move followed the recognition that there was an urgent need for strengthening the existing cancer registries and organization of new cancer registries in different regions of the country.

The programme was commenced with the following objectives:

1. To generate reliable data on the magnitude and patterns of cancer – this would be based on morbidity and mortality rates including incidence rates according to gender, age and residence of the patient, anatomical site of cancer and proportion of histological type or microscopic confirmation for each site; pattern of different types of cancer according to relative proportions or ratios in various population sub-groups such as religion, language spoken, educational status; clinical stage of disease when patients come to hospital for treatment and where possible the nature of treatment received and outcome;
2. To undertake epidemiologic studies in the form of case control or cohort studies based on observations of registry data;
3. Provide research base for developing appropriate strategies to aid in National Cancer Control Programme; this would be in the form of planning, monitoring and evaluation of activities under this programme;
4. Develop human resource in cancer registration and Epidemiology



Patterns of Patient Registration

Table 1: Pattern of patient registration

Type	Total
Malignant	3926
Non- Malignant	1430
Total	5356

STATE/ DISTRICT WISE ATTENDANCE OF CANCER PATIENTS REPORTED IN 2015




Table 2: District wise attendance of cancer patients

District	Pa-tients	%
Kannur	2173	55.35%
Kozhikode	650	16.56%
Kasaragod	541	13.78%
Wayanad	220	5.60%
Malappuram	169	4.30%
Palakkad	59	1.50%
Thrissur	29	0.74%
Ernakulam	9	0.23%
Kottayam	2	0.05%
Alappuzha	2	0.05%
Idukki	2	0.05%
Pathanamthitta	1	0.03%
Thiruvananthapuram	1	0.03%

Table 3: State wise attend-ance of cancer patients

Other states	Patients
Bihar	1
Karnataka	24
Lakshadweep	1
Pondicherry	29
Rajasthan	1
Tamilnadu	8
West Bengal	2
Total	66
Outside India	2

SUMMARY OF RESULTS

A total of 3926 new patients were registered in 2015. Among them 2162(55.1%) were males and 1764 (44.9%) were females. Total proportion of tobacco related cancer (TRC) relative to all sites is 51.4% and 17.2% among males and females respectively. TRC with respect to all sites Lung cancer predominates (20.4%) among males, whereas in females, it was mouth (6.6%). TRC with respect to specific site, among male it is Lung(39.6%) and among females it is mouth cancer (38.6%)

The ten leading cancers found in male were cancers of Lung (20.4%), Mouth (7.7%), Stomach(6.2%), Tongue(5.4%), NHL (5.4%), Larynx(4.9%), Rectum(4%), Oesophagus(3.7%), prostate(3.7%) and hypopharynx(3.5%) whereas in females it was Breast (30.1%), Cervix uteri(7.7%), Ovary (7.3%), Mouth(6.6%) Thyroid (4.3%), Rectum(3.7%), Lung (3.6%), NHL (3.4%), Corpus Uteri (3.1) and Tongue(2.9%).

Based in different methods of diagnosis microscopically diagnosed was 89% in males and 91.8% in females and 80.7% had histology of primary in males and 86.6% in females. According to Broad group of treatment among males 38.8% received treatment only at RI and among females it was 41%. The clinical extent of disease (Prior & treatment at RI) was regional in 15.31% in males and 16.2% in females.

The system wise leading cancers were, head

and neck (904, 66.6% in males and 33.4% in females). The second was digestive organs (761, 63.7% in males and 36.3% in females). The third was Breast (540, 1.7% in males and 98.3% in females), The fourth leading was Respiratory system (504, 87.3% in males and 12.7% in females), The fifth leading was hematological and RE (409, 62.6% in males and 37.4% in females). The sixth leading was Gynecological system (336), the seventh leading was Male Genital Organ (101). The eighth leading was Urinary tract (93, 87.1% in males and 12.9% in females). The ninth leading was skin (64, 65.6% in males and 34.4% in females) and the tenth leading was CNS(61, 68.9% in males and 31.1% in females). In 504 respiratory system cancer patients 43.7% were chronic smokers. In 904 head and neck cancer 16.9% were chronic alcoholic and 23.6% had chronic panchewing habit. Among hereditary cancers, 34.8 % of colon cancer patients had family history of cancer.

The ten leading cancers irrespective of sex were recorded as Breast(13.75%), Lung(12.81%), Mouth (7.21%), Stomach(4.51%), NHL (4.48%), Tongue(4.25%), Rectum (3.85%), Cervix(3.44%), Oesophagus (3.26%) and Ovary (3.26%) respectively. Among 36 (0-14 years) childhood cancers the leading cancers were Leukemia(61%). Among 3926 patients 2733(69.6%) were new cases and 1193(30.4%) were old cases.

RESULTS


Magnitude of Total Cancers

According to cancer registration in the Hospital Based Cancer Registry of MCC, Thalassery, Kannur during the year 2015, the number of cancer patients and their relative proportion according to sex and sex ratio percentage have been presented in Table 4. The number of cancer patients recorded in the HBCR was 3926 [males 2162(55.1%) and females 1764(44.9%)]

Table 4: Table Number(#) and Proportion(%) according to Sex and Sex Ratio Percent

Male		Female		Sex Ratio	Total Cases
#	%	#	%		
2162	55.1	1764	44.9	123	3926

PROPORTION(%) OF PATIENTS ACCORDING TO SEX



Tobacco Related Cancers (TRC)

Total proportion of tobacco related cancer (TRC) relative to all sites is 51.4% and 17.2% among males and females respectively. TRC with respect to all sites, lung cancer predominance (20.3%) among males, whereas females it is mouth (6.6%)

Table 5: Number and Proportion of Cancers associated with Use of Tobacco relative to all sites of Cancer

Males			Females		
All sites	#	%	All sites	#	%
2162	1112	51.4	1764	303	17.2

Relative Proportion of Cancers Associated with use of Tobacco relative to all sites of cancer




Table 6: Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) relative to all sites of Cancer

Site of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	14	0.6	8	0.5
Tongue (C01-02)	116	5.4	51	2.9
Mouth (C03-06)	166	7.7	117	6.6
Oropharynx (C10)	59	2.7	4	0.2
Hypopharynx (C12-13)	75	3.5	3	0.2
Oesophagus (C15)	81	3.7	47	2.7
Larynx (C32)	105	4.9	3	0.2
Lung (C33-34)	440	20.4	63	3.6
Urinary Bladder (C67)	56	2.6	7	0.4
TRC	1112	51.4	303	17.2
All Sites	2162	100	1764	100




Table 7: Number (#) and Proportion (%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)

Site of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	14	1.3	8	2.6
Tongue (C01-02)	116	10.4	51	16.8
Mouth (C03-06)	166	14.9	117	38.6
Oropharynx (C10)	59	5.3	4	1.3
Hypopharynx (C12-13)	75	6.7	3	1
Oesophagus (C15)	81	7.3	47	15.5
Larynx (C32)	105	9.4	3	1
Lung (C33-34)	440	39.6	63	20.8
Urinary Bladder (C67)	56	5	7	2.3
TRC	1112	100	303	100

Table 8: Number and Relative Proportion of Tobacco Related Cancers by Five-Year Age Groups

Age Group	Males		Females	
	#	%	#	%
25-29	2	0.2	6	2
30-34	11	1	8	2.6
35-39	15	1.3	5	1.7
40-44	39	3.5	8	2.6
45-49	64	5.8	15	5
50-54	96	8.6	28	9.2
55-59	164	14.7	34	11.2
60-64	263	23.7	43	14.2
65-69	184	16.5	52	17.2
70-74	137	12.3	37	12.2
75+	137	12.3	67	22.1
All Ages	1112	100	303	100

CHILDHOOD CANCERS

Table 9 : Number (#) and Proportion (%) of Cancers in Childhood relative to all Cancers

All Cancers	Boys		All Cancers	Girls	
	#	%		#	%
2162	21	1	1764	15	0.9




Table 10: Number (#) and Proportion (%) of Childhood Cancers by Five-year Age Group

Age Group	Boys		Girls		Total	
	#	%	#	%	#	%
00-04	6	28.6	3	20.0	9	25.0
05-09	7	33.3	5	33.3	12	33.3
10-14	8	38.1	7	46.7	15	33.3
All Childhood Cancers	21	100.0	15	100.0	36	100.0

LEADING SITES OF CANCER AND MAGNITUDE

Table 11: Rank, Number (#) and Relative Proportion (%) of Leading Sites of Cancer Males

Rank	Sites (ICD-10)	Males	
		%	#
1	Lung etc. (C33-34)	440	20.4
2	Mouth (C03-06)	166	7.7
3	Stomach (C16)	135	6.2
4	Tongue (C01-02)	116	5.4
5	NHL (C82-85,C96)	116	5.4
6	Larynx (C32)	105	4.9
7	Rectum (C19-20)	86	4
8	Oesophagus (C15)	81	3.7
9	Prostate (C61)	81	3.7
10	Hypopharynx (C12-13)	75	3.5
	All Sites	2162	100





Table 12: Rank, Number (#) and Relative Proportion (%) of Leading Sites of Cancer Females

Rank	Sites(ICD-10)	#	%
1	Breast (C50)	531	30.1
2	Cervix Uteri (C53)	135	7.7
3	Ovary etc. (C56)	128	7.3
4	Mouth (C03-06)	117	6.6
5	Thyroid (C73)	76	4.3
6	Rectum (C19-20)	65	3.7
7	Lung etc. (C33-34)	63	3.6
8	NHL (C82-85, C96)	60	3.4
9	Corpus Uteri (C54)	54	3.1
10	Tongue (C01-02)	51	2.9
	All Sites	1764	100



**DIAGNOSTIC,
CLINICAL AND
DEMOGRAPHIC
DETAILS**

DIAGNOSTIC INFORMATION

Table 13: Number (#) and Relative Proportion (%) of Cancers based on Different Methods of Diagnosis

Method of Diagnosis	Males		Females	
	#	%	#	%
Microscopic	1924	89	1619	91.8
All Imaging Techniques	172	8	71	4
Clinical	7	0.3	21	1.2
Others	59	2.7	53	3
Total	2162	100	1764	100

Table 14: Number (#) and Relative Proportion (%) of Cancers based on Different Types of Microscopic Diagnosis

Types of Microscopic Diagnosis	Males		Females	
	#	%	#	%
Histology of Primary	1744	80.7	1527	86.6
Histology of Metastasis	177	8.2	88	5
Cytology	3	0.1	3	0.2
Others	238	11	145	8.2
All Microscopic	2162	100	1764	100

CLINICAL INFORMATION

Table 15: Number (#) and Relative Proportion(%) of Cancer Patients according to clinical Extent of Disease(Treatment Only at RI)

Clinical Extent	Males		Females	
	#	%	#	%
Localised	11	1.3	6	0.8
Regional	455	54.5	488	67.5
L+R	466	55.8	494	68.3
Distant	276	33.1	155	21.4
Others	93	11.1	73	10.1
Unknown	-	-	1	0.1
Total	835	100	723	100

Table 16: Total Number of Cancer Patients Treated, Total Number of Treatment Procedures Performed and Procedures/Patient Ratio (Prior & Treatment at RI)

	Total Patients (Pts)	Total procedure (Pros)	Ratio
Males	202	256	1.3
Females	271	501	1.8

Table 17: Number (#) and Relative Proportion (%) of Cancer Patients according to Broad Group of Treatment at Reporting Institution and/or elsewhere

Treatment Group	Males		Females	
	#	%	#	%
Prior Treatment Only (PrT)	398	18.4	322	18.3
Prior and Treatment at RI (PrRI)	202	9.3	271	15.4
Treatment Only at RI (RI)	835	38.6	723	41
No Treatment (NoT)	727	33.6	448	25.4
Total	2162	100	1764	100

Table 18: Number (#) and Relative Proportion (%) of Cancer Patients according to Any Specific Treatment relative to all Treatment Procedures (Treatment Only at RI)

Treatments	Males		Females	
	#	%	#	%
Any Surgery	255	22.5	410	30.8
Any Radiotherapy	523	46.2	371	27.8
Any Chemotherapy	319	28.2	428	32.1
Any Hormone Therapy	18	1.6	122	9.2
Any Others	16	1.4	2	0.2
Unknown	-	-	-	-
Total	1131	100	1333	100

Table 19: Number(#) and Relative Proportion(%) of Cancer Patients according to Clinical Extent of Disease(Prior & Treatment at RI)

	Males		Females	
	#	%	#	%
Localised	1	0.5	1	0.4
Regional	31	15.3	44	16.2
L+R	32	15.8	45	16.6
Distant	30	14.9	18	6.6
Others	140	69.3	208	76.8
Unknown	-	-	-	-
Total	202	100	271	100

Table 20: Number(#) and Relative Proportion(%) of Patients according to Type of Treatment given (Treatment only at RI)

	Males		Females	
	#	%	#	%
Total Patients	835	100	723	100
Specific Treatment				
Surgery	125	15	123	17
Radiotherapy	294	35.2	97	13.4
Chemotherapy	143	17.1	112	15.5

S + R	69	8.3	43	5.9
S + C	20	2.4	64	8.9
R + C	112	13.4	69	9.5
S + R + C	38	4.6	91	12.6
Hormonotherapy	6	0.7	19	2.6
S + H	1	0.1	4	0.6
R + H	5	0.6	1	0.1
C + H	1	0.1	8	1.1
S + R + H	-	-	6	0.8
S + C + H	-	-	20	2.8
R + C + H	3	0.4	5	0.7
S + R + C + H	2	0.2	59	8.2
Others	16	1.9	2	0.3
Modality of Therapy				
Single	568	68	351	48.5
Combination	251	30.1	370	51.2

Table 21: Number (#) and Relative Proportion(%) of Patients according to Type of Treatment given (Prior Treatment only)

	Males		Females	
	#	%	#	%
Total Patients	398	100	322	100
Specific Treatment				
Surgery	124	31.2	116	36
Radiotherapy	35	8.8	15	4.7
Chemotherapy	83	20.9	43	13.4
S + R	15	3.8	15	4.7
S + C	45	11.3	49	15.2
R + C	39	9.8	28	8.7
S + R + C	25	6.3	38	11.8
Hormonotherapy	7	1.8	-	-
S + H	3	0.8	1	0.3
R + H	3	0.8	-	-
C + H	4	1	-	-
S + R + H	-	-	1	0.3
S + C + H	-	-	5	1.6
S + R + C + H	-	-	8	2.5
Others	14	3.5	2	0.6
Unknown	1	0.3	1	0.3
Modality of Therapy				
Single	249	62.6	174	54
Combination	134	33.7	145	45

Table 22: Number (#) and Relative Proportion (%) of Patients according to Type of Treatment given (Prior & Treatment at RI)

	Males		Females	
	#	%	#	%
Total Patients	202	100	271	100
Specific Treatment				
Surgery	105	52	175	64.6
Radiotherapy	15	7.4	14	5.2
Chemotherapy	36	17.8	23	8.5
S + R	5	2.5	6	2.2
S + C	7	3.5	28	10.3
R + C	9	4.5	10	3.7
S + R + C	6	3	4	1.5
Hormonotherapy	11	5.4	1	0.4
S + H	2	1	-	-
R + H	1	0.5	-	-
C + H	2	1	-	-
S + R + H	-	-	1	0.4
S + C + H	-	-	5	1.8
R + C + H	1	0.5	-	-
S + R + C + H	-	-	4	1.5
Others	2	1	-	-
Modality of Therapy				
Single	167	82.7	213	78.6
Combination	33	16.3	58	21.4

DEMOGRAPHIC INFORMATION

Table 23: Number (#) and Relative Proportion (%) of Cancer Patients according to Religious Groups

Religious Groups	Males		Females	
	#	%	#	%
Hindu	1287	59.5	1118	63.4
Muslim	625	28.9	470	26.6
Christian	234	10.8	160	9.1
Sikh	-	-	1	0.1
Jain	1	-	-	-
Unknown	15	0.7	15	0.9
Total	2162	100	1764	100

Table 24: Number (#) and Relative Proportion (%) of Cancer Patients according to Languages Spoken

Languages Spoken	Males		Females	
	#	%	#	%
Bengali	1	-	1	0.1
Gujarathi	1	-	-	-
Hindi	-	-	2	0.1
Kannada	8	0.4	8	0.5
Kashmiri	1	-	-	-
Malayalam	2125	98.3	1737	98.5
Oriya	2	0.1	-	-
Tamil	4	0.2	2	0.1
Telugu	-	-	1	0.1
Urdu	1	-	-	-
Konkani	1	-	-	-
Rajasthani	-	-	1	0.1
Others	2	0.1	2	0.1
Unknown	16	0.7	10	0.6
Total	2162	100	1764	100

Table 25: Number (#) and Relative Proportion (%) of Cancer Patients according to Educational Status

Educational Status	Males		Females	
	#	%	#	%
Below 5 years	4	0.2	3	0.2
Illiterate	115	5.3	145	8.2
Literate	100	4.6	71	4
Primary	413	19.1	250	14.2
Middle	256	11.8	167	9.5
Secondary	225	10.4	172	9.8
Technical	10	0.5	7	0.4
College	54	2.5	55	3.1
Others	10	0.5	13	0.7
Unknown	975	45.1	881	49.9
Total	2162	100	1764	100

Table 26: Number (#) and Relative Proportion (%) of Cancer Patients according to Marital Status

Marital Status	Males		Females	
	#	%	#	%
Unmarried	84	3.9	85	4.8
Married	1946	90.0	1178	66.8
Widowed	43	2.0	403	22.8
Divorced	5	0.2	17	1.0
Seperated	4	0.2	448	23.6
Others	1	1	0.1	1.5
Unknown	83	3.8	76	4.3
Total	2162	100.0	1764	100.0

**DETAILED
INFORMATION-
NCRP-ICMR
DIAGNOSTIC,
CLINICAL AND
DEMOGRAPHIC**

DIAGNOSTIC INFORMATION

Table 1(a): Number of cancers by site (ICD-10) and Five Year Age Group-Males

ICD10	Site Name	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total	%
C00	Lip	-	-	-	-	-	-	-	-	4	-	1	1	3	1	-	4	14	0.6
C01-02	Tongue	-	-	-	-	-	1	3	7	12	15	14	7	19	19	13	6	116	5.4
C03-06	Mouth	-	-	-	-	-	-	3	4	6	16	16	30	24	22	17	28	166	7.7
C07-08	Salivary Gland	-	-	-	-	-	-	1	-	3	3	-	-	2	1	1	2	13	0.6
C09	Tonsil	-	-	-	-	-	-	-	-	1	-	-	3	5	-	-	-	9	0.4
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	3	4	5	13	10	10	7	7	59	2.7
C11	Nasopharynx	-	-	-	-	-	-	1	-	-	-	2	2	3	2	1	-	11	0.5
C12-13	Hypopharynx	-	-	-	-	-	-	2	1	2	1	4	10	20	17	10	8	75	3.5
C15	Oesophagus	-	-	-	-	-	1	-	-	1	6	7	13	16	10	9	18	81	3.7
C16	Stomach	-	-	-	-	-	1	-	4	5	7	13	12	30	24	18	21	135	6.2
C17	Small Intestine	-	-	-	-	-	-	-	-	-	1	-	1	-	1	1	-	4	0.2
C18	Colon	-	-	-	-	1	-	2	4	1	6	10	11	13	7	3	4	62	2.9
C19-20	Rectum	-	-	-	-	1	-	1	1	3	8	8	10	19	13	10	12	86	4
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	1	3	0.1
C22	Liver	-	-	-	-	1	-	-	-	2	2	5	7	9	13	9	6	54	2.5
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	1	1	1	1	1	-	-	2	7	0.3
C25	Pancreas	-	-	-	-	-	-	-	1	3	4	5	6	11	4	2	6	42	1.9
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	1	-	-	-	2	1	1	-	-	3	8	0.4
C32	Larynx	-	-	-	-	-	-	-	1	4	5	8	15	28	18	13	13	105	4.9
C33-34	Lung etc.	-	-	-	-	-	-	3	1	5	15	31	67	127	81	62	48	440	20.4
C37-38	Other Thoracic Organs	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	2	0.1
C40-41	Bone	1	-	2	3	1	1	1	3	2	-	-	2	-	-	-	-	16	0.7
C43	Melanoma of Skin	-	-	-	-	-	-	1	-	-	1	1	2	-	8	1	1	15	0.7
C44	Other Skin	-	-	-	-	-	-	-	2	-	2	1	5	7	4	4	3	28	1.3
C47+C49	Conn. & Soft Tissue	-	-	-	2	1	1	-	-	3	3	3	2	3	3	4	3	28	1.3
C50	Breast	-	-	-	-	-	-	-	-	2	-	1	1	3	2	-	-	9	0.4
C60	Penis	-	-	-	-	-	-	-	-	2	-	-	1	2	1	3	3	12	0.6
C61	Prostate	-	-	-	-	-	-	-	-	-	2	2	9	23	16	10	19	81	3.7
C62	Testis	-	-	-	-	2	-	-	-	1	3	-	1	-	-	-	-	7	0.3
C63	Other Male Genital	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	1	0
C64	Kidney etc.	2	-	-	-	-	-	-	-	2	4	2	1	5	4	4	1	25	1.2
C67	Bladder	-	-	-	-	-	-	-	1	2	2	10	8	16	6	6	5	56	2.6
C69	Eye	-	-	-	-	-	-	-	-	1	-	-	1	-	-	-	-	2	0.1
C70-72	Brain, Nervous System	-	1	1	1	1	2	3	4	4	7	4	4	4	-	3	1	40	1.9
C73	Thyroid	-	-	-	-	-	-	2	1	5	2	2	3	1	2	2	-	20	0.9
C81	Hodgkins Disease	-	1	-	1	-	1	-	1	1	1	-	-	5	1	1	-	13	0.6
C82-85,C96	NHL	-	-	1	-	2	1	7	7	12	14	11	15	19	10	7	10	116	5.4
C88	Malignn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	2	0.1
C90	Multiple Myeloma	-	-	-	-	-	-	-	3	3	2	5	9	6	9	7	6	50	2.3
C91	Lymphoid Leuk.	3	3	2	5	3	-	1	1	2	5	2	1	3	3	2	1	37	1.7
C92-94	Myeloid Leukaemia	-	1	2	1	1	-	5	2	2	6	4	5	1	11	7	3	51	2.4
C95	LeukaemiaUns	-	1	-	-	1	-	-	-	-	-	1	-	-	-	-	-	3	0.1
O&U	Other and Uns	-	-	-	-	-	-	2	1	-	1	7	3	10	12	10	12	58	2.7
	All Sites	6	7	8	13	15	10	39	50	102	149	188	284	451	335	247	258	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 1(b): Number of cancers by site (ICD-10) and Five Year Age Group-Females

ICD10	Site Name	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total	%
C00	Lip	-	-	-	-	-	-	-	-	-	-	1	1	-	2	1	3	8	0.5
C01-02	Tongue	-	-	-	-	-	2	2	3	2	1	1	11	9	2	5	13	51	2.9
C03-06	Mouth	-	-	-	-	-	2	4	1	3	2	9	9	19	21	15	32	117	6.6
C07-08	Salivary Gland	-	-	-	-	-	-	1	1	-	1	-	-	1	5	1	1	11	0.6
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	2	-	-	2	1	5	0.3
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	1	2	-	-	1	-	-	4	0.2
C11	Nasopharynx	-	-	-	-	-	-	-	1	1	1	-	-	-	-	2	-	5	0.3
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	-	-	3	-	-	-	-	-	3	0.2
C15	Oesophagus	-	-	-	-	-	-	1	-	1	-	4	7	5	12	8	9	47	2.7
C16	Stomach	-	-	-	-	-	3	-	4	6	2	4	2	5	8	2	6	42	2.4
C17	Small Intestine	-	-	-	-	-	-	-	1	-	-	-	-	3	-	-	1	5	0.3
C18	Colon	-	-	-	-	1	1	-	1	1	4	-	6	7	15	4	10	50	2.8
C19-20	Rectum	-	-	-	-	-	-	-	4	3	5	9	8	7	11	5	13	65	3.7
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	2	0.1
C22	Liver	-	-	-	-	-	-	-	-	1	-	2	3	2	4	5	4	21	1.2
C23-24	Gallbladder etc.	-	-	-	-	-	1	-	-	1	1	1	2	4	3	-	1	14	0.8
C25	Pancreas	-	-	-	-	-	1	1	-	-	6	1	4	2	3	5	-	23	1.3
C30-31	Nose, Sinuses etc.	-	-	-	1	-	-	-	-	1	2	-	-	1	-	2	2	9	0.5
C32	Larynx	-	-	-	-	-	-	-	-	-	-	-	1	1	-	1	-	3	0.2
C33-34	Lung etc.	-	-	-	-	-	2	1	1	2	11	8	4	8	13	5	8	63	3.6
C37-38	Other Thoracic Organs	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	1	0.1
C40-41	Bone	-	-	1	3	-	1	1	2	1	1	-	-	1	1	-	-	12	0.7
C43	Melanoma of Skin	-	-	-	-	-	1	-	-	-	-	-	1	1	2	-	5	10	0.6
C44	Other Skin	-	-	-	-	-	-	-	-	-	1	-	5	2	2	5	4	19	1.1
C47+C49	Conn. & Soft Tissue	-	1	-	-	-	-	2	1	-	1	1	3	1	-	-	3	13	0.7
C50	Breast	-	-	-	-	1	4	22	44	68	90	91	70	56	37	24	24	531	30.1
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	2	4	0.2
C52	Vagina	-	-	-	-	-	-	-	-	1	-	1	-	-	1	2	2	7	0.4
C53	Cervix Uteri	-	-	-	-	-	-	1	5	14	21	27	18	14	13	8	14	135	7.7
C54	Corpus Uteri	-	-	-	-	-	-	-	-	3	5	9	7	9	11	6	4	54	3.1
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	2	1	1	-	1	-	-	5	0.3
C56	Ovary etc.	-	-	-	2	2	-	3	11	14	18	21	18	11	6	10	12	128	7.3
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	1	1	-	1	-	-	-	3	0.2
C64	Kidney etc.	-	-	-	-	-	-	-	-	1	1	-	-	1	1	-	1	5	0.3
C67	Bladder	-	-	-	-	-	-	-	-	-	-	-	1	1	1	2	2	7	0.4
C69	Eye	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	0.1
C70-72	Brain, Nervous System	-	1	-	-	-	1	4	1	-	3	2	2	-	3	-	1	18	1
C73	Thyroid	-	-	-	2	2	3	7	10	6	5	11	9	8	4	4	5	76	4.3
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	0.1
C81	Hodgkins Disease	-	-	1	-	2	2	1	-	1	1	-	-	-	-	-	-	8	0.5
C82-85,C96	NHL	-	-	1	1	-	2	4	2	8	3	4	4	10	6	4	11	60	3.4
C90	Multiple Myeloma	-	-	-	-	-	-	1	-	1	2	1	5	7	3	4	5	29	1.6
C91	Lymphoid Leuk.	3	3	3	-	-	-	1	-	-	-	-	2	-	1	2	-	15	0.9
C92-94	Myeloid Leukaemia	-	-	1	-	1	-	-	4	4	4	8	7	3	5	4	3	44	2.5
C95	LeukaemiaUns	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	2	3	0.2
O&U	Other and Uns	-	-	-	1	-	-	-	1	-	7	3	1	3	3	4	4	27	1.5
	All Sites	3	5	7	10	9	27	57	98	144	203	228	214	205	203	142	209	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table2(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis- Males

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	13	92.9	-	-	1	7.1	-	-	14	100
C01-02	Tongue	110	94.8	1	0.9	2	1.7	3	2.6	116	100
C03-06	Mouth	158	95.2	-	-	1	0.6	7	4.2	166	100
C07-08	Salivary Gland	13	100	-	-	-	-	-	-	13	100
C09	Tonsil	9	100	-	-	-	-	-	-	9	100
C10	Oth. Oropharynx	54	91.5	2	3.4	1	1.7	2	3.4	59	100
C11	Nasopharynx	10	90.9	-	-	-	-	1	9.1	11	100
C12-13	Hypopharynx	72	96	1	1.3	1	1.3	1	1.3	75	100
C15	Oesophagus	74	91.4	4	4.9	-	-	3	3.7	81	100
C16	Stomach	127	94.1	5	3.7	-	-	3	2.2	135	100
C17	Small Intestine	4	100	-	-	-	-	-	-	4	100
C18	Colon	58	93.5	2	3.2	-	-	2	3.2	62	100
C19-20	Rectum	82	95.3	-	-	-	-	4	4.7	86	100
C21	Anus & Anal Canal	3	100	-	-	-	-	-	-	3	100
C22	Liver	17	31.5	35	64.8	-	-	2	3.7	54	100
C23-24	Gallbladder etc.	4	57.1	3	42.9	-	-	-	-	7	100
C25	Pancreas	22	52.4	15	35.7	-	-	5	11.9	42	100
C30-31	Nose, Sinuses etc.	7	87.5	1	12.5	-	-	-	-	8	100
C32	Larynx	92	87.6	2	1.9	-	-	11	10.5	105	100
C33-34	Lung etc.	365	83	72	16.4	-	-	3	0.7	440	100
C37-38	Other Thoracic Organs	2	100	-	-	-	-	-	-	2	100
C40-41	Bone	16	100	-	-	-	-	-	-	16	100
C43	Melanoma of Skin	15	100	-	-	-	-	-	-	15	100
C44	Other Skin	28	100	-	-	-	-	-	-	28	100
C47+C49	Conn. & Soft Tissue	27	96.4	1	3.6	-	-	-	-	28	100
C50	Breast	9	100	-	-	-	-	-	-	9	100
C60	Penis	11	91.7	-	-	-	-	1	8.3	12	100
C61	Prostate	73	90.1	2	2.5	-	-	6	7.4	81	100
C62	Testis	5	71.4	1	14.3	1	14.3	-	-	7	100
C63	Other Male Genital	1	100	-	-	-	-	-	-	1	100
C64	Kidney etc.	24	96	1	4	-	-	-	-	25	100
C67	Bladder	52	92.9	4	7.1	-	-	-	-	56	100
C69	Eye	1	50	-	-	-	-	1	50	2	100
C70-72	Brain, Nervous System	33	82.5	6	15	-	-	1	2.5	40	100
C73	Thyroid	20	100	-	-	-	-	-	-	20	100
C81	Hodgkins Disease	12	92.3	-	-	-	-	1	7.7	13	100
C82-85,C96	NHL	116	100	-	-	-	-	-	-	116	100
C88	Maligmn.Prol D	2	100	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	48	96	-	-	-	-	2	4	50	100
C91	Lymphoid Leuk.	37	100	-	-	-	-	-	-	37	100
C92-94	Myeloid Leukaemia	51	100	-	-	-	-	-	-	51	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	3	100
O&U	Other and Uns	44	75.9	14	24.1	-	-	-	-	58	100
	All Sites	1924	89	172	8	7	0.3	59	2.7	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table2(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis- Females

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	8	100	-	-	-	-	-	-	8	100
C01-02	Tongue	45	88.2	-	-	3	5.9	3	5.9	51	100
C03-06	Mouth	113	96.6	-	-	4	3.4	-	-	117	100
C07-08	Salivary Gland	11	100	-	-	-	-	-	-	11	100
C09	Tonsil	4	80	-	-	-	-	1	20	5	100
C10	Oth. Oropharynx	4	100	-	-	-	-	-	-	4	100
C11	Nasopharynx	4	80	1	20	-	-	-	-	5	100
C12-13	Hypopharynx	3	100	-	-	-	-	-	-	3	100
C15	Oesophagus	42	89.4	3	6.4	-	-	2	4.3	47	100
C16	Stomach	38	90.5	2	4.8	-	-	2	4.8	42	100
C17	Small Intestine	5	100	-	-	-	-	-	-	5	100
C18	Colon	42	84	5	10	-	-	3	6	50	100
C19-20	Rectum	62	95.4	2	3.1	-	-	1	1.5	65	100
C21	Anus & Anal Canal	2	100	-	-	-	-	-	-	2	100
C22	Liver	10	47.6	8	38.1	-	-	3	14.3	21	100
C23-24	Gallbladder etc.	9	64.3	5	35.7	-	-	-	-	14	100
C25	Pancreas	15	65.2	8	34.8	-	-	-	-	23	100
C30-31	Nose, Sinuses etc.	9	100	-	-	-	-	-	-	9	100
C32	Larynx	2	66.7	-	-	-	-	1	33.3	3	100
C33-34	Lung etc.	52	82.5	11	17.5	-	-	-	-	63	100
C37-38	Other Thoracic Organs	1	100	-	-	-	-	-	-	1	100
C40-41	Bone	11	91.7	-	-	-	-	1	8.3	12	100
C43	Melanoma of Skin	10	100	-	-	-	-	-	-	10	100
C44	Other Skin	19	100	-	-	-	-	-	-	19	100
C47+C49	Conn. & Soft Tissue	13	100	-	-	-	-	-	-	13	100
C50	Breast	514	96.8	3	0.6	7	1.3	7	1.3	531	100
C51	Vulva	4	100	-	-	-	-	-	-	4	100
C52	Vagina	7	100	-	-	-	-	-	-	7	100
C53	Cervix Uteri	120	88.9	-	-	7	5.2	8	5.9	135	100
C54	Corpus Uteri	50	92.6	1	1.9	-	-	3	5.6	54	100
C55	Uterus Unspecified	5	100	-	-	-	-	-	-	5	100
C56	Ovary etc.	104	81.2	10	7.8	-	-	14	10.9	128	100
C57	Other Female Genital	3	100	-	-	-	-	-	-	3	100
C64	Kidney etc.	3	60	2	40	-	-	-	-	5	100
C67	Bladder	6	85.7	-	-	-	-	1	14.3	7	100
C69	Eye	1	100	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	14	77.8	4	22.2	-	-	-	-	18	100
C73	Thyroid	74	97.4	1	1.3	-	-	1	1.3	76	100
C74	Adrenal Gland	1	100	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	8	100	-	-	-	-	-	-	8	100
C82-85,C96	NHL	59	98.3	-	-	-	-	1	1.7	60	100
C90	Multiple Myeloma	28	96.6	-	-	-	-	1	3.4	29	100
C91	Lymphoid Leuk.	15	100	-	-	-	-	-	-	15	100
C92-94	Myeloid Leukaemia	44	100	-	-	-	-	-	-	44	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	3	100
O&U	Other and Uns	22	81.5	5	18.5	-	-	-	-	27	100
	All Sites	1619	91.8	71	4	21	1.2	53	3	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table3(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis- Males

ICD 10	Site Name	Histology of Primary		Histology of Secondary		Cytology		Blood Film		Bone Marrow		Others		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	13	92.9	-	-	-	-	-	-	-	-	1	7.1	14	100
C01-02	Tongue	105	90.5	4	3.4	1	0.9	-	-	-	-	6	5.2	116	100
C03-06	Mouth	157	94.6	1	0.6	-	-	-	-	-	-	8	4.8	166	100
C07-08	Salivary Gland	12	92.3	1	7.7	-	-	-	-	-	-	-	-	13	100
C09	Tonsil	8	88.9	1	11	-	-	-	-	-	-	-	-	9	100
C10	Oth. Oropharynx	45	76.3	9	15	-	-	-	-	-	-	5	8.5	59	100
C11	Nasopharynx	8	72.7	2	18	-	-	-	-	-	-	1	9.1	11	100
C12-13	Hypopharynx	63	84	9	12	-	-	-	-	-	-	3	4	75	100
C15	Oesophagus	73	90.1	1	1.2	-	-	-	-	-	-	7	8.6	81	100
C16	Stomach	120	88.9	7	5.2	-	-	-	-	-	-	8	5.9	135	100
C17	Small Intestine	3	75	1	25	-	-	-	-	-	-	-	-	4	100
C18	Colon	57	91.9	1	1.6	-	-	-	-	-	-	4	6.5	62	100
C19-20	Rectum	80	93	2	2.3	-	-	-	-	-	-	4	4.7	86	100
C21	Anus & Anal Canal	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C22	Liver	15	27.8	2	3.7	-	-	-	-	-	-	37	68.5	54	100
C23-24	Gallbladder etc.	3	42.9	1	14	-	-	-	-	-	-	3	42.9	7	100
C25	Pancreas	12	28.6	10	24	-	-	-	-	-	-	20	47.6	42	100
C30-31	Nose, Sinuses etc.	7	87.5	-	-	-	-	-	-	-	-	1	12.5	8	100
C32	Larynx	86	81.9	6	5.7	-	-	-	-	-	-	13	12.4	105	100
C33-34	Lung etc.	293	66.6	71	16	1	0.2	-	-	-	-	75	17	440	100
C37-38	Other Thoracic Organs	2	100	-	-	-	-	-	-	-	-	-	-	2	100
C40-41	Bone	16	100	-	-	-	-	-	-	-	-	-	-	16	100
C43	Melanoma of Skin	15	100	-	-	-	-	-	-	-	-	-	-	15	100
C44	Other Skin	27	96.4	1	3.6	-	-	-	-	-	-	-	-	28	100
C47+C49	Conn. & Soft Tissue	27	96.4	-	-	-	-	-	-	-	-	1	3.6	28	100
C50	Breast	8	88.9	1	11	-	-	-	-	-	-	-	-	9	100
C60	Penis	11	91.7	-	-	-	-	-	-	-	-	1	8.3	12	100
C61	Prostate	73	90.1	-	-	-	-	-	-	-	-	8	9.9	81	100
C62	Testis	5	71.4	-	-	-	-	-	-	-	-	2	28.6	7	100
C63	Other Male Genital	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C64	Kidney etc.	19	76	5	20	-	-	-	-	-	-	1	4	25	100
C67	Bladder	52	92.9	-	-	-	-	-	-	-	-	4	7.1	56	100
C69	Eye	1	50	-	-	-	-	-	-	-	-	1	50	2	100
C70-72	Brain, Nervous System	33	82.5	-	-	-	-	-	-	-	-	7	17.5	40	100
C73	Thyroid	19	95	1	5	-	-	-	-	-	-	-	-	20	100
C81	Hodgkins Disease	12	92.3	-	-	-	-	-	-	-	-	1	7.7	13	100
C82-85,C96	NHL	115	99.1	1	0.9	-	-	-	-	-	-	-	-	116	100
C88	Maliglmn.Prol D	2	100	-	-	-	-	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	48	96	-	-	-	-	-	-	-	-	2	4	50	100
C91	Lymphoid Leuk.	37	100	-	-	-	-	-	-	-	-	-	-	37	100
C92-94	Myeloid Leukaemia	51	100	-	-	-	-	-	-	-	-	-	-	51	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	-	-	-	-	3	100
O&U	Other and Uns	4	6.9	39	67	1	1.7	-	-	-	-	14	24.1	58	100
	All Sites	1744	80.7	177	8.2	3	0.1	-	-	-	-	238	11	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table3(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis- Females

ICD 10	Site Name	Histology of Primary		Histology of Secondary		Cytology		Blood Film		Bone Marrow		Others		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	8	100	-	-	-	-	-	-	-	-	-	-	8	100
C01-02	Tongue	43	84.3	2	3.9	-	-	-	-	-	-	6	11.8	51	100
C03-06	Mouth	113	96.6	-	-	-	-	-	-	-	-	4	3.4	117	100
C07-08	Salivary Gland	11	100	-	-	-	-	-	-	-	-	-	-	11	100
C09	Tonsil	2	40	2	40	-	-	-	-	-	-	1	20	5	100
C10	Oth. Oropharynx	3	75	1	25	-	-	-	-	-	-	-	-	4	100
C11	Nasopharynx	3	60	1	20	-	-	-	-	-	-	1	20	5	100
C12-13	Hypopharynx	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C15	Oesophagus	41	87.2	1	2.1	-	-	-	-	-	-	5	10.6	47	100
C16	Stomach	37	88.1	1	2.4	-	-	-	-	-	-	4	9.5	42	100
C17	Small Intestine	5	100	-	-	-	-	-	-	-	-	-	-	5	100
C18	Colon	41	82	1	2	-	-	-	-	-	-	8	16	50	100
C19-20	Rectum	61	93.8	1	1.5	-	-	-	-	-	-	3	4.6	65	100
C21	Anus & Anal Canal	2	100	-	-	-	-	-	-	-	-	-	-	2	100
C22	Liver	7	33.3	3	14.3	-	-	-	-	-	-	11	52.4	21	100
C23-24	Gallbladder etc.	6	42.9	3	21.4	-	-	-	-	-	-	5	35.7	14	100
C25	Pancreas	12	52.2	3	13	-	-	-	-	-	-	8	34.8	23	100
C30-31	Nose, Sinuses etc.	9	100	-	-	-	-	-	-	-	-	-	-	9	100
C32	Larynx	2	66.7	-	-	-	-	-	-	-	-	1	33.3	3	100
C33-34	Lung etc.	37	58.7	13	20.6	2	3.2	-	-	-	-	11	17.5	63	100
C37-38	Other Thoracic Organs	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C40-41	Bone	11	91.7	-	-	-	-	-	-	-	-	1	8.3	12	100
C43	Melanoma of Skin	10	100	-	-	-	-	-	-	-	-	-	-	10	100
C44	Other Skin	19	100	-	-	-	-	-	-	-	-	-	-	19	100
C47+C49	Conn. & Soft Tissue	13	100	-	-	-	-	-	-	-	-	-	-	13	100
C50	Breast	503	94.7	10	1.9	1	0.2	-	-	-	-	17	3.2	531	100
C51	Vulva	4	100	-	-	-	-	-	-	-	-	-	-	4	100
C52	Vagina	7	100	-	-	-	-	-	-	-	-	-	-	7	100
C53	Cervix Uteri	118	87.4	2	1.5	-	-	-	-	-	-	15	11.1	135	100
C54	Corpus Uteri	46	85.2	4	7.4	-	-	-	-	-	-	4	7.4	54	100
C55	Uterus Unspecified	5	100	-	-	-	-	-	-	-	-	-	-	5	100
C56	Ovary etc.	83	64.8	21	16.4	-	-	-	-	-	-	24	18.8	128	100
C57	Other Female Genital	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C64	Kidney etc.	3	60	-	-	-	-	-	-	-	-	2	40	5	100
C67	Bladder	6	85.7	-	-	-	-	-	-	-	-	1	14.3	7	100
C69	Eye	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	14	77.8	-	-	-	-	-	-	-	-	4	22.2	18	100
C73	Thyroid	72	94.7	2	2.6	-	-	-	-	-	-	2	2.6	76	100
C74	Adrenal Gland	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	8	100	-	-	-	-	-	-	-	-	-	-	8	100
C82-85,C96	NHL	59	98.3	-	-	-	-	-	-	-	-	1	1.7	60	100
C90	Multiple Myeloma	28	96.6	-	-	-	-	-	-	-	-	1	3.4	29	100
C91	Lymphoid Leuk.	15	100	-	-	-	-	-	-	-	-	-	-	15	100
C92-94	Myeloid Leukaemia	44	100	-	-	-	-	-	-	-	-	-	-	44	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	-	-	-	-	3	100
O&U	Other and Uns	5	18.5	17	63	-	-	-	-	-	-	5	18.5	27	100
	All Sites	1528	86.6	88	5	3	0.2	-	-	-	-	145	8.2	1764	100

CLINICAL INFORMATION

Table 4(a) : Number(#) and Proportion(%) of Cancers by site (ICD-10) and Broad Treatment Groups- Males

ICD	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	4	28.6	-	-	8	57.1	2	14.3	14	100
C01-02	Tongue	11	9.5	11	9.5	71	61.2	23	19.8	116	100
C03-06	Mouth	22	13.3	14	8.4	99	59.6	31	18.7	166	100
C07-08	Salivary Gland	3	23.1	-	-	7	53.8	3	23.1	13	100
C09	Tonsil	-	-	1	11.1	8	88.9	-	-	9	100
C10	Oth. Oropharynx	7	11.9	3	5.1	39	66.1	10	16.9	59	100
C11	Nasopharynx	2	18.2	-	-	8	72.7	1	9.1	11	100
C12-13	Hypopharynx	9	12	2	2.7	45	60	19	25.3	75	100
C15	Oesophagus	10	12.3	3	3.7	36	44.4	32	39.5	81	100
C16	Stomach	36	26.7	8	5.9	35	25.9	56	41.5	135	100
C17	Small Intestine	2	50	1	25	-	-	1	25	4	100
C18	Colon	22	35.5	15	24.2	11	17.7	14	22.6	62	100
C19-20	Rectum	23	26.7	11	12.8	29	33.7	23	26.7	86	100
C21	Anus & Anal Canal	-	-	-	-	3	100	-	-	3	100
C22	Liver	9	16.7	5	9.3	4	7.4	36	66.7	54	100
C23-24	Gallbladder etc.	2	28.6	-	-	-	-	5	71.4	7	100
C25	Pancreas	11	26.2	2	4.8	10	23.8	19	45.2	42	100
C30-31	Nose, Sinuses etc.	4	50	-	-	2	25	2	25	8	100
C32	Larynx	22	21	7	6.7	47	44.8	29	27.6	105	100
C33-34	Lung etc.	31	7	17	3.9	154	35	238	54.1	440	100
C37-38	Other Thoracic Organs	-	-	-	-	2	100	-	-	2	100
C40-41	Bone	7	43.8	5	31.2	2	12.5	2	12.5	16	100
C43	Melanoma of Skin	8	53.3	3	20	2	13.3	2	13.3	15	100
C44	Other Skin	6	21.4	11	39.3	9	32.1	2	7.1	28	100
C47+C49	Conn. & Soft Tissue	10	35.7	5	17.9	8	28.6	5	17.9	28	100
C50	Breast	3	33.3	3	33.3	3	33.3	-	-	9	100
C60	Penis	2	16.7	-	-	9	75	1	8.3	12	100
C61	Prostate	25	30.9	19	23.5	20	24.7	17	21	81	100
C62	Testis	2	28.6	2	28.6	2	28.6	1	14.3	7	100
C63	Other Male Genital	-	-	1	100	-	-	-	-	1	100
C64	Kidney etc.	8	32	4	16	8	32	5	20	25	100
C67	Bladder	24	42.9	13	23.2	8	14.3	11	19.6	56	100
C69	Eye	2	100	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	20	50	12	30	2	5	6	15	40	100
C73	Thyroid	7	35	7	35	4	20	2	10	20	100
C81	Hodgkins Disease	4	30.8	-	-	5	38.5	4	30.8	13	100
C82-85,C96	NHL	20	17.2	8	6.9	59	50.9	29	25	116	100
C88	Maligmn.Prol D	-	-	-	-	2	100	-	-	2	100
C90	Multiple Myeloma	6	12	2	4	31	62	11	22	50	100
C91	Lymphoid Leuk.	5	13.5	1	2.7	17	45.9	14	37.8	37	100
C92-94	Myeloid Leukaemia	3	5.9	4	7.8	19	37.3	25	49	51	100
C95	LeukaemiaUns	1	33.3	-	-	-	-	2	66.7	3	100
O&U	Other and Uns	5	8.6	2	3.4	7	12.1	44	75.9	58	100
	All Sites	398	18.4	202	9.3	835	38.6	727	33.6	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 4(b) : Number(#) and Proportion(%) of Cancers by site (ICD-10) and Broad Treatment Groups- Females

ICD	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	1	12.5	3	37.5	4	50	8	100
C01-02	Tongue	12	23.5	3	5.9	26	51	10	19.6	51	100
C03-06	Mouth	10	8.5	7	6	74	63.2	26	22.2	117	100
C07-08	Salivary Gland	3	27.3	2	18.2	4	36.4	2	18.2	11	100
C09	Tonsil	2	40	-	-	2	40	1	20	5	100
C10	Oth. Oropharynx	-	-	-	-	3	75	1	25	4	100
C11	Nasopharynx	-	-	1	20	1	20	3	60	5	100
C12-13	Hypopharynx	1	33.3	-	-	1	33.3	1	33.3	3	100
C15	Oesophagus	6	12.8	2	4.3	19	40.4	20	42.6	47	100
C16	Stomach	6	14.3	4	9.5	8	19	24	57.1	42	100
C17	Small Intestine	3	60	-	-	2	40	-	-	5	100
C18	Colon	10	20	14	28	10	20	16	32	50	100
C19-20	Rectum	14	21.5	15	23.1	20	30.8	16	24.6	65	100
C21	Anus & Anal Canal	-	-	-	-	2	100	-	-	2	100
C22	Liver	6	28.6	-	-	2	9.5	13	61.9	21	100
C23-24	Gallbladder etc.	3	21.4	1	7.1	1	7.1	9	64.3	14	100
C25	Pancreas	8	34.8	2	8.7	2	8.7	11	47.8	23	100
C30-31	Nose, Sinuses etc.	2	22.2	3	33.3	2	22.2	2	22.2	9	100
C32	Larynx	1	33.3	1	33.3	-	-	1	33.3	3	100
C33-34	Lung etc.	5	7.9	3	4.8	17	27	38	60.3	63	100
C37-38	Other Thoracic Organs	-	-	-	-	-	-	1	100	1	100
C40-41	Bone	5	41.7	-	-	6	50	1	8.3	12	100
C43	Melanoma of Skin	3	30	1	10	3	30	3	30	10	100
C44	Other Skin	3	15.8	4	21.1	10	52.6	2	10.5	19	100
C47+C49	Conn. & Soft Tissue	1	7.7	3	23.1	3	23.1	6	46.2	13	100
C50	Breast	83	15.6	119	22.4	244	46	85	16	531	100
C51	Vulva	-	-	-	-	2	50	2	50	4	100
C52	Vagina	1	14.3	2	28.6	3	42.9	1	14.3	7	100
C53	Cervix Uteri	28	20.7	21	15.6	61	45.2	25	18.5	135	100
C54	Corpus Uteri	19	35.2	14	25.9	16	29.6	5	9.3	54	100
C55	Uterus Unspecified	1	20	1	20	3	60	-	-	5	100
C56	Ovary etc.	30	23.4	21	16.4	41	32	36	28.1	128	100
C57	Other Female Genital	-	-	2	66.7	-	-	1	33.3	3	100
C64	Kidney etc.	-	-	-	-	2	40	3	60	5	100
C67	Bladder	3	42.9	3	42.9	-	-	1	14.3	7	100
C69	Eye	-	-	-	-	-	-	1	100	1	100
C70-72	Brain, Nervous System	8	44.4	5	27.8	1	5.6	4	22.2	18	100
C73	Thyroid	26	34.2	4	5.3	33	43.4	13	17.1	76	100
C74	Adrenal Gland	1	100	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	-	-	2	25	4	50	2	25	8	100
C82-85,C96	NHL	8	13.3	4	6.7	34	56.7	14	23.3	60	100
C90	Multiple Myeloma	3	10.3	1	3.4	18	62.1	7	24.1	29	100
C91	Lymphoid Leuk.	2	13.3	1	6.7	11	73.3	1	6.7	15	100
C92-94	Myeloid Leukaemia	2	4.5	3	6.8	26	59.1	13	29.5	44	100
C95	LeukaemiaUns	-	-	-	-	1	33.3	2	66.7	3	100
O&U	Other and Uns	3	11.1	1	3.7	2	7.4	21	77.8	27	100
	All Sites	322	18.3	271	15.4	723	41	448	25.4	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 5(a) : Number(#) and Proportion(%) of Cancers by site (ICD-10) and Clinical Extent of Disease-Males
(Treatment Only at RI)**

ICD	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	8	100	-	-	-	-	-	-	8	100
C01-02	Tongue	3	4.2	65	91.5	3	4.2	-	-	-	-	71	100
C03-06	Mouth	1	1	85	85.9	13	13.1	-	-	-	-	99	100
C07-08	Salivary Gland	-	-	4	57.1	3	42.9	-	-	-	-	7	100
C09	Tonsil	-	-	7	87.5	1	12.5	-	-	-	-	8	100
C10	Oth. Oropharynx	-	-	38	97.4	1	2.6	-	-	-	-	39	100
C11	Nasopharynx	-	-	7	87.5	1	12.5	-	-	-	-	8	100
C12-13	Hypopharynx	-	-	38	84.4	7	15.6	-	-	-	-	45	100
C15	Oesophagus	-	-	8	22.2	28	77.8	-	-	-	-	36	100
C16	Stomach	1	2.9	10	28.6	24	68.6	-	-	-	-	35	100
C18	Colon	-	-	7	63.6	3	27.3	1	9.1	-	-	11	100
C19-20	Rectum	1	3.4	18	62.1	10	34.5	-	-	-	-	29	100
C21	Anus & Anal Canal	-	-	-	-	3	100	-	-	-	-	3	100
C22	Liver	-	-	-	-	4	100	-	-	-	-	4	100
C25	Pancreas	-	-	1	10	9	90	-	-	-	-	10	100
C30-31	Nose, Sinuses etc.	-	-	-	-	2	100	-	-	-	-	2	100
C32	Larynx	2	4.3	43	91.5	2	4.3	-	-	-	-	47	100
C33-34	Lung etc.	1	0.6	27	17.5	126	81.8	-	-	-	-	154	100
C37-38	Other Thoracic Organs	-	-	1	50	1	50	-	-	-	-	2	100
C40-41	Bone	-	-	2	100	-	-	-	-	-	-	2	100
C43	Melanoma of Skin	-	-	2	100	-	-	-	-	-	-	2	100
C44	Other Skin	-	-	5	55.6	3	33.3	1	11.1	-	-	9	100
C47+C49	Conn. & Soft Tissue	-	-	4	50	4	50	-	-	-	-	8	100
C50	Breast	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C60	Penis	-	-	9	100	-	-	-	-	-	-	9	100
C61	Prostate	-	-	5	25	15	75	-	-	-	-	20	100
C62	Testis	-	-	1	50	1	50	-	-	-	-	2	100
C64	Kidney etc.	-	-	2	25	6	75	-	-	-	-	8	100
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	12.5	4	50	3	37.5	-	-	-	-	8	100
C70-72	Brain, Nervous System	1	50	1	50	-	-	-	-	-	-	2	100
C73	Thyroid	-	-	4	100	-	-	-	-	-	-	4	100
C81	Hodgkins Disease	-	-	4	80	1	20	-	-	-	-	5	100
C82-85,C96	NHL	-	-	40	67.8	1	1.7	18	30.5	-	-	59	100
C88	Maliglmn.Prol D	-	-	-	-	-	-	2	100	-	-	2	100
C90	Multiple Myeloma	-	-	2	6.5	-	-	29	93.5	-	-	31	100
C91	Lymphoid Leuk.	-	-	1	5.9	-	-	16	94.1	-	-	17	100
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	19	100	-	-	19	100
O&U	Other and Uns	-	-	-	-	-	-	7	100	-	-	7	100
	All Sites	11	1.3	455	54.5	276	33.1	93	11.1	-	-	835	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 5(b) : Number(#) and Proportion(%) of Cancers by site (ICD-10) and Clinical Extent of Disease-Females
(Treatment Only at RI, No Treatment)**

ICD	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	3	100	-	-	-	-	-	-	3	100
C01-02	Tongue	1	3.8	20	76.9	5	19.2	-	-	-	-	26	100
C03-06	Mouth	1	1.4	60	81.1	13	17.6	-	-	-	-	74	100
C07-08	Salivary Gland	-	-	3	75	1	25	-	-	-	-	4	100
C09	Tonsil	-	-	1	50	1	50	-	-	-	-	2	100
C10	Oth. Oropharynx	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C11	Nasopharynx	-	-	1	100	-	-	-	-	-	-	1	100
C12-13	Hypopharynx	-	-	1	100	-	-	-	-	-	-	1	100
C15	Oesophagus	-	-	2	10.5	17	89.5	-	-	-	-	19	100
C16	Stomach	-	-	5	62.5	3	37.5	-	-	-	-	8	100
C17	Small Intestine	-	-	-	-	1	50	1	50	-	-	2	100
C18	Colon	-	-	8	80	2	20	-	-	-	-	10	100
C19-20	Rectum	-	-	11	55	8	40	-	-	1	5	20	100
C21	Anus & Anal Canal	1	50	1	50	-	-	-	-	-	-	2	100
C22	Liver	-	-	1	50	1	50	-	-	-	-	2	100
C23-24	Gallbladder etc.	-	-	1	100	-	-	-	-	-	-	1	100
C25	Pancreas	-	-	-	-	2	100	-	-	-	-	2	100
C30-31	Nose, Sinuses etc.	-	-	2	100	-	-	-	-	-	-	2	100
C33-34	Lung etc.	-	-	2	11.8	15	88.2	-	-	-	-	17	100
C40-41	Bone	-	-	5	83.3	-	-	1	16.7	-	-	6	100
C43	Melanoma of Skin	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C44	Other Skin	-	-	9	90	-	-	1	10	-	-	10	100
C47+C49	Conn. & Soft Tissue	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C50	Breast	1	0.4	205	84	37	15.2	1	0.4	-	-	244	100
C51	Vulva	-	-	2	100	-	-	-	-	-	-	2	100
C52	Vagina	-	-	1	33.3	2	66.7	-	-	-	-	3	100
C53	Cervix Uteri	-	-	51	83.6	10	16.4	-	-	-	-	61	100
C54	Corpus Uteri	-	-	14	87.5	2	12.5	-	-	-	-	16	100
C55	Uterus Unspecified	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C56	Ovary etc.	1	2.4	19	46.3	21	51.2	-	-	-	-	41	100
C64	Kidney etc.	-	-	2	100	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	-	-	1	100	-	-	-	-	-	-	1	100
C73	Thyroid	1	3	23	69.7	9	27.3	-	-	-	-	33	100
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	4	100	-	-	-	-	-	-	4	100
C82-85,C96	NHL	-	-	21	61.8	1	2.9	12	35.3	-	-	34	100
C90	Multiple Myeloma	-	-	-	-	-	-	18	100	-	-	18	100
C91	Lymphoid Leuk.	-	-	-	-	-	-	11	100	-	-	11	100
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	26	100	-	-	26	100
C95	LeukaemiaUns	-	-	-	-	-	-	1	100	-	-	1	100
O&U	Other and Uns	-	-	1	50	-	-	1	50	-	-	2	100
	All Sites	6	0.8	488	67.5	155	21.4	73	10.1	1	0.1	723	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 6(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment_ Males (Treatment Only at RI)

ICD 10	Site	Type of Treatment																			
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	50	2	25	-	-	2	25	-	-	-	-	-	-	-	-	-	-	8	100
C01-02	Tongue	29	40.8	11	16	-	-	21	30	-	-	2	3	8	11	-	-	-	-	71	100
C03-06	Mouth	32	32.3	31	31	1	1	25	25	-	-	1	1	9	9.1	-	-	-	-	99	100
C07-08	Salivary Gland	2	28.6	4	57	-	-	1	14	-	-	-	-	-	-	-	-	-	-	7	100
C09	Tonsil	-	-	4	50	-	-	-	-	-	-	4	50	-	-	-	-	-	-	8	100
C10	Oth. Oropharynx	-	-	25	64	-	-	-	-	-	-	13	33	1	2.6	-	-	-	-	39	100
C11	Nasopharynx	-	-	2	25	1	13	-	-	-	-	5	63	-	-	-	-	-	-	8	100
C12-13	Hypopharynx	2	4.4	24	53	1	2.2	2	4.4	-	-	15	33	1	2.2	-	-	-	-	45	100
C15	Oesophagus	-	-	31	86	1	2.8	2	5.6	-	-	2	6	-	-	-	-	-	-	36	100
C16	Stomach	12	34.3	8	23	6	17	-	-	6	17	-	-	2	5.7	1	2.9	-	-	35	100
C18	Colon	2	18.2	-	-	4	36	-	-	5	46	-	-	-	-	-	-	-	-	11	100
C19-20	Rectum	5	17.2	1	3.4	2	6.9	1	3.4	5	17	3	10	12	41	-	-	-	-	29	100
C21	Anus & Anal Canal	-	-	1	33	-	-	-	-	1	33	1	33	-	-	-	-	-	-	3	100
C22	Liver	-	-	2	50	1	25	-	-	-	-	-	-	-	1	25	-	-	-	4	100
C25	Pancreas	2	20	1	10	5	50	-	-	-	-	2	20	-	-	-	-	-	-	10	100
C30-31	Nose, Sinuses etc.	1	50	1	50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C32	Larynx	9	19.1	23	49	-	-	8	17	-	-	6	13	-	-	1	2.1	-	-	47	100
C33-34	Lung etc.	-	-	92	60	17	11	-	-	2	1.3	40	26	-	-	3	1.9	-	-	154	100
C37-38	Other Thoracic Organs	-	-	1	50	1	50	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C40-41	Bone	-	-	1	50	-	-	-	-	-	-	1	50	-	-	-	-	-	-	2	100
C43	Melanoma of Skin	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C44	Other Skin	5	55.6	2	22	-	-	-	-	-	-	-	2	22	-	-	-	-	-	9	100
C47+C49	Conn. & Soft Tissue	2	25	1	13	1	13	3	38	-	-	-	-	1	13	-	-	-	-	8	100
C50	Breast	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100	-	-	-	3	100
C60	Penis	6	66.7	1	11	-	-	1	11	-	-	-	-	1	11	-	-	-	-	9	100
C61	Prostate	2	10	4	20	-	-	-	-	-	-	-	-	-	14	70	-	-	-	20	100
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100	-	-	-	2	100
C64	Kidney etc.	2	25	3	38	2	25	-	-	-	-	-	-	-	1	13	-	-	-	8	100
C67	Bladder	3	37.5	2	25	-	-	3	38	-	-	-	-	-	-	-	-	-	-	8	100
C70-72	Brain, Nervous System	-	-	1	50	-	-	-	-	-	-	1	50	-	-	-	-	-	-	2	100
C73	Thyroid	3	75	1	25	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	100
C81	Hodgkins Disease	-	-	-	-	3	60	-	-	-	-	2	40	-	-	-	-	-	-	5	100
C82-85,C96	NHL	-	-	3	5.1	40	68	-	-	1	1.7	7	12	-	-	8	14	-	-	59	100
C88	Malignn.Prol D	-	-	-	-	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	-	-	5	16	25	81	-	-	-	-	1	3	-	-	-	-	-	-	31	100
C91	Lymphoid Leuk.	-	-	-	-	13	77	-	-	-	-	4	24	-	-	-	-	-	-	17	100
C92-94	Myeloid Leukaemia	-	-	-	-	17	90	-	-	-	-	2	11	-	-	-	-	-	-	19	100
C95	LeukaemiaUns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	6	86	-	-	-	-	-	-	-	-	1	14	-	-	-	-	7	100
	All Sites	125	15	294	35	143	17	69	8.3	20	2.4	112	13	38	4.6	34	4.1	-	-	835	100

O & U: C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 6(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment_ Females (Treatment Only at RI)

ICD 10	Site	Type of Treatment																		
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	2	66.7	1	33.3	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100
C01-02	Tongue	8	30.8	6	23.1	1	3.8	10	38.5	-	-	-	-	1	3.8	-	-	26	100	
C03-06	Mouth	23	31.1	31	41.9	-	-	17	23	-	-	1	1.4	2	2.7	-	-	74	100	
C07-08	Salivary Gland	3	75	-	-	-	-	-	-	1	25	-	-	-	-	-	-	4	100	
C09	Tonsil	-	-	1	50	-	-	-	-	-	-	1	50	-	-	-	-	2	100	
C10	Oth. Oropharynx	-	-	1	33.3	-	-	-	-	-	-	2	67	-	-	-	-	3	100	
C11	Nasopharynx	-	-	-	-	-	-	-	-	-	-	1	100	-	-	-	-	1	100	
C12-13	Hypopharynx	-	-	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100	
C15	Oesophagus	1	5.3	14	73.7	-	-	-	-	-	-	4	21	-	-	-	-	19	100	
C16	Stomach	2	25	1	12.5	1	13	-	-	3	38	-	-	1	13	-	-	8	100	
C17	Small Intestine	1	50	-	-	-	-	-	-	-	-	-	-	-	-	1	50	2	100	
C18	Colon	5	50	-	-	1	10	-	-	4	40	-	-	-	-	-	-	10	100	
C19-20	Rectum	6	30	4	20	2	10	-	-	2	10	2	10	4	20	-	-	20	100	
C21	Anus & Anal Canal	-	-	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100	
C22	Liver	-	-	-	-	1	50	-	-	-	-	1	50	-	-	-	-	2	100	
C23-24	Gallbladder etc.	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100	
C25	Pancreas	1	50	-	-	1	50	-	-	-	-	-	-	-	-	-	-	2	100	
C30-31	Nose, Sinuses etc.	1	50	1	50	-	-	-	-	-	-	-	-	-	-	-	-	2	100	
C32	Larynx	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C33-34	Lung etc.	-	-	7	41.2	6	35	-	-	-	-	4	24	-	-	-	-	17	100	
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
C40-41	Bone	2	33.3	-	-	1	17	-	-	3	50	-	-	-	-	-	-	6	100	
C43	Melanoma of Skin	2	66.7	-	-	-	-	-	-	-	-	1	33	-	-	-	-	3	100	
C44	Other Skin	9	90	-	-	-	-	1	10	-	-	-	-	-	-	-	-	10	100	
C47+C49	Conn. & Soft Tissue	-	-	1	33.3	-	-	1	33.3	-	-	-	-	1	33	-	-	3	100	
C50	Breast	12	4.9	-	-	8	3.3	-	-	23	9.4	4	1.6	77	32	120	49	244	100	
C51	Vulva	1	50	-	-	-	-	1	50	-	-	-	-	-	-	-	-	2	100	
C52	Vagina	-	-	2	66.7	-	-	-	-	-	-	1	33	-	-	-	-	3	100	
C53	Cervix Uteri	3	4.9	13	21.3	1	1.6	4	6.6	-	-	39	64	1	1.6	-	-	61	100	
C54	Corpus Uteri	5	31.2	1	6.2	-	-	8	50	-	-	-	-	2	13	-	-	16	100	
C55	Uterus Unspecified	2	66.7	1	33.3	-	-	-	-	-	-	-	-	-	-	-	-	3	100	
C56	Ovary etc.	4	9.8	-	-	7	17	-	-	28	68	-	-	2	4.9	-	-	41	100	
C64	Kidney etc.	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100	
C70-72	Brain, Nervous System	-	-	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100	
C73	Thyroid	26	78.8	5	15.2	-	-	1	3	-	-	-	-	-	-	1	3	33	100	
C81	Hodgkins Disease	-	-	-	-	2	50	-	-	-	-	2	50	-	-	-	-	4	100	
C82-85,C96	NHL	-	-	2	5.9	27	79	-	-	-	-	3	8.8	-	-	2	5.9	34	100	
C90	Multiple Myeloma	-	-	1	5.6	17	94	-	-	-	-	-	-	-	-	-	-	18	100	
C91	Lymphoid Leuk.	-	-	-	-	10	91	-	-	-	-	1	9.1	-	-	-	-	11	100	
C92-94	Myeloid Leukaemia	-	-	-	-	25	96	-	-	-	-	1	3.8	-	-	-	-	26	100	
C95	LeukaemiaUns	-	-	-	-	1	100	-	-	-	-	-	-	-	-	-	-	1	100	
O&U	Other and Uns	1	50	-	-	-	-	-	-	-	-	1	50	-	-	-	-	2	100	
	All Sites	123	17	97	13.4	112	16	43	5.9	64	8.9	69	9.5	91	13	124	17	723	100	

Table 7(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment Males (Treatment Only at RI)

ICD 10	Site	Type of Treatment													
		Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	60	4	40	-	-	-	-	-	-	-	-	10	100
C01-02	Tongue	58	52.7	42	38.2	10	9.1	-	-	-	-	-	-	110	100
C03-06	Mouth	66	46.2	66	46.2	11	7.7	-	-	-	-	-	-	143	100
C07-08	Salivary Gland	3	37.5	5	62.5	-	-	-	-	-	-	-	-	8	100
C09	Tonsil	-	-	8	66.7	4	33.3	-	-	-	-	-	-	12	100
C10	Oth. Oropharynx	1	1.9	39	72.2	14	25.9	-	-	-	-	-	-	54	100
C11	Nasopharynx	-	-	7	53.8	6	46.2	-	-	-	-	-	-	13	100
C12-13	Hypopharynx	5	7.8	42	65.6	17	26.6	-	-	-	-	-	-	64	100
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	2	5	35	87.5	3	7.5	-	-	-	-	-	-	40	100
C16	Stomach	20	43.5	11	23.9	14	30.4	1	2.2	-	-	-	-	46	100
C17	Small Intestine	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C18	Colon	7	43.8	-	-	9	56.2	-	-	-	-	-	-	16	100
C19-20	Rectum	23	37.1	17	27.4	22	35.5	-	-	-	-	-	-	62	100
C21	Anus & Anal Canal	1	20	2	40	2	40	-	-	-	-	-	-	5	100
C22	Liver	-	-	2	50	1	25	-	-	1	25	-	-	4	100
C25	Pancreas	2	16.7	3	25	7	58.3	-	-	-	-	-	-	12	100
C30-31	Nose, Sinuses etc.	1	50	1	50	-	-	-	-	-	-	-	-	2	100
C32	Larynx	17	27.9	37	60.7	6	9.8	-	-	1	1.6	-	-	61	100
C33-34	Lung etc.	2	1	132	67.3	59	30.1	-	-	3	1.5	-	-	196	100
C37-38	Other Thoracic Organs	-	-	1	50	1	50	-	-	-	-	-	-	2	100
C40-41	Bone	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C43	Melanoma of Skin	2	100	-	-	-	-	-	-	-	-	-	-	2	100
C44	Other Skin	7	53.8	4	30.8	2	15.4	-	-	-	-	-	-	13	100
C47+C49	Conn. & Soft Tissue	6	46.2	5	38.5	2	15.4	-	-	-	-	-	-	13	100
C50	Breast	2	18.2	3	27.3	3	27.3	3	27	-	-	-	-	11	100
C60	Penis	8	66.7	3	25	1	8.3	-	-	-	-	-	-	12	100
C61	Prostate	2	6.9	10	34.5	3	10.3	12	41	2	6.9	-	-	29	100
C62	Testis	1	33.3	-	-	-	-	2	67	-	-	-	-	3	100
C64	Kidney etc.	2	25	3	37.5	2	25	-	-	1	13	-	-	8	100
C67	Bladder	6	54.5	5	45.5	-	-	-	-	-	-	-	-	11	100
C70-72	Brain, Nervous System	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C73	Thyroid	3	75	1	25	-	-	-	-	-	-	-	-	4	100
C81	Hodgkins Disease	-	-	2	28.6	5	71.4	-	-	-	-	-	-	7	100
C82-85,C96	NHL	1	1.5	10	14.9	48	71.6	-	-	8	12	-	-	67	100
C88	Malignn.Prol D	-	-	-	-	2	100	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	-	-	6	18.8	26	81.2	-	-	-	-	-	-	32	100
C91	Lymphoid Leuk.	-	-	4	19	17	81	-	-	-	-	-	-	21	100
C92-94	Myeloid Leukaemia	-	-	2	9.5	19	90.5	-	-	-	-	-	-	21	100
O&U	Other and Uns	1	11.1	7	77.8	1	11.1	-	-	-	-	-	-	9	100
	All Sites	255	22.5	523	46.2	319	28.2	18	1.6	16	1.4	-	-	1131	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 7(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment-Females (Treatment Only at RI)

ICD 10	Site	Type of Treatment													
		Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100
C01-02	Tongue	19	50	17	44.7	2	5.3	-	-	-	-	-	-	38	100
C03-06	Mouth	42	43.8	51	53.1	3	3.1	-	-	-	-	-	-	96	100
C07-08	Salivary Gland	4	80	-	-	1	20	-	-	-	-	-	-	5	100
C09	Tonsil	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C10	Oth. Oropharynx	-	-	3	60	2	40	-	-	-	-	-	-	5	100
C11	Nasopharynx	-	-	1	50	1	50	-	-	-	-	-	-	2	100
C12-13	Hypopharynx	-	-	1	100	-	-	-	-	-	-	-	-	1	100
C15	Oesophagus	1	4.3	18	78.3	4	17.4	-	-	-	-	-	-	23	100
C16	Stomach	6	46.2	2	15.4	5	38.5	-	-	-	-	-	-	13	100
C17	Small Intestine	1	50	-	-	-	-	1	50	-	-	-	-	2	100
C18	Colon	9	64.3	-	-	5	35.7	-	-	-	-	-	-	14	100
C19-20	Rectum	12	37.5	10	31.2	10	31.2	-	-	-	-	-	-	32	100
C21	Anus & Anal Canal	-	-	2	100	-	-	-	-	-	-	-	-	2	100
C22	Liver	-	-	1	33.3	2	66.7	-	-	-	-	-	-	3	100
C23-24	Gallbladder etc.	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C25	Pancreas	1	50	-	-	1	50	-	-	-	-	-	-	2	100
C30-31	Nose, Sinuses etc.	1	50	1	50	-	-	-	-	-	-	-	-	2	100
C33-34	Lung etc.	-	-	11	52.4	10	47.6	-	-	-	-	-	-	21	100
C40-41	Bone	5	55.6	-	-	4	44.4	-	-	-	-	-	-	9	100
C43	Melanoma of Skin	2	50	1	25	1	25	-	-	-	-	-	-	4	100
C44	Other Skin	10	90.9	1	9.1	-	-	-	-	-	-	-	-	11	100
C47+C49	Conn. & Soft Tissue	2	33.3	3	50	1	16.7	-	-	-	-	-	-	6	100
C50	Breast	200	29.6	152	22.5	204	30.2	120	18	-	-	-	-	676	100
C51	Vulva	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100
C52	Vagina	-	-	3	75	1	25	-	-	-	-	-	-	4	100
C53	Cervix Uteri	8	7.5	57	53.8	41	38.7	-	-	-	-	-	-	106	100
C54	Corpus Uteri	15	53.6	11	39.3	2	7.1	-	-	-	-	-	-	28	100
C55	Uterus Unspecified	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100
C56	Ovary etc.	34	46.6	2	2.7	37	50.7	-	-	-	-	-	-	73	100
C64	Kidney etc.	2	100	-	-	-	-	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	-	-	1	100	-	-	-	-	-	-	-	-	1	100
C73	Thyroid	28	80	6	17.1	-	-	1	2.9	-	-	-	-	35	100
C81	Hodgkins Disease	-	-	2	33.3	4	66.7	-	-	-	-	-	-	6	100
C82-85,C96	NHL	-	-	5	13.5	30	81.1	-	-	2	5.4	-	-	37	100
C90	Multiple Myeloma	-	-	1	5.6	17	94.4	-	-	-	-	-	-	18	100
C91	Lymphoid Leuk.	-	-	1	8.3	11	91.7	-	-	-	-	-	-	12	100
C92-94	Myeloid Leukaemia	-	-	1	3.7	26	96.3	-	-	-	-	-	-	27	100
C95	LeukaemiaUns	-	-	-	-	1	100	-	-	-	-	-	-	1	100
O&U	Other and Uns	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	3	100
	All Sites	410	30.8	371	27.8	428	32.1	122	9.2	2	0.2	-	-	1333	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 8(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment status at Reporting Institution (Excluding the Cancers Previously Treated)-Males

ICD 10	Sites	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	8	80	2	20	-	-	-	-	-	-	10	100
C01-02	Tongue	71	75.5	20	21.3	-	-	3	3.2	-	-	94	100
C03-06	Mouth	99	76.2	30	23.1	-	-	1	0.8	-	-	130	100
C07-08	Salivary Gland	7	70	3	30	-	-	-	-	-	-	10	100
C09	Tonsil	8	100	-	-	-	-	-	-	-	-	8	100
C10	Oth. Oropharynx	39	79.6	8	16.3	-	-	2	4.1	-	-	49	100
C11	Nasopharynx	8	88.9	1	11.1	-	-	-	-	-	-	9	100
C12-13	Hypopharynx	45	70.3	15	23.4	-	-	4	6.2	-	-	64	100
C15	Oesophagus	36	52.9	28	41.2	-	-	4	5.9	-	-	68	100
C16	Stomach	35	38.5	52	57.1	-	-	4	4.4	-	-	91	100
C17	Small Intestine	-	-	1	100	-	-	-	-	-	-	1	100
C18	Colon	11	44	10	40	-	-	4	16	-	-	25	100
C19-20	Rectum	29	55.8	21	40.4	-	-	2	3.8	-	-	52	100
C21	Anus & Anal Canal	3	100	-	-	-	-	-	-	-	-	3	100
C22	Liver	4	10	35	87.5	-	-	1	2.5	-	-	40	100
C23-24	Gallbladder etc.	-	-	5	100	-	-	-	-	-	-	5	100
C25	Pancreas	10	34.5	18	62.1	-	-	1	3.4	-	-	29	100
C30-31	Nose, Sinuses etc.	2	50	2	50	-	-	-	-	-	-	4	100
C32	Larynx	47	61.8	28	36.8	-	-	1	1.3	-	-	76	100
C33-34	Lung etc.	154	39.3	199	50.8	2	0.5	37	9.4	-	-	392	100
C37-38	Other Thoracic Organs	2	100	-	-	-	-	-	-	-	-	2	100
C40-41	Bone	2	50	2	50	-	-	-	-	-	-	4	100
C43	Melanoma of Skin	2	50	2	50	-	-	-	-	-	-	4	100
C44	Other Skin	9	81.8	2	18.2	-	-	-	-	-	-	11	100
C47+C49	Conn. & Soft Tissue	8	61.5	5	38.5	-	-	-	-	-	-	13	100
C50	Breast	3	100	-	-	-	-	-	-	-	-	3	100
C60	Penis	9	90	1	10	-	-	-	-	-	-	10	100
C61	Prostate	20	54.1	14	37.8	-	-	3	8.1	-	-	37	100
C62	Testis	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C64	Kidney etc.	8	61.5	5	38.5	-	-	-	-	-	-	13	100
C67	Bladder	8	42.1	11	57.9	-	-	-	-	-	-	19	100
C70-72	Brain, Nervous System	2	25	6	75	-	-	-	-	-	-	8	100
C73	Thyroid	4	66.7	2	33.3	-	-	-	-	-	-	6	100
C81	Hodgkins Disease	5	55.6	2	22.2	-	-	2	22.2	-	-	9	100
C82-85,C96	NHL	59	67	24	27.3	-	-	5	5.7	-	-	88	100
C88	Malignn.Prol D	2	100	-	-	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	31	73.8	6	14.3	-	-	5	11.9	-	-	42	100
C91	Lymphoid Leuk.	17	54.8	9	29	-	-	5	16.1	-	-	31	100
C92-94	Myeloid Leukaemia	19	43.2	17	38.6	-	-	8	18.2	-	-	44	100
C95	LeukaemiaUns	-	-	2	100	-	-	-	-	-	-	2	100
O&U	Other and Uns	7	13.7	42	82.4	-	-	2	3.9	-	-	51	100
	All Sites	835	53.5	631	40.4	2	0.1	94	6	-	-	1562	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

TABLE 8(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment status at Reporting Institution (Excluding the Cancers Previously Treated)-Females

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	43	4	57.1	-	-	-	-	-	-	7	100
C01-02	Tongue	26	72	9	25	-	-	1	2.8	-	-	36	100
C03-06	Mouth	74	74	24	24	-	-	2	2	-	-	100	100
C07-08	Salivary Gland	4	67	2	33.3	-	-	-	-	-	-	6	100
C09	Tonsil	2	67	1	33.3	-	-	-	-	-	-	3	100
C10	Oth. Oropharynx	3	75	-	-	-	-	1	25	-	-	4	100
C11	Nasopharynx	1	25	3	75	-	-	-	-	-	-	4	100
C12-13	Hypopharynx	1	50	1	50	-	-	-	-	-	-	2	100
C15	Oesophagus	19	49	20	51.3	-	-	-	-	-	-	39	100
C16	Stomach	8	25	20	62.5	-	-	4	12.5	-	-	32	100
C17	Small Intestine	2	100	-	-	-	-	-	-	-	-	2	100
C18	Colon	10	39	13	50	-	-	3	11.5	-	-	26	100
C19-20	Rectum	20	56	15	41.7	-	-	1	2.8	-	-	36	100
C21	Anus & Anal Canal	2	100	-	-	-	-	-	-	-	-	2	100
C22	Liver	2	13	13	86.7	-	-	-	-	-	-	15	100
C23-24	Gallbladder etc.	1	10	9	90	-	-	-	-	-	-	10	100
C25	Pancreas	2	15	11	84.6	-	-	-	-	-	-	13	100
C30-31	Nose, Sinuses etc.	2	50	2	50	-	-	-	-	-	-	4	100
C32	Larynx	-	-	1	100	-	-	-	-	-	-	1	100
C33-34	Lung etc.	17	31	38	69.1	-	-	-	-	-	-	55	100
C37-38	Other Thoracic Organs	-	-	1	100	-	-	-	-	-	-	1	100
C40-41	Bone	6	86	1	14.3	-	-	-	-	-	-	7	100
C43	Melanoma of Skin	3	50	3	50	-	-	-	-	-	-	6	100
C44	Other Skin	10	83	2	16.7	-	-	-	-	-	-	12	100
C47+C49	Conn. & Soft Tissue	3	33	6	66.7	-	-	-	-	-	-	9	100
C50	Breast	244	74	63	19.1	1	0.3	21	6.4	-	-	329	100
C51	Vulva	2	50	2	50	-	-	-	-	-	-	4	100
C52	Vagina	3	75	1	25	-	-	-	-	-	-	4	100
C53	Cervix Uteri	61	71	22	25.6	1	1.2	2	2.3	-	-	86	100
C54	Corpus Uteri	16	76	5	23.8	-	-	-	-	-	-	21	100
C55	Uterus Unspecified	3	100	-	-	-	-	-	-	-	-	3	100
C56	Ovary etc.	41	53	33	42.9	-	-	3	3.9	-	-	77	100
C57	Other Female Genital	-	-	1	100	-	-	-	-	-	-	1	100
C64	Kidney etc.	2	40	3	60	-	-	-	-	-	-	5	100
C67	Bladder	-	-	1	100	-	-	-	-	-	-	1	100
C69	Eye	-	-	1	100	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	1	20	4	80	-	-	-	-	-	-	5	100
C73	Thyroid	33	72	13	28.3	-	-	-	-	-	-	46	100
C81	Hodgkins Disease	4	67	2	33.3	-	-	-	-	-	-	6	100
C82-85, C96	NHL	34	71	11	22.9	-	-	3	6.2	-	-	48	100
C90	Multiple Myeloma	18	72	6	24	-	-	1	4	-	-	25	100
C91	Lymphoid Leuk.	11	92	1	8.3	-	-	-	-	-	-	12	100
C92-94	Myeloid Leukaemia	26	67	10	25.6	-	-	3	7.7	-	-	39	100
C95	LeukaemiaUns	1	33	2	66.7	-	-	-	-	-	-	3	100
O&U	Other and Uns	2	8.7	21	91.3	-	-	-	-	-	-	23	100
	All Sites	723	62	401	34.2	2	0.2	45	3.8	-	-	1171	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**Table 9(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and intention to treat at Reporting institution
(Excluding the cancers previously treated)-Males**

ICD 10	Sites	Radical		Palliative		Pain relief only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	75	2	25	-	-	-	-	-	-	8	100
C01-02	Tongue	58	81.7	13	18.3	-	-	-	-	-	-	71	100
C03-06	Mouth	68	68.7	30	30.3	1	1	-	-	-	-	99	100
C07-08	Salivary Gland	3	42.9	4	57.1	-	-	-	-	-	-	7	100
C09	Tonsil	7	87.5	1	12.5	-	-	-	-	-	-	8	100
C10	Oth. Oropharynx	27	69.2	12	30.8	-	-	-	-	-	-	39	100
C11	Nasopharynx	6	75	2	25	-	-	-	-	-	-	8	100
C12-13	Hypopharynx	23	51.1	22	48.9	-	-	-	-	-	-	45	100
C15	Oesophagus	3	8.3	33	91.7	-	-	-	-	-	-	36	100
C16	Stomach	20	57.1	15	42.9	-	-	-	-	-	-	35	100
C18	Colon	9	81.8	2	18.2	-	-	-	-	-	-	11	100
C19-20	Rectum	26	89.7	3	10.3	-	-	-	-	-	-	29	100
C21	Anus & Anal Canal	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C22	Liver	1	25	3	75	-	-	-	-	-	-	4	100
C25	Pancreas	2	20	7	70	-	-	1	10	-	-	10	100
C30-31	Nose, Sinuses etc.	-	-	2	100	-	-	-	-	-	-	2	100
C32	Larynx	39	83	8	17	-	-	-	-	-	-	47	100
C33-34	Lung etc.	27	17.5	126	81.8	-	-	1	0.6	-	-	154	100
C37-38	Other Thoracic Organs	1	50	1	50	-	-	-	-	-	-	2	100
C40-41	Bone	1	50	1	50	-	-	-	-	-	-	2	100
C43	Melanoma of Skin	2	100	-	-	-	-	-	-	-	-	2	100
C44	Other Skin	7	77.8	2	22.2	-	-	-	-	-	-	9	100
C47+C49	Conn. & Soft Tissue	6	75	2	25	-	-	-	-	-	-	8	100
C50	Breast	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C60	Penis	8	88.9	1	11.1	-	-	-	-	-	-	9	100
C61	Prostate	12	60	7	35	-	-	1	5	-	-	20	100
C62	Testis	2	100	-	-	-	-	-	-	-	-	2	100
C64	Kidney etc.	3	37.5	5	62.5	-	-	-	-	-	-	8	100
C67	Bladder	5	62.5	3	37.5	-	-	-	-	-	-	8	100
C70-72	Brain, Nervous System	2	100	-	-	-	-	-	-	-	-	2	100
C73	Thyroid	3	75	1	25	-	-	-	-	-	-	4	100
C81	Hodgkins Disease	5	100	-	-	-	-	-	-	-	-	5	100
C82-85,C96	NHL	56	94.9	3	5.1	-	-	-	-	-	-	59	100
C88	Malignn.Prol D	2	100	-	-	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	29	93.5	2	6.5	-	-	-	-	-	-	31	100
C91	Lymphoid Leuk.	15	88.2	2	11.8	-	-	-	-	-	-	17	100
C92-94	Myeloid Leukaemia	11	57.9	8	42.1	-	-	-	-	-	-	19	100
O&U	Other and Uns	2	28.6	5	71.4	-	-	-	-	-	-	7	100
	All Sites	501	60	330	39.5	1	0.1	3	0.4	-	-	835	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 9(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and intention to treat at Reporting institution (Excluding the cancers previously treated)-Females

ICD 10	Sites	Radical		Palliative		Pain relief only		Total	
		#	%	#	%	#	%	#	%
C00	Lip	2	66.7	1	33.3	-	-	3	100
C01-02	Tongue	18	69.2	8	30.8	-	-	26	100
C03-06	Mouth	43	58.1	31	41.9	-	-	74	100
C07-08	Salivary Gland	4	100	-	-	-	-	4	100
C09	Tonsil	1	50	1	50	-	-	2	100
C10	Oth. Oropharynx	1	33.3	2	66.7	-	-	3	100
C11	Nasopharynx	1	100	-	-	-	-	1	100
C12-13	Hypopharynx	-	-	1	100	-	-	1	100
C15	Oesophagus	3	15.8	16	84.2	-	-	19	100
C16	Stomach	6	75	2	25	-	-	8	100
C17	Small Intestine	2	100	-	-	-	-	2	100
C18	Colon	7	70	3	30	-	-	10	100
C19-20	Rectum	14	70	6	30	-	-	20	100
C21	Anus & Anal Canal	-	-	2	100	-	-	2	100
C22	Liver	-	-	2	100	-	-	2	100
C23-24	Gallbladder etc.	1	100	-	-	-	-	1	100
C25	Pancreas	-	-	2	100	-	-	2	100
C30-31	Nose, Sinuses etc.	2	100	-	-	-	-	2	100
C33-34	Lung etc.	3	17.6	14	82.4	-	-	17	100
C40-41	Bone	6	100	-	-	-	-	6	100
C43	Melanoma of Skin	2	66.7	1	33.3	-	-	3	100
C44	Other Skin	10	100	-	-	-	-	10	100
C45	Mesothelioma	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	66.7	1	33.3	-	-	3	100
C50	Breast	208	85.2	36	14.8	-	-	244	100
C51	Vulva	2	100	-	-	-	-	2	100
C52	Vagina	-	-	3	100	-	-	3	100
C53	Cervix Uteri	47	77	13	21.3	1	2	61	100
C54	Corpus Uteri	15	93.8	1	6.2	-	-	16	100
C55	Uterus Unspecified	2	66.7	1	33.3	-	-	3	100
C56	Ovary etc.	37	90.2	3	7.3	1	2	41	100
C64	Kidney etc.	2	100	-	-	-	-	2	100
C70-72	Brain, Nervous System	1	100	-	-	-	-	1	100
C73	Thyroid	29	87.9	4	12.1	-	-	33	100
C81	Hodgkins Disease	4	100	-	-	-	-	4	100
C82-85,C96	NHL	28	82.4	6	17.6	-	-	34	100
C90	Multiple Myeloma	17	94.4	1	5.6	-	-	18	100
C91	Lymphoid Leuk.	9	81.8	2	18.2	-	-	11	100
C92-94	Myeloid Leukaemia	16	61.5	10	38.5	-	-	26	100
C95	LeukaemiaUns	1	100	-	-	-	-	1	100
O&U	Other and Uns	1	50	1	50	-	-	2	100
	All Sites	547	75.7	174	24.1	2	0	723	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

DEMOGRAPHIC INFORMATION

Table 10(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and marital status-Males

ICD 10	Sites	Unmarried		Married		Widowed		Divorced		Others		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	12	85.7	1	7.1	1	7.1	-	-	14	100
C01-02	Tongue	4	3.4	105	90.5	3	2.6	-	-	4	3.4	116	100
C03-06	Mouth	3	1.8	152	91.6	3	1.8	-	-	8	4.8	166	100
C07-08	Salivary Gland	-	-	12	92.3	1	7.7	-	-	-	-	13	100
C09	Tonsil	1	11.1	8	88.9	-	-	-	-	-	-	9	100
C10	Oth. Oropharynx	-	-	55	93.2	3	5.1	-	-	1	1.7	59	100
C11	Nasopharynx	-	-	11	100	-	-	-	-	-	-	11	100
C12-13	Hypopharynx	1	1.3	73	97.3	-	-	1	1.3	-	-	75	100
C15	Oesophagus	5	6.2	74	91.4	1	1.2	-	-	1	1.2	81	100
C16	Stomach	1	0.7	128	94.8	3	2.2	1	0.7	2	1.5	135	100
C17	Small Intestine	-	-	4	100	-	-	-	-	-	-	4	100
C18	Colon	3	4.8	57	91.9	1	1.6	-	-	1	1.6	62	100
C19-20	Rectum	1	1.2	78	90.7	1	1.2	-	-	6	7	86	100
C21	Anus & Anal Canal	-	-	2	66.7	1	33.3	-	-	-	-	3	100
C22	Liver	1	1.9	49	90.7	1	1.9	-	-	3	5.6	54	100
C23-24	Gallbladder etc.	1	14.3	4	57.1	1	14.3	-	-	1	14	7	100
C25	Pancreas	2	4.8	38	90.5	-	-	-	-	2	4.8	42	100
C30-31	Nose, Sinuses etc.	-	-	8	100	-	-	-	-	-	-	8	100
C32	Larynx	-	-	98	93.3	1	1	-	-	6	5.7	105	100
C33-34	Lung etc.	6	1.4	408	92.7	6	1.4	1	0.2	19	4.3	440	100
C37-38	Other Thoracic Organs	1	50	-	-	1	50	-	-	-	-	2	100
C40-41	Bone	7	43.8	8	50	-	-	-	-	1	6.2	16	100
C43	Melanoma of Skin	-	-	13	86.7	1	6.7	-	-	1	6.7	15	100
C44	Other Skin	-	-	27	96.4	1	3.6	-	-	-	-	28	100
C47+C49	Conn. & Soft Tissue	5	17.9	21	75	1	3.6	-	-	1	3.6	28	100
C50	Breast	-	-	8	88.9	-	-	-	-	1	11	9	100
C60	Penis	-	-	11	91.7	-	-	-	-	1	8.3	12	100
C61	Prostate	2	2.5	74	91.4	2	2.5	-	-	3	3.7	81	100
C62	Testis	2	28.6	5	71.4	-	-	-	-	-	-	7	100
C63	Other Male Genital	-	-	1	100	-	-	-	-	-	-	1	100
C64	Kidney etc.	1	4	21	84	1	4	-	-	1	4	25	100
C67	Bladder	2	3.6	49	87.5	1	1.8	1	1.8	3	5.4	56	100
C69	Eye	-	-	2	100	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	6	15	31	77.5	1	2.5	-	-	2	5	40	100
C73	Thyroid	-	-	19	95	-	-	-	-	1	5	20	100
C81	Hodgkins Disease	2	15.4	11	84.6	-	-	-	-	-	-	13	100
C82-85,C96	NHL	4	3.4	106	91.4	3	2.6	-	-	3	2.6	116	100
C88	Maliglmn.Prol D	-	-	2	100	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	-	-	48	96	-	-	-	-	2	4	50	100
C91	Lymphoid Leuk.	16	43.2	19	51.4	-	-	-	-	2	5.4	37	100
C92-94	Myeloid Leukaemia	5	9.8	40	78.4	2	3.9	-	-	4	7.8	51	100
C95	LeukaemiaUns	2	66.7	1	33.3	-	-	-	-	-	-	3	100
O&U	Other and Uns	-	-	53	91.4	2	3.4	-	-	3	5.2	58	100
	All Sites	84	3.9	1946	90	43	2	5	0.2	83	3.8	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 10(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and marital status-Females

ICD 10	Sites	Unmarried		Married		Widowed		Divorced		Seperated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	4	50	2	25	-	-	-	-	-	-	2	25	8	100
C01-02	Tongue	1	2	34	66.7	14	27.5	-	-	-	-	-	-	2	3.9	51	100
C03-06	Mouth	1	0.9	62	53	49	41.9	1	0.9	-	-	-	-	4	3.4	117	100
C07-08	Salivary Gland	-	-	4	36.4	5	45.5	-	-	-	-	-	-	2	18	11	100
C09	Tonsil	1	20	1	20	3	60	-	-	-	-	-	-	-	-	5	100
C10	Oth. Oropharynx	-	-	4	100	-	-	-	-	-	-	-	-	-	-	4	100
C11	Nasopharynx	-	-	2	40	2	40	-	-	1	20	-	-	-	-	5	100
C12-13	Hypopharynx	-	-	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C15	Oesophagus	5	10.6	22	46.8	16	34	1	2.1	-	-	-	-	3	6.4	47	100
C16	Stomach	1	2.4	32	76.2	7	16.7	1	2.4	-	-	-	-	1	2.4	42	100
C17	Small Intestine	-	-	3	60	2	40	-	-	-	-	-	-	-	-	5	100
C18	Colon	2	4	26	52	17	34	1	2	1	2	-	-	3	6	50	100
C19-20	Rectum	2	3.1	35	53.8	23	35.4	1	1.5	-	-	-	-	4	6.2	65	100
C21	Anus & Anal Canal	-	-	1	50	1	50	-	-	-	-	-	-	-	-	2	100
C22	Liver	-	-	15	71.4	5	23.8	-	-	-	-	-	-	1	4.8	21	100
C23-24	Gallbladder etc.	1	7.1	11	78.6	2	14.3	-	-	-	-	-	-	-	-	14	100
C25	Pancreas	-	-	17	73.9	5	21.7	-	-	-	-	-	-	1	4.3	23	100
C30-31	Nose, Sinuses etc.	1	11.1	5	55.6	1	11.1	1	11	-	-	-	-	1	11	9	100
C32	Larynx	-	-	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C33-34	Lung etc.	-	-	41	65.1	18	28.6	-	-	-	-	-	-	4	6.3	63	100
C37-38	Other Thoracic Organs	-	-	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C40-41	Bone	3	25	8	66.7	-	-	1	8.3	-	-	-	-	-	-	12	100
C43	Melanoma of Skin	2	20	6	60	2	20	-	-	-	-	-	-	-	-	10	100
C44	Other Skin	1	5.3	10	52.6	6	31.6	-	-	-	-	-	-	2	11	19	100
C47+C49	Conn. & Soft Tissue	1	7.7	7	53.8	4	30.8	1	7.7	-	-	-	-	-	-	13	100
C50	Breast	23	4.3	399	75.1	84	15.8	4	0.8	1	0.2	-	-	20	3.8	531	100
C51	Vulva	-	-	1	25	3	75	-	-	-	-	-	-	-	-	4	100
C52	Vagina	-	-	5	71.4	1	14.3	-	-	-	-	-	-	1	14	7	100
C53	Cervix Uteri	1	0.7	93	68.9	37	27.4	1	0.7	-	-	1	0.7	2	1.5	135	100
C54	Corpus Uteri	2	3.7	36	66.7	13	24.1	-	-	1	1.9	-	-	2	3.7	54	100
C55	Uterus Unspecified	-	-	5	100	-	-	-	-	-	-	-	-	-	-	5	100
C56	Ovary etc.	6	4.7	88	68.8	26	20.3	1	0.8	-	-	-	-	7	5.5	128	100
C57	Other Female Genital	-	-	3	100	-	-	-	-	-	-	-	-	-	-	3	100
C64	Kidney etc.	-	-	5	100	-	-	-	-	-	-	-	-	-	-	5	100
C67	Bladder	1	14.3	3	42.9	2	28.6	-	-	-	-	-	-	1	14	7	100
C69	Eye	-	-	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	2	11.1	15	83.3	-	-	-	-	-	-	-	-	1	5.6	18	100
C73	Thyroid	6	7.9	49	64.5	14	18.4	2	2.6	-	-	-	-	5	6.6	76	100
C74	Adrenal Gland	-	-	1	100	-	-	-	-	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	3	37.5	5	62.5	-	-	-	-	-	-	-	-	-	-	8	100
C82-85,C96	NHL	4	6.7	39	65	12	20	-	-	-	-	-	-	5	8.3	60	100
C90	Multiple Myeloma	2	6.9	16	55.2	11	37.9	-	-	-	-	-	-	-	-	29	100
C91	Lymphoid Leuk.	9	60	2	13.3	4	26.7	-	-	-	-	-	-	-	-	15	100
C92-94	Myeloid Leukaemia	2	4.5	33	75	6	13.6	1	2.3	-	-	-	-	2	4.5	44	100
C95	LeukaemiaUns	-	-	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100
O&U	Other and Uns	2	7.4	20	74.1	5	18.5	-	-	-	-	-	-	-	-	27	100
	All Sites	85	4.8	1178	66.8	403	22.8	17	1	4	0.2	1	0.1	76	4.3	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 11(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Mother Tongue-Males

ICD 10	Sites	Malayalam		Kannada		Tamil		Oriya		Konkani		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	14	100	-	-	-	-	-	-	-	-	-	-	-	-	14	100
C01-02	Tongue	114	98.3	-	-	-	-	1	0.9	-	-	-	-	1	0.9	116	100
C03-06	Mouth	161	97	1	0.6	-	-	1	0.6	-	-	-	-	3	1.8	166	100
C07-08	Salivary Gland	13	100	-	-	-	-	-	-	-	-	-	-	-	-	13	100
C09	Tonsil	9	100	-	-	-	-	-	-	-	-	-	-	-	-	9	100
C10	Oth. Oropharynx	57	96.6	2	3.4	-	-	-	-	-	-	-	-	-	-	59	100
C11	Nasopharynx	11	100	-	-	-	-	-	-	-	-	-	-	-	-	11	100
C12-13	Hypopharynx	75	100	-	-	-	-	-	-	-	-	-	-	-	-	75	100
C15	Oesophagus	80	98.8	-	-	1	1.2	-	-	-	-	-	-	-	-	81	100
C16	Stomach	133	98.5	-	-	1	0.7	-	-	1	0.7	-	-	-	-	135	100
C17	Small Intestine	4	100	-	-	-	-	-	-	-	-	-	-	-	-	4	100
C18	Colon	60	96.8	1	1.6	-	-	-	-	-	-	1	1.6	-	-	62	100
C19-20	Rectum	86	100	-	-	-	-	-	-	-	-	-	-	-	-	86	100
C21	Anus & Anal Canal	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
C22	Liver	54	100	-	-	-	-	-	-	-	-	-	-	-	-	54	100
C23-24	Gallbladder etc.	7	100	-	-	-	-	-	-	-	-	-	-	-	-	7	100
C25	Pancreas	40	95.2	-	-	-	-	-	-	-	-	-	-	2	4.8	42	100
C30-31	Nose, Sinuses etc.	8	100	-	-	-	-	-	-	-	-	-	-	-	-	8	100
C32	Larynx	100	95.2	1	1	1	1	-	-	-	-	1	1	2	1.9	105	100
C33-34	Lung etc.	435	98.9	1	0.2	-	-	-	-	-	-	1	0.2	3	0.7	440	100
C37-38	Other Thoracic Organs	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C40-41	Bone	16	100	-	-	-	-	-	-	-	-	-	-	-	-	16	100
C43	Melanoma of Skin	14	93.3	-	-	-	-	-	-	-	-	-	-	1	6.7	15	100
C44	Other Skin	28	100	-	-	-	-	-	-	-	-	-	-	-	-	28	100
C47+C49	Conn. & Soft Tissue	27	96.4	-	-	-	-	-	-	-	-	1	3.6	-	-	28	100
C50	Breast	9	100	-	-	-	-	-	-	-	-	-	-	-	-	9	100
C60	Penis	11	91.7	-	-	-	-	-	-	-	-	1	8.3	-	-	12	100
C61	Prostate	81	100	-	-	-	-	-	-	-	-	-	-	-	-	81	100
C62	Testis	7	100	-	-	-	-	-	-	-	-	-	-	-	-	7	100
C63	Other Male Genital	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100
C64	Kidney etc.	24	96	1	4	-	-	-	-	-	-	-	-	-	-	25	100
C67	Bladder	55	98.2	-	-	-	-	-	-	-	-	-	-	1	1.8	56	100
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	40	100	-	-	-	-	-	-	-	-	-	-	-	-	40	100
C73	Thyroid	19	95	-	-	-	-	-	-	-	-	-	-	1	5	20	100
C81	Hodgkins Disease	12	92.3	-	-	1	7.7	-	-	-	-	-	-	-	-	13	100
C82-85,C96	NHL	114	98.3	-	-	-	-	-	-	-	-	1	0.9	1	0.9	116	100
C88	Maligmn.Prol D	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C90	Multiple Myeloma	50	100	-	-	-	-	-	-	-	-	-	-	-	-	50	100
C91	Lymphoid Leuk.	37	100	-	-	-	-	-	-	-	-	-	-	-	-	37	100
C92-94	Myeloid Leukaemia	51	100	-	-	-	-	-	-	-	-	-	-	-	-	51	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
O&U	Other and Uns	56	96.6	1	1.7	-	-	-	-	-	-	-	-	1	1.7	58	100
	All Sites	2125	98.3	8	0.4	4	0.2	2	0.1	1	0	6	0.3	16	0.7	2162	100

O&U:C26,C39,C48,C75,C76,C77,C78,C79,C80,C97

Table 11(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Mother Tongue-Females

ICD 10	Sites	Malayalam		Kannada		Tamil		Hindi		Telugu		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%		
C00	Lip	7	87.5	-	-	-	-	-	-	-	-	-	-	1	12.5	8	100
C01-02	Tongue	51	100	-	-	-	-	-	-	-	-	-	-	-	-	51	100
C03-06	Mouth	116	99.1	1	0.9	-	-	-	-	-	-	-	-	-	-	117	100
C07-08	Salivary Gland	11	100	-	-	-	-	-	-	-	-	-	-	-	-	11	100
C09	Tonsil	5	100	-	-	-	-	-	-	-	-	-	-	-	-	5	100
C10	Oth. Oropharynx	4	100	-	-	-	-	-	-	-	-	-	-	-	-	4	100
C11	Nasopharynx	5	100	-	-	-	-	-	-	-	-	-	-	-	-	5	100
C12-13	Hypopharynx	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
C15	Oesophagus	46	97.9	-	-	-	-	-	-	-	-	1	2	-	-	47	100
C16	Stomach	42	100	-	-	-	-	-	-	-	-	-	-	-	-	42	100
C17	Small Intestine	5	100	-	-	-	-	-	-	-	-	-	-	-	-	5	100
C18	Colon	48	96	-	-	-	-	-	-	-	-	-	-	2	4	50	100
C19-20	Rectum	65	100	-	-	-	-	-	-	-	-	-	-	-	-	65	100
C21	Anus & Anal Canal	2	100	-	-	-	-	-	-	-	-	-	-	-	-	2	100
C22	Liver	21	100	-	-	-	-	-	-	-	-	-	-	-	-	21	100
C23-24	Gallbladder etc.	14	100	-	-	-	-	-	-	-	-	-	-	-	-	14	100
C25	Pancreas	23	100	-	-	-	-	-	-	-	-	-	-	-	-	23	100
C30-31	Nose, Sinuses etc.	9	100	-	-	-	-	-	-	-	-	-	-	-	-	9	100
C32	Larynx	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
C33-34	Lung etc.	60	95.2	2	3.2	-	-	-	-	-	-	-	-	1	1.6	63	100
C37-38	Other Thoracic Organs	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100
C40-41	Bone	10	83.3	1	8.3	1	8.3	-	-	-	-	-	-	-	-	12	100
C43	Melanoma of Skin	10	100	-	-	-	-	-	-	-	-	-	-	-	-	10	100
C44	Other Skin	18	94.7	-	-	-	-	-	-	-	-	-	-	1	5.3	19	100
C47+C49	Conn. & Soft Tissue	12	92.3	-	-	-	-	-	-	-	-	-	-	1	7.7	13	100
C50	Breast	526	99.1	1	0.2	-	-	-	-	-	-	2	0	2	0.4	531	100
C51	Vulva	4	100	-	-	-	-	-	-	-	-	-	-	-	-	4	100
C52	Vagina	7	100	-	-	-	-	-	-	-	-	-	-	-	-	7	100
C53	Cervix Uteri	135	100	-	-	-	-	-	-	-	-	-	-	-	-	135	100
C54	Corpus Uteri	54	100	-	-	-	-	-	-	-	-	-	-	-	-	54	100
C55	Uterus Unspecified	5	100	-	-	-	-	-	-	-	-	-	-	-	-	5	100
C56	Ovary etc.	124	96.9	2	1.6	-	-	1	1	-	-	-	-	1	0.8	128	100
C57	Other Female Genital	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	100	-	-	-	-	-	-	-	-	-	-	-	-	5	100
C67	Bladder	7	100	-	-	-	-	-	-	-	-	-	-	-	-	7	100
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	17	94.4	1	5.6	-	-	-	-	-	-	-	-	-	-	18	100
C73	Thyroid	75	98.7	-	-	1	1.3	-	-	-	-	-	-	-	-	76	100
C74	Adrenal Gland	1	100	-	-	-	-	-	-	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	8	100	-	-	-	-	-	-	-	-	-	-	-	-	8	100
C82-85,C96	NHL	60	100	-	-	-	-	-	-	-	-	-	-	-	-	60	100
C90	Multiple Myeloma	29	100	-	-	-	-	-	-	-	-	-	-	-	-	29	100
C91	Lymphoid Leuk.	14	93.3	-	-	-	-	-	-	1	6.7	-	-	-	-	15	100
C92-94	Myeloid Leukaemia	43	97.7	-	-	-	-	-	-	-	-	-	-	1	2.3	44	100
C95	LeukaemiaUns	3	100	-	-	-	-	-	-	-	-	-	-	-	-	3	100
O&U	Other and Uns	25	92.6	-	-	-	-	1	4	-	-	1	4	-	-	27	100
	All Sites	1737	98.5	8	0.5	2	0.1	2	0	1	0.1	4	0	10	0.6	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 12(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion-Males

ICD 10	Sites	Hindu		Muslim		Christian		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	11	78.6	2	14.3	1	7.1	-	-	-	-	14	100
C01-02	Tongue	82	70.7	22	19	12	10.3	-	-	-	-	116	100
C03-06	Mouth	100	60.2	36	21.7	30	18.1	-	-	-	-	166	100
C07-08	Salivary Gland	5	38.5	8	61.5	-	-	-	-	-	-	13	100
C09	Tonsil	9	100	-	-	-	-	-	-	-	-	9	100
C10	Oth. Oropharynx	46	78	6	10.2	6	10.2	-	-	1	1.7	59	100
C11	Nasopharynx	8	72.7	3	27.3	-	-	-	-	-	-	11	100
C12-13	Hypopharynx	46	61.3	20	26.7	9	12	-	-	-	-	75	100
C15	Oesophagus	58	71.6	15	18.5	8	9.9	-	-	-	-	81	100
C16	Stomach	74	54.8	45	33.3	16	11.9	-	-	-	-	135	100
C17	Small Intestine	3	75	1	25	-	-	-	-	-	-	4	100
C18	Colon	35	56.5	23	37.1	3	4.8	-	-	1	1.6	62	100
C19-20	Rectum	53	61.6	21	24.4	10	11.6	-	-	2	2.3	86	100
C21	Anus & Anal Canal	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100
C22	Liver	34	63	17	31.5	3	5.6	-	-	-	-	54	100
C23-24	Gallbladder etc.	5	71.4	2	28.6	-	-	-	-	-	-	7	100
C25	Pancreas	21	50	16	38.1	4	9.5	-	-	1	2.4	42	100
C30-31	Nose, Sinuses etc.	3	37.5	4	50	1	12.5	-	-	-	-	8	100
C32	Larynx	64	61	27	25.7	13	12.4	-	-	1	1	105	100
C33-34	Lung etc.	239	54.3	149	33.9	50	11.4	-	-	2	0.5	440	100
C37-38	Other Thoracic Organs	1	50	-	-	1	50	-	-	-	-	2	100
C40-41	Bone	7	43.8	5	31.2	4	25	-	-	-	-	16	100
C43	Melanoma of Skin	9	60	4	26.7	1	6.7	-	-	1	6.7	15	100
C44	Other Skin	13	46.4	11	39.3	4	14.3	-	-	-	-	28	100
C47+C49	Conn. & Soft Tissue	13	46.4	14	50	1	3.6	-	-	-	-	28	100
C50	Breast	6	66.7	2	22.2	1	11.1	-	-	-	-	9	100
C60	Penis	11	91.7	-	-	-	-	1	8.3	-	-	12	100
C61	Prostate	55	67.9	22	27.2	3	3.7	-	-	1	1.2	81	100
C62	Testis	3	42.9	4	57.1	-	-	-	-	-	-	7	100
C63	Other Male Genital	1	100	-	-	-	-	-	-	-	-	1	100
C64	Kidney etc.	11	44	13	52	1	4	-	-	-	-	25	100
C67	Bladder	27	48.2	22	39.3	6	10.7	-	-	1	1.8	56	100
C69	Eye	1	50	-	-	1	50	-	-	-	-	2	100
C70-72	Brain, Nervous System	26	65	10	25	4	10	-	-	-	-	40	100
C73	Thyroid	11	55	4	20	4	20	-	-	1	5	20	100
C81	Hodgkins Disease	4	30.8	6	46.2	3	23.1	-	-	-	-	13	100
C82-85,C96	NHL	69	59.5	36	31	10	8.6	-	-	1	0.9	116	100
C88	Malignn.Prol D	-	-	1	50	1	50	-	-	-	-	2	100
C90	Multiple Myeloma	33	66	14	28	3	6	-	-	-	-	50	100
C91	Lymphoid Leuk.	24	64.9	8	21.6	5	13.5	-	-	-	-	37	100
C92-94	Myeloid Leukaemia	28	54.9	17	33.3	6	11.8	-	-	-	-	51	100
C95	LeukaemiaUns	2	66.7	1	33.3	-	-	-	-	-	-	3	100
O&U	Other and Uns	35	60.3	13	22.4	8	13.8	-	-	2	3.4	58	100
	All Sites	1287	59.5	625	28.9	234	10.8	1	0	15	0.7	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 12(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion-Females

ICD 10	Sites	Hindu		Muslim		Christian		Sikh		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	7	87.5	-	-	-	-	-	-	1	12.5	8	100
C01-02	Tongue	35	68.6	13	25.5	3	5.9	-	-	-	-	51	100
C03-06	Mouth	83	70.9	25	21.4	9	7.7	-	-	-	-	117	100
C07-08	Salivary Gland	10	90.9	1	9.1	-	-	-	-	-	-	11	100
C09	Tonsil	1	20	3	60	1	20	-	-	-	-	5	100
C10	Oth. Oropharynx	2	50	1	25	1	25	-	-	-	-	4	100
C11	Nasopharynx	2	40	1	20	2	40	-	-	-	-	5	100
C12-13	Hypopharynx	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C15	Oesophagus	29	61.7	10	21.3	7	14.9	-	-	1	2.1	47	100
C16	Stomach	22	52.4	16	38.1	4	9.5	-	-	-	-	42	100
C17	Small Intestine	2	40	3	60	-	-	-	-	-	-	5	100
C18	Colon	33	66	10	20	4	8	-	-	3	6	50	100
C19-20	Rectum	35	53.8	23	35.4	7	10.8	-	-	-	-	65	100
C21	Anus & Anal Canal	1	50	1	50	-	-	-	-	-	-	2	100
C22	Liver	14	66.7	6	28.6	1	4.8	-	-	-	-	21	100
C23-24	Gallbladder etc.	10	71.4	3	21.4	1	7.1	-	-	-	-	14	100
C25	Pancreas	14	60.9	8	34.8	1	4.3	-	-	-	-	23	100
C30-31	Nose, Sinuses etc.	6	66.7	2	22.2	1	11.1	-	-	-	-	9	100
C32	Larynx	1	33.3	2	66.7	-	-	-	-	-	-	3	100
C33-34	Lung etc.	36	57.1	22	34.9	4	6.3	-	-	1	1.6	63	100
C37-38	Other Thoracic Organs	-	-	1	100	-	-	-	-	-	-	1	100
C40-41	Bone	9	75	2	16.7	1	8.3	-	-	-	-	12	100
C43	Melanoma of Skin	5	50	3	30	2	20	-	-	-	-	10	100
C44	Other Skin	13	68.4	4	21.1	1	5.3	-	-	1	5.3	19	100
C47+C49	Conn. & Soft Tissue	8	61.5	3	23.1	2	15.4	-	-	-	-	13	100
C50	Breast	347	65.3	130	24.5	52	9.8	-	-	2	0.4	531	100
C51	Vulva	2	50	2	50	-	-	-	-	-	-	4	100
C52	Vagina	3	42.9	2	28.6	1	14.3	-	-	1	14.3	7	100
C53	Cervix Uteri	99	73.3	27	20	9	6.7	-	-	-	-	135	100
C54	Corpus Uteri	40	74.1	9	16.7	5	9.3	-	-	-	-	54	100
C55	Uterus Unspecified	2	40	2	40	1	20	-	-	-	-	5	100
C56	Ovary etc.	78	60.9	39	30.5	11	8.6	-	-	-	-	128	100
C57	Other Female Genital	2	66.7	1	33.3	-	-	-	-	-	-	3	100
C64	Kidney etc.	1	20	4	80	-	-	-	-	-	-	5	100
C67	Bladder	1	14.3	4	57.1	1	14.3	-	-	1	14.3	7	100
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	100	-	-	-	-	-	-	-	-	1	100
C70-72	Brain, Nervous System	8	44.4	8	44.4	-	-	1	5.6	1	5.6	18	100
C73	Thyroid	50	65.8	16	21.1	9	11.8	-	-	1	1.3	76	100
C74	Adrenal Gland	1	100	-	-	-	-	-	-	-	-	1	100
C81	Hodgkins Disease	5	62.5	2	25	1	12.5	-	-	-	-	8	100
C82-85, C96	NHL	26	43.3	22	36.7	12	20	-	-	-	-	60	100
C90	Multiple Myeloma	19	65.5	8	27.6	2	6.9	-	-	-	-	29	100
C91	Lymphoid Leuk.	7	46.7	6	40	1	6.7	-	-	1	6.7	15	100
C92-94	Myeloid Leukaemia	26	59.1	15	34.1	2	4.5	-	-	1	2.3	44	100
C95	LeukaemiaUns	2	66.7	1	33.3	-	-	-	-	-	-	3	100
O&U	Other and Uns	18	66.7	8	29.6	1	3.7	-	-	-	-	27	100
	All Sites	1118	63.4	470	26.6	160	9.1	1	0.1	15	0.9	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 13(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education-Males

ICD 10	Sites	Primary		Middle		Secondary		Illiterate		Literate		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	2	14.3	2	14	-	-	1	7.1	-	-	-	-	9	64	14	100
C01-02	Tongue	16	13.8	12	10	13	11.2	5	4.3	5	4.3	6	5.2	59	51	116	100
C03-06	Mouth	24	14.5	13	7.8	11	6.6	9	5.4	5	3	2	1.2	102	61	166	100
C07-08	Salivary Gland	-	-	3	23	2	15.4	1	7.7	-	-	-	-	7	54	13	100
C09	Tonsil	2	22.2	-	-	1	11.1	1	11.1	-	-	-	-	5	56	9	100
C10	Oth. Oropharynx	10	16.9	9	15	3	5.1	3	5.1	1	1.7	-	-	33	56	59	100
C11	Nasopharynx	2	18.2	-	-	-	-	-	-	1	9.1	-	-	8	73	11	100
C12-13	Hypopharynx	14	18.7	3	4	2	2.7	6	8	5	6.7	-	-	45	60	75	100
C15	Oesophagus	20	24.7	15	19	4	4.9	5	6.2	6	7.4	-	-	31	38	81	100
C16	Stomach	35	25.9	18	13	12	8.9	13	9.6	6	4.4	3	2.2	48	36	135	100
C17	Small Intestine	1	25	-	-	2	50	-	-	-	-	-	-	1	25	4	100
C18	Colon	13	21	8	13	7	11.3	2	3.2	4	6.5	3	4.8	25	40	62	100
C19-20	Rectum	15	17.4	11	13	11	12.8	3	3.5	6	7	3	3.5	37	43	86	100
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-	3	100	3	100
C22	Liver	16	29.6	4	7.4	7	13	2	3.7	1	1.9	2	3.7	22	41	54	100
C23-24	Gallbladder etc.	1	14.3	-	-	2	28.6	-	-	-	-	-	-	4	57	7	100
C25	Pancreas	5	11.9	2	4.8	5	11.9	2	4.8	4	9.5	2	4.8	22	52	42	100
C30-31	Nose, Sinuses etc.	2	25	1	13	-	-	-	-	1	12.5	2	25	2	25	8	100
C32	Larynx	27	25.7	7	6.7	5	4.8	6	5.7	5	4.8	1	1	54	51	105	100
C33-34	Lung etc.	102	23.2	62	14	31	7	28	6.4	26	5.9	6	1.4	185	42	440	100
C37-38	Other Thoracic Organs	-	-	1	50	-	-	-	-	-	-	1	50	-	-	2	100
C40-41	Bone	-	-	-	-	6	37.5	-	-	-	-	4	25	6	38	16	100
C43	Melanoma of Skin	3	20	5	33	1	6.7	1	6.7	1	6.7	-	-	4	27	15	100
C44	Other Skin	8	28.6	4	14	2	7.1	2	7.1	1	3.6	-	-	11	39	28	100
C47+C49	Conn. & Soft Tissue	4	14.3	3	11	3	10.7	3	10.7	1	3.6	4	14	10	36	28	100
C50	Breast	-	-	-	-	1	11.1	-	-	1	11.1	2	22	5	56	9	100
C60	Penis	3	25	2	17	2	16.7	-	-	1	8.3	-	-	4	33	12	100
C61	Prostate	15	18.5	9	11	13	16	4	4.9	2	2.5	4	4.9	34	42	81	100
C62	Testis	-	-	2	29	1	14.3	-	-	-	-	2	29	2	29	7	100
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	1	100	1	100
C64	Kidney etc.	3	12	3	12	4	16	-	-	-	-	1	4	14	56	25	100
C67	Bladder	9	16.1	12	21	6	10.7	4	7.1	2	3.6	1	1.8	22	39	56	100
C69	Eye	-	-	-	-	2	100	-	-	-	-	-	-	-	-	2	100
C70-72	Brain, Nervous System	5	12.5	6	15	8	20	-	-	3	7.5	3	7.5	15	38	40	100
C73	Thyroid	3	15	5	25	4	20	1	5	-	-	2	10	5	25	20	100
C81	Hodgkins Disease	3	23.1	1	7.7	4	30.8	-	-	-	-	1	7.7	4	31	13	100
C82-85,C96	NHL	17	14.7	11	9.5	26	22.4	3	2.6	3	2.6	14	12	42	36	116	100
C88	Maliglmn.Prol D	-	-	1	50	-	-	-	-	-	-	-	-	1	50	2	100
C90	Multiple Myeloma	9	18	4	8	7	14	-	-	2	4	2	4	26	52	50	100
C91	Lymphoid Leuk.	3	8.1	3	8.1	10	27	1	2.7	2	5.4	4	11	14	38	37	100
C92-94	Myeloid Leukaemia	8	15.7	3	5.9	3	5.9	5	9.8	3	5.9	2	3.9	27	53	51	100
C95	LeukaemiaUns	1	33.3	-	-	-	-	-	-	-	-	1	33	1	33	3	100
O&U	Other and Uns	12	20.7	11	19	4	6.9	4	6.9	2	3.4	-	-	25	43	58	100
	All Sites	413	19.1	256	12	225	10.4	115	5.3	100	4.6	78	3.6	975	45	2162	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

Table 13(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education-Females

ICD 10	Sites	Primary		Middle		Secondary		Illiterate		Literate		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	-	-	-	-	1	12.5	-	-	-	-	7	87.5	8	100
C01-02	Tongue	6	12	-	-	2	3.9	5	9.8	4	7.8	1	2	33	64.7	51	100
C03-06	Mouth	16	14	3	2.6	8	6.8	21	17.9	2	1.7	2	1.7	65	55.6	117	100
C07-08	Salivary Gland	1	9.1	1	9.1	3	27.3	1	9.1	-	-	-	-	5	45.5	11	100
C09	Tonsil	-	-	-	-	1	20	-	-	-	-	-	-	4	80	5	100
C10	Oth. Oropharynx	1	25	-	-	-	-	-	-	-	-	-	-	3	75	4	100
C11	Nasopharynx	1	20	-	-	-	-	-	-	-	-	1	20	3	60	5	100
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	-	-	-	-	3	100	3	100
C15	Oesophagus	2	4.3	6	12.8	2	4.3	11	23.4	4	8.5	-	-	22	46.8	47	100
C16	Stomach	6	14	1	2.4	7	16.7	6	14.3	1	2.4	1	2.4	20	47.6	42	100
C17	Small Intestine	-	-	-	-	-	-	-	-	2	40	-	-	3	60	5	100
C18	Colon	8	16	3	6	10	20	5	10	2	4	1	2	21	42	50	100
C19-20	Rectum	8	12	4	6.2	8	12.3	9	13.8	2	3.1	2	3.1	32	49.2	65	100
C21	Anus & Anal Canal	1	50	-	-	-	-	-	-	-	-	-	-	1	50	2	100
C22	Liver	6	29	1	4.8	-	-	3	14.3	1	4.8	2	9.5	8	38.1	21	100
C23-24	Gallbladder etc.	2	14	3	21.4	1	7.1	2	14.3	-	-	-	-	6	42.9	14	100
C25	Pancreas	3	13	2	8.7	7	30.4	-	-	2	8.7	-	-	9	39.1	23	100
C30-31	Nose, Sinuses etc.	1	11	-	-	2	22.2	1	11.1	-	-	-	-	5	55.6	9	100
C32	Larynx	-	-	1	33.3	-	-	1	33.3	-	-	-	-	1	33.3	3	100
C33-34	Lung etc.	13	21	5	7.9	6	9.5	7	11.1	3	4.8	3	4.8	26	41.3	63	100
C37-38	Other Thoracic Organs	-	-	-	-	1	100	-	-	-	-	-	-	-	-	1	100
C40-41	Bone	-	-	4	33.3	1	8.3	2	16.7	1	8.3	1	8.3	3	25	12	100
C43	Melanoma of Skin	2	20	1	10	1	10	1	10	-	-	-	-	5	50	10	100
C44	Other Skin	2	11	1	5.3	1	5.3	2	10.5	2	10.5	1	5.3	10	52.6	19	100
C47+C49	Conn. & Soft Tissue	1	7.7	1	7.7	-	-	2	15.4	2	15.4	-	-	7	53.8	13	100
C50	Breast	58	11	69	13	40	7.5	19	3.6	17	3.2	31	5.8	297	55.9	531	100
C51	Vulva	2	50	1	25	-	-	-	-	-	-	-	-	1	25	4	100
C52	Vagina	-	-	-	-	3	42.9	-	-	2	28.6	-	-	2	28.6	7	100
C53	Cervix Uteri	19	14	6	4.4	12	8.9	11	8.1	6	4.4	3	2.2	78	57.8	135	100
C54	Corpus Uteri	14	26	4	7.4	5	9.3	5	9.3	2	3.7	2	3.7	22	40.7	54	100
C55	Uterus Unspecified	1	20	-	-	-	-	-	-	1	20	-	-	3	60	5	100
C56	Ovary etc.	25	20	15	11.7	17	13.3	7	5.5	5	3.9	7	5.5	52	40.6	128	100
C57	Other Female Genital	-	-	1	33.3	-	-	-	-	-	-	-	-	2	66.7	3	100
C64	Kidney etc.	2	40	-	-	-	-	1	20	1	20	-	-	1	20	5	100
C67	Bladder	2	29	-	-	1	14.3	-	-	-	-	-	-	4	57.1	7	100
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-	1	100	1	100
C70-72	Brain, Nervous System	3	17	1	5.6	1	5.6	-	-	-	-	1	5.6	12	66.7	18	100
C73	Thyroid	11	15	13	17.1	7	9.2	8	10.5	-	-	7	9.2	30	39.5	76	100
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	1	100	1	100
C81	Hodgkins Disease	1	13	-	-	2	25	-	-	-	-	1	13	4	50	8	100
C82-85,C96	NHL	11	18	9	15	4	6.7	5	8.3	-	-	3	5	28	46.7	60	100
C90	Multiple Myeloma	7	24	6	20.7	4	13.8	2	6.9	2	6.9	-	-	8	27.6	29	100
C91	Lymphoid Leuk.	1	6.7	1	6.7	2	13.3	1	6.7	1	6.7	4	27	5	33.3	15	100
C92-94	Myeloid Leukaemia	8	18	5	11.4	6	13.6	3	6.8	2	4.5	1	2.3	19	43.2	44	100
C95	LeukaemiaUns	-	-	-	-	-	-	1	33.3	1	33.3	-	-	1	33.3	3	100
O&U	Other and Uns	5	19	4	14.8	2	7.4	2	7.4	3	11.1	3	11	8	29.6	27	100
	All Sites	250	14	172	9.8	167	9.5	145	8.2	71	4	78	4.4	881	49.9	1764	100

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**DETAILED
INFORMATION-MCC**

**HABITS,
SYSTEM WISE,
STAGING ETC.**

Table 1: Number of New and Old Cancer Cases

Sex	Old		New		Total
	#	%	#	%	
Male	1562	72.2	600	27.8	2162
Female	1171	66.4	593	33.6	1764
Total	2733	69.6	1193	30.4	3926

Table 2: Number (#) and Proportion of System Wise & Sex wise Cancer Incidence

System and Sex wise distribution of patients					
System	Male	%	Female	%	Total
Head & Neck	602	66.6%	302	33.4%	904
Digestive Organs	485	63.7%	276	36.3%	761
Breast	9	1.7%	531	98.3%	540
Respiratory system	440	87.3%	64	12.7%	504
Hematological and RE System	256	62.6%	153	37.4%	409
Gynaecological system	0	0.0%	336	100.0%	336
Male genital organ	101	100.0%	0	0.0%	101
Urinary tract	81	87.1%	12	12.9%	93
Primary unknown	54	71.1%	22	28.9%	76
skin	42	65.6%	22	34.4%	64
CNS	42	68.9%	19	31.1%	61
Soft tissue system	25	67.6%	12	32.4%	37
skeletal-bones etc	19	63.3%	11	36.7%	30
Intrathoracic organs	2	50.0%	2	50.0%	4
Peripheral nervous system	3	75.0%	1	25.0%	4
Endocrine glands	1	50.0%	1	50.0%	2
Total	2162	55%	1764	100%	3926

Table 3: Numbers (#) and Proportion of System Wise & Alcohol Habit

System wise Alcohol Habit													
System	No-Habit	%	Habit	%	Chronic	%	Occasional	%	Ex-Habit	%	Unknown	%	Total
Head & Neck	482	53.3	59	6.5	153	16.9	71	7.9	129	14.3	10	1.1	904
Digestive Organs	493	64.8	36	4.7	71	9.3	53	7.0	89	11.7	19	2.5	761
Breast	531	98.3	0	0.0	2	0.4	1	0.2	0	0.0	6	1.1	540
Respiratory system	268	53.2	27	5.4	67	13.3	46	9.1	80	15.9	16	3.2	504
Hematological and RE System	298	72.9	21	5.1	18	4.4	32	7.8	26	6.4	14	3.4	409
Gynaecological system	321	95.5	1	0.3	0	0.0	2	0.6	0	0.0	12	3.6	336
Male genital organ	56	55.4	6	5.9	11	10.9	16	15.8	9	8.9	3	3.0	101

Urinary tract	61	65.6	6	6.5	8	8.6	9	9.7	6	6.5	3	3.2	93
Primary unknown	39	51.3	8	10.5	12	15.8	5	6.6	10	13.2	2	2.6	76
skin	44	68.8	4	6.3	3	4.7	8	12.5	5	7.8	0	0.0	64
CNS	47	77.0	4	6.6	4	6.6	2	3.3	3	4.9	1	1.6	61
Soft tissue system	34	91.9	1	2.7	0	0.0	2	5.4	0	0.0	0	0.0	37
skeletal-bones etc	24	80.0	0	0.0	1	3.3	2	6.7	1	3.3	2	6.7	30
Intrathoracic organs	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	4
Peripheral nervous system	3	75.0	0	0.0	0	0.0	1	25.0	0	0.0	0	0.0	4
Endocrane glands	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	2
Total	2705	69	173	4	352	9	250	6	358	9	88	2	3926

Table 4 : Number (#) and Proportion of System Wise & Pan chewing Habit

System wise Pan Chewing Habit													
System	No-Habit	%	Habit	%	Chronic	%	Occa-sional	%	Ex-Habit	%	Un-known	%	Total
Head & Neck	486	53.8	32	3.5	213	23.6	14	1.5	148	16.4	11	1.2	904
Digestive Organs	588	77.3	19	2.5	70	9.2	10	1.3	55	7.2	19	2.5	761
Breast	494	91.5	3	0.6	18	3.3	3	0.6	16	3.0	6	1.1	540
Respiratory system	409	81.2	11	2.2	31	6.2	10	2.0	27	5.4	16	3.2	504
Hematological and RE System	330	80.7	7	1.7	29	7.1	5	1.2	24	5.9	14	3.4	409
Gynaecological system	271	80.7	2	0.6	28	8.3	0	0.0	23	6.8	12	3.6	336
Male genital organ	83	82.2	2	2.0	8	7.9	1	1.0	4	4.0	3	3.0	101
Urinary tract	75	80.6	2	2.2	9	9.7	1	1.1	2	2.2	4	4.3	93
Primary unknown	58	76.3	2	2.6	7	9.2	0	0.0	7	9.2	2	2.6	76
skin	52	81.3	1	1.6	6	9.4	0	0.0	5	7.8	0	0.0	64
CNS	52	85.2	1	1.6	4	6.6	1	1.6	2	3.3	1	1.6	61
Soft tissue system	32	86.5	0	0.0	3	8.1	0	0.0	2	5.4	0	0.0	37
skeletal-bones etc	23	76.7	1	3.3	1	3.3	0	0.0	3	10.0	2	6.7	30
Intrathoracic organs	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	4
Peripheral nervous system	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4
Endocrane glands	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	2
Total	2961	75	83	2	429	11	45	1	318	8	90	2	3926

Table 5: Numbers (#) and Proportion of System Wise & Smoking Habit

System wise Smoking Habit													
System	No-Habit	%	Habit	%	Chronic	%	Occa-sional	%	Ex-Habit	%	Un-known	%	Total
Head & Neck	426	47.1	37	4.1	245	27.1	10	1.1	175	19.4	11	1.2	904
Digestive Organs	405	53.2	27	3.5	165	21.7	16	2.1	130	17.1	18	2.4	761
Breast	525	97.2	3	0.6	2	0.4	0	0.0	4	0.7	6	1.1	540
Respiratory system	91	18.1	29	5.8	220	43.7	0	0.0	149	29.6	15	3.0	504

Hematological and RE System	275	67.2	14	3.4	53	13.0	5	1.2	48	11.7	14	3.4	409
Gynaecological system	320	95.2	1	0.3	2	0.6	0	0.0	1	0.3	12	3.6	336
Male genital organ	35	34.7	9	8.9	29	28.7	5	5.0	20	19.8	3	3.0	101
Urinary tract	34	36.6	3	3.2	32	34.4	2	2.2	19	20.4	3	3.2	93
Primary unknown	29	38.2	7	9.2	21	27.6	1	1.3	16	21.1	2	2.6	76
skin	33	51.6	7	10.9	12	18.8	2	3.1	10	15.6	0	0.0	64
CNS	42	68.9	3	4.9	6	9.8	3	4.9	6	9.8	1	1.6	61
Soft tissue system	29	78.4	1	2.7	4	10.8	2	5.4	1	2.7	0	0.0	37
skeletal-bones etc	25	83.3	0	0.0	1	3.3	0	0.0	2	6.7	2	6.7	30
Intrathoracic organs	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	4
Peripheral nervous system	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	4
Endocrane glands	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	2
Total	2276	58.0	141	3.6	795	20.2	46	1.2	581	14.8	87	2.2	3926

Family History/ Hereditary Cancer

Table 6: Numbers (#) and Proportion of Family History with Hereditary Cancers

Site wise Family History							
Site	Family History	%	No family History	%	Unknown	%	Total
Breast	139	25.7%	374	69.3%	27	5.0%	540
ovary	34	26.6%	82	64.1%	12	9.4%	128
colon	39	34.8%	64	57.1%	9	8.0%	112
Prostate	13	16.0%	67	82.7%	1	1.2%	81
Total	225	26.1%	587	68.2%	49	5.7%	861

Table 7: Numbers (#) and Proportion of System Wise & Family History

System wise Family History							
Site	Family History	%	No family History	%	Unknown	%	Total
Head & Neck	175	19.4	692	76.5	37	4.1	904
Digestive Organs	181	23.8	542	71.2	38	5.0	761
Breast	139	25.7	374	69.3	27	5.0	540
Respiratory system	45	8.9	374	74.2	85	16.9	504
Hematological and RE System	44	10.8	342	83.6	23	5.6	409
Gynaecological system	68	20.2	235	69.9	33	9.8	336
Male genital organ	17	16.8	82	81.2	2	2.0	101
Urinary tract	19	20.4	67	72.0	7	7.5	93
Primary unknown	11	14.5	57	75.0	8	10.5	76
skin	13	20.3	51	79.7	0	0.0	64
CNS	12	19.7	44	72.1	5	8.2	61

Soft tissue system	8	21.6	29	78.4	0	0.0	37
skeletal-bones etc	4	13.3	22	73.3	4	13.3	30
Peripheral nervous system	1	25.0	2	50.0	1	25.0	4
Intrathoracic organs	0	0.0	4	100.0	0	0.0	4
Endocrine glands	1	50.0	1	50.0	0	0.0	2
Total	738	18.8	2918	74.3	270	6.9	3926

Staging

Table 8: Staging Type

Staging	Male		Female		Total
	#	%	#	%	
Ann Arbor	100	4.6	56	3.2	156
FIGO	0	0.0	336	19.0	336
Clinical	1015	46.9	453	25.7	1468
TNM	806	37.3	785	44.5	1591
Not Applicable	229	10.6	127	7.2	356
Unknown	12	0.6	7	0.4	19
Total	2162	100	1764	100	3926

Table:9 staging Type → Ann Arbor

Composit Stage	Male		Female		Total
	#	%	#	%	
stage1	8	8.0	4	7.1	12
stage2	19	19.0	7	12.5	26
stage3	21	21.0	10	17.9	31
stage4	26	26.0	17	30.4	43
Unknown	22	22.0	16	28.6	38
Not Applicable	4	4.0	2	3.6	6
Total	100	100.0	56	100.0	156

Table : 10 Staging Type → FIGO

Composit Stage	Female		Total
	#	%	
stage1	71	15.5	71
stage2	59	16.5	59
stage3	98	26.4	98
stage4	66	13.4	66
Unknown	41	24.8	41
Not Applicable	1	3.4	1
Total	336	100	336

Table 11 : Staging Type → Clinical

Stagging	Male		Female		Total
	#	%	#	%	
stage1	120	11.8%	97	21.4%	217
stage2	135	13.3%	48	10.6%	183
stage3	676	66.6%	262	57.8%	938
stage4	2	0.2%	0	0.0%	2
Unknown	81	8.0%	41	9.1%	122
Not Applicable	1	0.1%	5	1.1%	6
Total	1015	100.0%	453	100.0%	1468

Table: 12 Staging Type → TNM

Composit Stage	Male		Female		Total
	#	%	#	%	
stage1	134	16.6%	79	10.1%	213
stage2	90	11.2%	264	33.6%	354
stage3	201	24.9%	243	31.0%	444
stage4	315	39.1%	138	17.6%	453
Unknown	66	8.2%	60	7.6%	126
Not Applicable	0	0.0%	1	0.1%	1
Total	806	100.0%	785	100.0%	1591

Table: 13 Staging Type → Unknown

Composit Stage	Male		Female		Total
	#	%	#	%	
stage1	1	8.3%	1	14.3%	2
stage2	0	0.0%	1	14.3%	1
stage3	2	16.7%	0	0.0%	2
stage4	5	41.7%	1	14.3%	6
Unknown	4	33.3%	2	28.6%	6
Not Applicable	0	0.0%	2	28.6%	2
Total	12	100.0%	7	100.0%	19

Table: 14 Staging Type → Not Applicable

Composit Stage	Male		Female		Total
	#	%	#	%	
stage1	2	0.9%	0	0.0%	2
stage2	2	0.9%	0	0.0%	2
stage3	1	0.4%	1	0.8%	2
stage4	2	0.9%	1	0.8%	3

Unknown	4	1.7%	2	1.6%	6
Not Applicable	218	95.2%	123	96.9%	341
Total	229	100.0%	127	100.0%	356

Table 15 : Comparison of Performance status(WHO) before and after treatment

Performance Status after register at RI							
Performance status before register at RI		0	1	2	3	4	9
	0	4	105	7	0	4	60
	1	4	1060	476	112	52	855
	2	1	74	277	47	26	244
	3	0	13	27	233	10	120
	4	0	6	4	0	49	28
	9	0	6	3	4	1	14

0	Able to carry out all normal activity without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out light work
2	Ambulatory and capable of all self-care but unable to carry out any work: up and about more than 50% of waking hours
3	Capable of only limited self-care; confined to bed or chair more than 50% waking hours
4	Completely disabled; cannot carry on any self-care totally confined to bed or chair
9	Unknown

Ten Leading Cancers - irrespective of Sex

Table 16: Leading cancers irrespective of Sex

Sl. No	Site	#	%
1	Breast	540	13.75
2	Lung	503	12.81
3	Mouth	283	7.21
4	Stomach	177	4.51
5	NHL	176	4.48

6	Tongue	167	4.25
7	Rectum	151	3.85
8	Cervix Uteri	135	3.44
9	Oesophagus	128	3.26
10	Ovary etc	128	3.26

I. Breast Cancer

- Total Number (ICD 10: C50) :540 (98.3% in females and 1.7% in males)
- Breast cancer in females ranks first among all the cancers.
- Ist leading cancer among females : 30.1 %
- Male to female ratio:0.01:1
- Peak age group: 50-54 years in females 60-64 years in males
- Histology: Infiltrating Ductal Carcinoma: 86.6% in females and 77.8 % in males.
- Method of diagnosis: Microscopic : 96.8 % in females and 100% in males
- Detailed Microscopic diagnosis: Histology of Primary: 94.7% in females and 88.9% in males.
- Broad treatment group: Treatment only at RI: 46% in females and 33.3% in males
- Clinical extent of disease(Trmt only at RI, no treatment): Regional: 80.2% in females and 66.7% in males
- Type of treatment (Trmt only at RI) : S+R+C: 32% in females
- Treatment status(Excluding cancer previously treated) : Received: 74% in females and 100% in males
- Intention to treat : Curative/Radical: 85.1% in females and 66.7% in males
- Marital status : Married:75.1 % in females and 88.9 % in males
- Religion : Hindu: 65.3% in females and 66.7% in males
- Education : Secondary: 13.0% in females and 11.1 % in males.
- Mother Tongue : Malayalam :99.1% in females and 100% in males

Table 17: Number and Relative Proportion of Breast cancer by five year age group

Breast					
Age	Males	%	Females	%	Total
20-24	0	0.0%	1	0.2%	1
25-29	0	0.0%	4	0.8%	4
30-34	0	0.0%	22	4.1%	22
35-39	0	0.0%	44	8.3%	44
40-44	2	22.2%	68	12.8%	70
45-49	0	0.0%	90	16.9%	90
50-54	1	11.1%	91	17.1%	92
55-59	1	11.1%	70	13.2%	71
60-64	3	33.3%	56	10.5%	59
65-69	2	22.2%	37	7.0%	39
70-74	0	0.0%	24	4.5%	24
>=75	0	0.0%	24	4.5%	24
Total	9	100%	531	100%	540

Table 18: Number and Relative Proportion of Breast Cancer by method of diagnosis

Breast					
Method of diagnosis	Male	%	Female	%	Total
Clinical Only	0	0.0%	7	1.3%	7
Microscopic	9	100.0%	514	96.8%	523
X-Ray/Imaging Techniques	0	0.0%	3	0.6%	3
Others	0	0.0%	7	1.3%	7
Total	9	100%	531	100%	540

Table 19: Number and Relative Proportion of Breast detailed Microscopic Diagnosis

Breast					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Cytology of Primary	0	0.0%	1	0.2%	1
Histology of Metastasis	1	11.1%	10	1.9%	11
Histology of Primary	8	88.9%	503	94.7%	511
Others	0	0.0%	16	3.0%	16
Ultrasonogram	0	0.0%	1	0.2%	1
Total	9	100%	531	100%	540

Table 20: Number and Relative Proportion of Breast cancer by histology

Morphology	Male	%	Female	%	total
Adenocystic Carcinoma	0	0.0%	1	0.2%	1
Carcinoma	1	11.1%	11	2.1%	12
Infiltrating Duct Carcinoma	7	77.8%	460	86.6%	467
Lobular Carcinoma	0	0.0%	14	2.6%	14
Medullary Carcinoma	0	0.0%	3	0.6%	3
MusinousAdenoCarcinoma	0	0.0%	5	0.9%	5
Neoplasam Malignant	1	11.1%	27	5.1%	28
Others	0	0.0%	8	1.5%	8
Papillary Carcinoma	0	0.0%	1	0.2%	1
Phylloids Tumor	0	0.0%	1	0.2%	1
Total	9	100%	531	100%	540

Clinical Information

Table 21: Number and Relative Proportion of Breast cancer by Broad Treatment Groups

Breast					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	3	33.3	83	15.6	86
Prior & Treatment at RI	3	33.3	119	22.4	122
Treatment only at RI	3	33.3	244	46	247
No Treatment	-	-	85	16	85

Table 22: Number and Relative Proportion of Breast cancer by Clinical Extent of Disease

Breast					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	2	22.2%	113	21.3%	115
Direct Extension with Regional Nodes	1	11.1%	176	33.1%	177
Distant Metastasis	2	22.2%	62	11.7%	64
Localised	0	0.0%	3	0.6%	3
Others (specify)	0	0.0%	5	0.9%	5
Recurrent	0	0.0%	4	0.8%	4
Too Advanced	0	0.0%	2	0.4%	2
Treated Elsewhere	4	44.4%	166	31.3%	170
Total	9	100%	531	100%	540

Table 23: Number and Relative Proportion of Breast cancer by Clinical Extent of Disease(Treatment only at RI, no treatment)

Breast					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	-	-	1	0.3	1
Regional	2	66.7	264	80.2	266
Distant	1	33.3	58	17.6	59
Others	-	-	6	1.8	6
Total	3	100	329	100	332
Recurrent	0	0.0%	4	0.8%	4
Too Advanced	0	0.0%	2	0.4%	2
Treated Elsewhere	4	44.4%	166	31.3%	170
Total	9	100%	531	100%	540

Table 24: Number and Proportion of Breast cancers by type of treatment (Treatment Only at RI)

Breast					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery			12	4.9	12
C-Therapy			8	3.3	8
S+C			23	9.4	23
R+C			4	1.6	4
S+R+C			77	32	77
Others	3	100	120	49	123
Total	3	100	244		247

Table 25: Number and Relative Proportion of Breast cancer by any specific treatment (Treatment Only at RI)

Breast					
Any specific Treatment	Male	%	Female	%	Total
Any S	2	18.2	200	29.6	202
Any R	3	27.3	152	22.5	155
Any C	3	27.3	204	30.2	207
Any H	3	27.3	120	18	123
Total	11	100	676	100	687

Table 26: Number and Relative Proportion of Breast cancer by Treatment Status (Excluding the cancers previously treated)

Breast					
Treatment Status	Male	%	Female	%	Total
Received	3	100	244	74	247
Not Received			63	19.1	63
Not Accepted			1	0.3	1
Incomplete			21	6.4	21
Total	3	100	329	100	332

Table 27: Number and Relative Proportion of Breast Cancer intention to treat at MCC

Breast					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	2	66.7%	206	85.1%	208
Pallative	1	33.3%	36	14.9%	37
Total	3	100%	242	100%	245

Basic Demographic Parameters

Table 28: Number and Relative Proportion of Breast cancer by marital Status

Breast					
Marital Status	Male	%	Female	%	Total
Married	8	88.9%	399	75.1%	407
Divorced	0	0.0%	4	0.8%	4
Seperated	0	0.0%	1	0.2%	1
Unmarried	0	0.0%	23	4.3%	23
Widowed	0	0.0%	84	15.8%	84
Unknown	1	11.1%	20	3.8%	21
Total	9	100%	531	100%	540

Table 29: Number and Relative Proportion of Breast cancer by Religion

Breast					
Religion	Male	%	Female	%	Total
Christian	1	11.1%	52	9.8%	53
Hindu	6	66.7%	347	65.3%	353
Muslim	2	22.2%	130	24.5%	132
Unknown	0	0.0%	2	0.4%	2
Total	9	100%	531	100%	540

Table 30: Number and Relative Proportion of Breast cancer by Education

Breast					
Education	Male	%	Female	%	Total
Illiterate	0	0.0%	19	3.6%	19
Literate	1	11.1%	17	3.2%	18
Primary	0	0.0%	58	10.9%	58
Middle	0	0.0%	40	7.5%	40
Secondary	1	11.1%	69	13.0%	70
College and above	2	22.2%	24	4.5%	26
Technical-after matric	0	0.0%	4	0.8%	4
Others	0	0.0%	10	1.9%	10
Unknown	5	55.6%	290	54.6%	295
Total	9	100%	531	100%	540

Table 31: Number and Relative Proportion of Breast cancer by mother Tongue

Breast					
Mother Tongue	Male	%	Female	%	Total
Malayalam	9	100.0%	526	99.1%	535
Kannada	0	0.0%	1	0.2%	1
Bengali	0	0.0%	1	0.2%	1
Other	0	0.0%	1	0.2%	1
Unknown	0	0.0%	2	0.4%	2
Total	9	100%	531	100%	540

II. Lung Cancer

- Total Number (ICD 10: C33-34) :503 (12.52% in females and 87.78% in males)
- Lung cancer in males ranks first and second rank among all cancers
- Ist leading cancer among males : 87.48%
- Male to female ratio:1:0.14
- Peak age group: 65-69 years in females and 60-64 years in males.
- Histology:Adenocarcinoma: 41.3% in femalesand 19.5% in males.
- Method of diagnosis: Microscopic : 82.5% in females and 83.0% in males
- Detailed Microscopic diagnosis: Histology of Primary: 58.7% in females and 66.6% in males.
- Broad treatment group: Treatment only at RI: 27% in females and 35% in males
- Clinical extent of disease(Trmt only at RI): Distant: 87.3% in females and 77% in males
- Type of treatment (Trmt only at RI, no treatment) : R-Therapy: 41.2% in females and 59.7% in males
- Treatment status(Excluding cancer previously treated) : Received: 31% in females and 39.3% in males
- Intention to treat : Palliative: 82.4% in females and 81.8% in males
- Marital status : Married: 65.1% in females and 92.7% in males
- Religion : Hindu: 57.1% in females and 54.3% in males
- Education : Primary: 20.6% in females and 23.2% in males.

Table 32: Number and Relative Proportion of Lung cancer by five year age group

Lung					
Age	Male	%	Female	%	Total
25-29	0	0.0%	2	3.2%	2
30-34	3	0.7%	1	1.6%	4
35-39	1	0.2%	1	1.6%	2
40-44	5	1.1%	2	3.2%	7
45-49	15	3.4%	11	17.5%	26
50-54	31	7.0%	8	12.7%	39
55-59	67	15.2%	4	6.3%	71
60-64	127	28.9%	8	12.7%	135
65-69	81	18.4%	13	20.6%	94
70-74	62	14.1%	5	7.9%	67
>=75	48	10.9%	8	12.7%	56
Total	440	100%	63	100%	503

Table 33: Number and Relative Proportion of Lung Cancer by method of diagnosis

Lung					
Method of diagnosis	Male	%	Female	%	Total
Microscopic	365	83.0%	52	82.5%	417
X-Ray/Imaging Techniques	72	16.4%	11	17.5%	83
Others	3	0.7%	0	0.0%	3
Total	440	100%	63	100%	503

Table 34: Number and Relative Proportion of Lung detailed Microscopic Diagnosis

Lung					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.2%	2	3.2%	3
Histology of Metastasis	71	16.1%	13	20.6%	84
Histology of Primary	293	66.6%	37	58.7%	330
Others	73	16.6%	11	17.5%	84
X-Ray	2	0.5%	0	0.0%	2
Total	440	100%	63	100%	503

Table 35: Number and Relative Proportion of Lung cancer by histology

Lung					
Morphology	Male	%	Female	%	total
Adenocarcinoma	86	19.5%	26	41.3%	112
AdenoSquamous Cell Carcinoma	3	0.7%	0	0.0%	3
Carcinoma	28	6.4%	1	1.6%	29
MusinousAdenoCarcinoma	5	1.1%	0	0.0%	5
Neoplasam Malignant	147	33.4%	26	41.3%	173
Neuroendocrine Carcinoma	3	0.7%	1	1.6%	4
Non SmallCell Carcinoma	19	4.3%	0	0.0%	19
Others	2	0.5%	0	0.0%	2
Papillary AdenoCarcinoma	1	0.2%	0	0.0%	1
Small Cell Carcinoma	26	5.9%	3	4.8%	29
Squamous Cell Carcinoma	120	27.3%	6	9.5%	126
Total	440	100%	63	100%	503

Clinical Information

Table 36: Number and Relative Proportion of Lung cancer by Broad Treatment Group

Lung					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	31	7	5	7.9	36
Prior & Treatment at RI	17	3.9	3	4.8	20
Treatment only at RI	154	35	17	27	171
No Treatment	238	54.1	38	60.3	276
Total	410	100	63	100	503

Table 37: Number and Relative Proportion of Lung cancer by Clinical Extent of Disease

Lung					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	7	1.6%	2	3.2%	9
Direct Extension with Regional Nodes	53	12.0%	1	1.6%	54
Distant Metastasis	224	50.9%	43	68.3%	267
Localised	2	0.5%	0	0.0%	2
Others (specify)	29	6.6%	4	6.3%	33
Too Advanced	97	22.0%	7	11.1%	104
Treated Elsewhere	28	6.4%	6	9.5%	34
Total	440	100%	63	100%	503

Table 38: Number and Relative Proportion of Lung cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Lung					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	2	0.5			2
Regional	58	14.8	3	5.5	61
Distant	302	77	48	87.3	350
Others	30	7.7	4	7.3	34
Total	392	100	55	100	447

Table 39: Number and Proportion of Lung cancers by type of treatment (Treatment Only at RI)

Lung					
Clinical Extent of Disease	Male	%	Female	%	Total
R-Therapy	92	59.7	7	41.2	99
C-Therapy	17	11	6	35.3	23
S+C	2	1.3			2
R+C	40	26	4	23.5	44
Others	3	1.9			3
Total	154	100	17	100	171

Table 40: Number and Relative Proportion of Lung cancer by any specific treatment (Treatment Only at RI)

Lung					
Any specific Treatment	Male	%	Female	%	Total
Any S	2	1			2
Any R	132	67.3	11	52.4	143
Any C	59	30.1	10	47.6	69
Others	3	1.5			3
Total	196	100	21	100	217

Table 41: Number and Relative Proportion of Lung cancer by Treatment Status (Excluding the cancers previously treated)

Lung					
Treatment Status	Male	%	Female	%	Total
Received	154	39.3	17	31	171
Not Received	199	50.8	38	49.1	237
Not Accepted	2	0.5			2
Incomplete	37	9.4			37
Total	392	100	55	100	447

Table 42: Number and Relative Proportion of Lung Cancer intention to treat at MCC

Lung					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	27	17.5%	3	17.6%	30
Pallative	126	81.8%	14	82.4%	140
Symptomatic	1	0.6%	0	0.0%	1
Total	154	100%	17	100%	171

Basic Demographic Parameters

Table 43: Number and Relative Proportion of Lung cancer by marital Status

Lung					
Marital Status	Male	%	Female	%	Total
Married	408	92.7%	41	65.1%	449
Unmarried	6	1.4%	0	0.0%	6
Widowed	6	1.4%	18	28.6%	24
Divorced	1	0.2%	0	0.0%	1
Unknown	19	4.3%	4	6.3%	23
Total	440	100%	63	100%	503

Table 44: Number and Relative Proportion of Lung cancer by Religion

Lung					
Religion	Male	%	Female	%	Total
Christian	50	11.4%	4	6.3%	54
Hindu	239	54.3%	36	57.1%	275
Muslim	149	33.9%	22	34.9%	171
Unknown	2	0.5%	1	1.6%	3
Total	440	100%	63	100%	503

Table 45: Number and Relative Proportion of Lung cancer by Education

Lung					
Education	Male	%	Female	%	Total
College and above	3	0.7%	1	1.6%	4
Illiterate	28	6.4%	7	11.1%	35
Literate	26	5.9%	3	4.8%	29
Primary	102	23.2%	13	20.6%	115
Secondary	31	7.0%	5	7.9%	36
Middle	62	14.1%	6	9.5%	68
Technical-after matric	1	0.2%	0	0.0%	1
Others	2	0.5%	2	3.2%	4
Unknown	185	42.0%	26	41.3%	211
Total	440	100%	63	100%	503

Table 46: Number and Relative Proportion of Lung cancer by Mother Tongue

Lung					
Mother Tongue	Male	%	Female	%	Total
Malayalam	436	99.1%	61	96.8%	497
Gujarathi	1	0.2%	0	0.0%	1
Kannada	1	0.2%	2	3.2%	3
Unknown	2	0.5%	0	0.0%	2
Total	440	100%	63	100%	503

III. Mouth Cancer

Total Number (ICD 10: C03-06) : 283 [41.3% in females and 58.7% in males]

Mouth cancer is the third leading cancer among all the cancers.

1st leading cancer among males.

Male to female ratio:1:0.7

Peak age group: 55-59 years in males and ≥75 years in females

Histology : Squamous cell carcinoma : 80.3% in females and 80.7% in males

Method of diagnosis: Microscopic: 96.6% in females and 95.2% in males

Detailed Microscopic diagnosis: Histology of Primary: 96.6 % in females and 94.6% in males.

Broad treatment group: Treatment Only at RI: 63.2% in females and 59.6% in males

Clinical extent of disease(Treatment only at RI, No treatment): 79% in females and 85.4% in males

Type of treatment (Treatment only at RI) :R-Therapy : 41.9% in females and 31.3% in males.

Treatment status(Excluding cancer previously treated) : Received: 74% in females and 76.2% in males

Intention to treat : Curative/Radical: 58.1% in females and 68.7% in males

Marital status : Married : 53% in females and 91.6% in males

Religion : Hindu: 70.9% in females and 60.2% in males.

Education : Primary: 13.7% in females and 14.5% in males.

Table 47: Number and Relative Proportion of Mouth cancer by five year age group

Mouth					
Age	Male	%	Female	%	Total
25-29	0	0.0%	2	1.7%	2
30-34	3	1.8%	4	3.4%	7
35-39	4	2.4%	1	0.9%	5
40-44	6	3.6%	3	2.6%	9
45-49	16	9.6%	2	1.7%	18
50-54	16	9.6%	9	7.7%	25
55-59	30	18.1%	9	7.7%	39
60-64	24	14.5%	19	16.2%	43
65-69	22	13.3%	21	17.9%	43
70-74	17	10.2%	15	12.8%	32
>=75	28	16.9%	32	27.4%	60
Total	166	100%	117	100%	283

Table 48: Number and Relative Proportion of Mouth Cancer by method of diagnosis

Mouth					
Method of diagnosis	Male	%	Female	%	Total
Clinical Only	1	0.6%	4	3.4%	5
Microscopic	158	95.2%	113	96.6%	271
Others	7	4.2%	0	0.0%	7
Total	166	100%	117	100%	283

Table 49: Number and Relative Proportion of Mouth detailed Microscopic Diagnosis

Mouth					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Histology of Metastasis	1	0.6%	0	0.0%	1
Histology of Primary	157	94.6%	113	96.6%	270
Others	7	4.2%	4	3.4%	11
Specific Biochemical and/or immunological Tests	1	0.6%	0	0.0%	1
Total	166	100%	117	100%	283

Table 50: Number and Relative Proportion of Mouth cancer by histology

Mouth					
Morphology	Male	%	Female	%	total
Adenocystic Carcinoma	1	0.6%	3	2.6%	4
Carcinoma	1	0.6%	1	0.9%	2
Malignant Melanoma	1	0.6%	0	0.0%	1

Microinvasive Squamous Cell Carcinoma	16	9.6%	8	6.8%	24
Mucoepidermoid Carcinoma	0	0.0%	1	0.9%	1
Neoplasms Malignant	9	5.4%	4	3.4%	13
others	0	0.0%	2	1.7%	2
Squamous Cell Carcinoma	134	80.7%	94	80.3%	228
Verrucous Carcinoma	4	2.4%	4	3.4%	8
Total	166	100%	117	100%	283

Clinical Information

Table 51: Number and Relative Proportion of Mouth Cancer by Broad Treatment Group

Mouth					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	22	13.3	10	8.5	32
Prior & Treatment at RI	14	8.4	7	6	21
Treatment only at RI	99	59.6	74	63.2	173
No Treatment	31	18.7	26	22.2	57
Total	166	100	117	100	283

Table 52: Number and Relative Proportion of Mouth cancer by Clinical Extent of Disease

Mouth					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	54	32.5%	44	37.6%	98
Direct Extension with Regional Nodes	63	38.0%	35	29.9%	98
Distant Metastasis	3	1.8%	7	6.0%	10
Localised	1	0.6%	2	1.7%	3
Recurrent	5	3.0%	2	1.7%	7
Too Advanced	21	12.7%	13	11.1%	34
Treated Elsewhere	19	11.4%	14	12.0%	33
Total	166	100%	117	100%	283

Table 53: Number and Relative Proportion of Mouth cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Mouth					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	1	0.8	2	2	3
Regional	111	85.4	79	79	190
Distant	18	13.8	19	19	37
Total	130	100	100	100	230

Table 54: Number and Proportion of Mouth cancers by type of treatment (Treatment Only at RI)

Mouth					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery	32	32.3	23	31.1	55
R-Therapy	31	31.3	31	41.9	62
C-Therapy	1	1			1
S+R	25	25.3	17	23	42
R+C	1	1	1	1.4	2
S+R+C	9	9.1	2	2.7	11
Total	99	100	74	100	173

Table 55: Number and Relative Proportion of Mouth cancer by any specific treatment (Treatment Only at RI)

Mouth					
Any specific Treatment	Male	%	Female	%	Total
Any S	66	46.2	42	43.8	108
Any R	66	46.2	51	53.1	117
Any C	11	7.7	3	3.1	14
Total	143	100	96	100	239

Table 56: Number and Relative Proportion of Mouth cancer by Treatment Status (Excluding the cancers previously treated)

Mouth					
Treatment Status	Male	%	Female	%	Total
Received	99	76.2	74	74	173
Not Received	30	23.1	24	24	54
Incomplete	1	0.8	2	2	3
Total	130	100	100	100	230

Table 57: Number and Relative Proportion of Mouth Cancer intention to treat at MCC

Mouth					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	68	68.7%	43	58.1%	111
Pain Relief only	1	1.0%	0	0.0%	1
Pallative	30	30.3%	31	41.9%	61
Total	99	100%	74	100%	173

Basic Demographic Parameters

Table 58: Number and Relative Proportion of Mouthcancer by marital Status

Mouth					
Marital Status	Male	%	Female	%	Total
Divorced	0	0.0%	1	0.9%	1
Married	152	91.6%	62	53.0%	214
Unknown	8	4.8%	4	3.4%	12
Unmarried	3	1.8%	1	0.9%	4
Widowed	3	1.8%	49	41.9%	52
Total	166	100%	117	100%	283

Table 59: Number and Relative Proportion of Mouth cancer by Religion

Mouth					
Religion	Male	%	Female	%	Total
Christian	30	18.1%	9	7.7%	39
Hindu	100	60.2%	83	70.9%	183
Muslim	36	21.7%	25	21.4%	61
Total	166	100%	117	100%	283

Table 60: Number and Relative Proportion of Mouth cancer by Education

Mouth					
Education	Male	%	Female	%	Total
Illiterate	9	5.4%	21	17.9%	30
Literate	5	3.0%	2	1.7%	7
Primary	24	14.5%	16	13.7%	40
Secondary	11	6.6%	3	2.6%	14
Middle	13	7.8%	8	6.8%	21
College and above	1	0.6%	1	0.9%	2
Others	1	0.6%	1	0.9%	2
Unknown	102	61.4%	65	55.6%	167
Total	166	100%	117	100%	283

Table 61: Number and Relative Proportion of Mouth cancer by mother Tongue

Mouth					
Mother Tongue	Male	%	Female	%	Total
Malayalam	161	97.0%	116	99.1%	277
Kannada	1	0.6%	1	0.9%	2
Oriya	1	0.6%	0	0.0%	1
Unknown	3	1.8%	0	0.0%	3
Total	166	100%	117	100%	283

IV. Stomach Cancer

- Total Number (ICD 10: C16) :177 (76.3% in males and 23.7% in females)
- Stomach cancer is the 4th leading site among all cancers
- 3rd leading cancer among males
- Male to female ratio: 1:0.03
- Peak age group: 60-64years in males and 65-69 years in females
- Histology : Adenocarcinoma :59.3 % in males and 50.0% in females
- Method of diagnosis: Microscopic: 94.1% in males and 90.5% in females
- Detailed Microscopic diagnosis: Histology of Primary: 88.9% in males and 88.1% in females.
- Broad treatment group: Treatment only at RI: 25.9% in males and 19% in females
- Clinical extent of disease(Treatment only at RI, No treatment): Distant: 68.1% in males and 65.6% in females
- Type of treatment (Treatment only at RI, no treatment):R-therapy : 22.9% in males and 12.5% in females.
- Treatment status(Excluding cancer previously treated) : Received: 38.5% in males and 25% in females
- Intention to treat : Curative: 58.8% in males and 75.0% in females.
- Marital status : Married: 95.5% in males and 78.0% in females.
- Religion : Hindu: 54.8% in males and 52.4% in females
- Education : Primary: 25.9% in males and 14.3% in females

Table 62: Number and Relative Proportion of Stomach cancer by five year age group

Stomach					
Age	Male	%	Female	%	Total
25-29	1	0.7%	3	7.1%	4
35-39	4	3.0%	4	9.5%	8
40-44	5	3.7%	6	14.3%	11
45-49	7	5.2%	2	4.8%	9
50-54	13	9.6%	4	9.5%	17
55-59	12	8.9%	2	4.8%	14
60-64	30	22.2%	5	11.9%	35
65-69	24	17.8%	8	19.0%	32
70-74	18	13.3%	2	4.8%	20
>=75	21	15.6%	6	14.3%	27
Total	135	100%	42	100%	177

Table 63: Number and Relative Proportion of Stomach Cancer by method of diagnosis

Stomach					
Method of diagnosis	Male	%	Female	%	Total
Microscopic	127	94.1%	38	90.5%	165
X-Ray/Imaging Techniques	5	3.7%	2	4.8%	7
Others	3	2.2%	2	4.8%	5
Total	135	100%	42	100%	177

Table 64: Number and Relative Proportion of Stomach detailed Microscopic Diagnosis

Stomach					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Endoscopy	0	0.0%	1	2.4%	1
Histology of Metastasis	7	5.2%	1	2.4%	8
Histology of Primary	120	88.9%	37	88.1%	157
Others	7	5.2%	2	4.8%	9
Ultrasonogram	1	0.7%	1	2.4%	2
Total	135	100%	42	100%	177

Table 65: Number and Relative Proportion of Stomach cancer by histology

Stomach					
Morphology	Male	%	Female	%	total
Adenocarcinoma	80	59.3%	21	50.0%	101
Adenocarcinoma Intestinal Type	1	0.7%	0	0.0%	1
AdenoSquamous Cell Carcinoma	1	0.7%	0	0.0%	1
Carcinoma	6	4.4%	3	7.1%	9
Carcinoma Diffuse Type	2	1.5%	1	2.4%	3
Gastrointestinal Stromal Tumor	2	1.5%	1	2.4%	3
Mucin SecretingAdenoCarcinoma	2	1.5%	0	0.0%	2
MusinousAdenoCarcinoma	0	0.0%	1	2.4%	1
Neoplasam Malignant	15	11.1%	5	11.9%	20
Neuroendocrine Carcinoma	2	1.5%	0	0.0%	2
others	2	1.5%	1	2.4%	3
Signet RingCell Carcinoma	14	10.4%	5	11.9%	19
Squamous Cell Carcinoma	5	3.7%	4	9.5%	9
Tubular Adenocarcinoma	3	2.2%	0	0.0%	3
Total	135	100%	42	100%	177

Clinical Information

Table 66: Number and Relative Proportion of Stomach Cancer by Broad Treatment Group

Stomach					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	36	26.7	6	14.3	42
Prior & Treatment at RI	8	5.9	4	9.5	12
Treatment only at RI	35	25.9	8	19	43
No Treatment	56	41.5	24	57.1	80
Total	135	100	42	100	177

Table 67: Number and Relative Proportion of Stomach Cancer by Clinical Extent of Disease

Stomach					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	12	8.9%	4	9.5%	16
Direct Extension with Regional Nodes	12	8.9%	6	14.3%	18
Distant Metastasis	31	23.0%	11	26.2%	42
Localised	1	0.7%	0	0.0%	1
Others (specify)	4	3.0%	2	4.8%	6
Recurrent	5	3.7%	0	0.0%	5
Too Advanced	38	28.1%	11	26.2%	49
Treated Elsewhere	32	23.7%	8	19.0%	40
Total	135	1	42	100%	177

Table 68: Number and Relative Proportion of Stomach cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Stomach					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	1	1.1			1
Regional	23	25.3	9	28.1	32
Distant	62	68.1	21	65.6	83
Others	5	5.5	2	6.2	7
Total	91	100	32	100	123

Table 69: Number and Proportion of Stomach cancers by type of treatment (Treatment Only at RI)

Stomach					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery	12	34.3	2	25	14
R-Therapy	8	22.9	1	12.5	9
C-Therapy	6	17.1	1	12.5	7
S+C	6	17.1	3	38	9
S+R+C	2	5.7	1	13	3
Others	1	2.9			1
Total	35	100	8	100	43

Table 70: Number and Relative Proportion of Stomach cancer by any specific treatment (Treatment Only at RI)

Stomach					
Any specific Treatment	Male	%	Female	%	Total
Any S	20	43.5	6	46.2	26
Any R	11	23.9	2	15.4	13
Any C	14	30.4	5	38.5	19
Any H	1	2.2			1
Total	46	100	13	100	59

Table 71: Number and Relative Proportion of Stomach cancer by Treatment Status (Excluding the cancers previously treated)

Stomach					
Treatment Status	Male	%	Female	%	Total
Received	35	38.5	8	25	43
Not Received	52	57.1	20	62.5	72
Incomplete	4	4.4	4	12.5	8
Total	91	100	32	100	123

Table 72: Number and Relative Proportion of Stomach Cancer intention to treat at MCC

Stomach					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	20	58.8%	6	75.0%	26
Palliative	14	41.2%	2	25.0%	16
Total	34	100%	8	100%	42

Basic Demographic Parameters

Table 73: Number and Relative Proportion of Stomach cancer by marital Status

Stomach					
Marital Status	Male	%	Female	%	Total
Married	128	95.5%	32	78.0%	160
Unmarried	1	0.7%	1	2.4%	2
Widowed	3	2.2%	7	17.1%	10
Unknown	2	1.5%	1	2.4%	3
Total	134	100%	41	100%	175

Table 74: Number and Relative Proportion of Stomach cancer by Religion

Stomach					
Religion	Male	%	Female	%	Total
Christian	16	11.9%	4	9.5%	20
Hindu	74	54.8%	22	52.4%	96
Muslim	45	33.3%	16	38.1%	61
Total	135	100%	42	100%	177

Table 75: Number and Relative Proportion of Stomach cancer by Education

Stomach					
Education	Male	%	Female	%	Total
Illiterate	13	9.6%	6	14.3%	19
LIterate	6	4.4%	1	2.4%	7
Primary	35	25.9%	6	14.3%	41
Secondary	12	8.9%	1	2.4%	13
Middle	18	13.3%	7	16.7%	25
College and above	2	1.5%	1	2.4%	3
Others	1	0.7%	0	0.0%	1
Unknown	48	35.6%	20	47.6%	68
Total	135	100%	42	100%	177

Table 76: Number and Relative Proportion of Stomach cancer by mother Tongue

Stomach					
Mother Tongue	Male	%	Female	%	Total
Malayalam	133	98.5%	42	100.0%	175
Konkani	1	0.7%	0	0.0%	1
Tamil	1	0.7%	0	0.0%	1
Total	135	100%	42	100%	177

V. NHL

- Total Number (ICD 10: C01-02) :176 (34.1% in females and 65.9% in males)
- NHL cancer is the fifth leading cancer among all
- 5th leading cancer among males
- Male to female ratio:1:0.5
- Peak age group: ≥ 75 years in females and 60-64 years in males
- Histology : NHL, Large Bcell diffuse: 28.4% in males and 35% in females
- Method of diagnosis: Microscopic: 100% in males and 98.3% in females
- Detailed Microscopic diagnosis: Histology of Primary: 99.1% in males and 98.3% in females
- Broad treatment group: Treatment only at RI : 50.9% in males and 56.7% in females
- Clinical extent of disease (Treatment Only at RI, no treatment): Regional: 65.9% in males and 62.5% in females
- Type of treatment (Treatment only at RI): C-Therapy: 79.4% in females and 67.8% in males
- Treatment status(Excluding cancer previously treated) : Received: 67% in males and 71% in females
- Intention to treat :Curative/Radical : 94.9% in males and 82.4% in females
- Marital status : Married: 91.4% in males and 65.0% in females
- Religion : Hindu: 59.5% in males and 43.3% in females.
- Education : Secondary: 15.0% in females and 22.4% in males.

Table 77: Number and Relative Proportion of NHL cancer by five year age group

NHL					
Age	Male	%	Female	%	Total
10-14	1	0.9%	1	1.7%	2
15-19	0	0.0%	1	1.7%	1
20-24	2	1.7%	0	0.0%	2
25-29	1	0.9%	2	3.3%	3
30-34	7	6.0%	4	6.7%	11
35-39	7	6.0%	2	3.3%	9
40-44	12	10.3%	8	13.3%	20
45-49	14	12.1%	3	5.0%	17
50-54	11	9.5%	4	6.7%	15
55-59	15	12.9%	4	6.7%	19
60-64	19	16.4%	10	16.7%	29
65-69	10	8.6%	6	10.0%	16
70-74	7	6.0%	4	6.7%	11
>=75	10	8.6%	11	18.3%	21
Total	116	100%	60	100%	176

Table 78: Number and Relative Proportion of NHL Cancer by method of diagnosis

NHL					
Method of diagnosis	Male	%	Female	%	Total
Microscopic	116	100.0%	59	98.3%	175
Others	0	0.0%	1	1.7%	1
Total	116	100%	60	100%	176

Table 79: Number and Relative Proportion of NHL detailed Microscopic Diagnosis

NHL					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Histology of Metastasis	1	0.9%	0	0.0%	1
Histology of Primary	115	99.1%	59	98.3%	174
Others	0	0.0%	1	1.7%	1
Total	116	100%	60	100%	176

Table 80: Number and Relative Proportion of NHL Cancer by histology

NHL					
Morphology	Male	%	Female	%	total
Anaplastic Large Cell Lymphoma T-Cell and Null Cell Type	4	3.4%	2	3.3%	6

Chronic Myeloproliferative Disease	0	0.0%	1	1.7%	1
Cutaneous T-Cell Lymphoma	1	0.9%	0	0.0%	1
Malignant Lymphoma	1	0.9%	1	1.7%	2
Mature T-Cell Lymphoma	7	6.0%	4	6.7%	11
NHL,Follicular Lymphoma	19	16.4%	7	11.7%	26
NHL,Large B Cell Diffuse	33	28.4%	21	35.0%	54
NHL,Mantle Cell Lymphoma	3	2.6%	0	0.0%	3
NHL,Marginal Zone B Cell lymphoma	0	0.0%	1	1.7%	1
NHL,Mixed Small and Large Cell Diffuse	2	1.7%	0	0.0%	2
NHL,Small B Lymphocytic	2	1.7%	0	0.0%	2
NHLNos	14	12.1%	11	18.3%	25
others	29	25.0%	11	18.3%	40
Precursor Cell Lymphoblastic Lymphoma	0	0.0%	1	1.7%	1
Precursor T-Cell Lymphoblastic Lymphoma	1	0.9%	0	0.0%	1
Total	116	100%	60	100%	176

Clinical Information

Table 81: Number and Relative Proportion of NHL Cancer by Broad Treatment Group

NHL					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	20	17.2	8	13.3	28
Prior & Treatment at RI	8	6.9	4	6.7	12
Treatment only at RI	59	50.9	34	56.7	93
No Treatment	29	25	14	23.3	43
Total	116	100	60	100	176

Table 82: Number and Relative Proportion of NHL Cancer by Clinical Extent of Disease

NHL					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	15	12.9%	7	11.7%	22
Distant Metastasis	2	1.7%	1	1.7%	3
Not Palpable	35	30.2%	17	28.3%	52
Others (specify)	2	1.7%	1	1.7%	3
Recurrent	2	1.7%	1	1.7%	3
Regional Nodes	44	37.9%	26	43.3%	70
Too Advanced	1	0.9%	0	0.0%	1
Treated Elsewhere	15	12.9%	7	11.7%	22
Total	116	100%	60	100%	176

Table 83: Number and Relative Proportion of NHL Cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

NHL					
Clinical Extent of Disease	Male	%	Female	%	Total
Regional	58	65.9	30	62.5	88
Distant	3	3.4	1	2.1	4
Others	27	30.7	17	35.4	44
Total	88	100	48	100	136

Table 84: Number and Proportion of NHL Cancers by type of treatment (Treatment Only at RI)

NHL					
Clinical Extent of Disease	Male	%	Female	%	Total
R-Therapy	3	5.1	2	5.9	5
C-Therapy	40	67.8	27	79.4	67
S+C	1	1.7			1
R+C	7	12	3	8.8	10
Others	8	13.6	2	5.9	10
Total	59	100	34	100	93

Table 85: Number and Relative Proportion of NHL Cancer by any specific treatment (Treatment Only at RI)

NHL					
Any specific Treatment	Male	%	Female	%	Total
Any S	1	1.5			1
Any R	10	14.9	5	13.5	15
Any C	48	71.6	30	81.1	78
Others	8	11.9	2	5.4	10
Total	67	100	37	100	104

Table 86: Number and Relative Proportion of NHL Cancer by Treatment Status (Excluding the cancers previously treated)

NHL					
Treatment Status	Male	%	Female	%	Total
Received	59	67	34	71	93
Not Received	24	27.3	11	22.9	35
Incomplete	5	5.7	3	6.2	8
Total	88	100	48	100	136

Table 87: Number and Relative Proportion of NHL Cancer intention to treat at MCC

NHL					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	56	94.9%	28	82.4%	84
Palliative	3	5.1%	6	17.6%	9
Total	59	100%	34	100%	93

Basic Demographic Parameters

Table 88: Number and Relative Proportion of NHL Cancer by marital Status

NHL					
Marital Status	Male	%	Female	%	Total
Married	106	91.4%	39	65.0%	145
Unmarried	4	3.4%	4	6.7%	8
Widowed	3	2.6%	12	20.0%	15
Unknown	3	2.6%	5	8.3%	8
Total	116	100%	60	100%	176

Table 89: Number and Relative Proportion of NHL Cancer by Religion

NHL					
Religion	Male	%	Female	%	Total
Christian	10	8.6%	12	20.0%	22
Hindu	69	59.5%	26	43.3%	95
Muslim	36	31.0%	22	36.7%	58
Unknown	1	0.9%	0	0.0%	1
Total	116	100%	60	100%	176

Table 90: Number and Relative Proportion of NHL cancer by Education

NHL					
Education	Male	%	Female	%	Total
Illiterate	3	2.6%	5	8.3%	8
Literate	3	2.6%	0	0.0%	3
Primary	17	14.7%	11	18.3%	28
Secondary	26	22.4%	9	15.0%	35
Middle	11	9.5%	4	6.7%	15
College and above	10	8.6%	2	3.3%	12
Technical-after matric	3	2.6%	1	1.7%	4
Others	1	0.9%	0	0.0%	1
Unknown	42	36.2%	28	46.7%	70
Total	116	100%	60	100%	176

Table 91: Number and Relative Proportion of NHLcancer by mother Tongue

NHL					
Mother Tongue	Male	%	Female	%	Total
Malayalam	114	98.3%	60	100.0%	174
Kashmiri	1	0.9%	0	0.0%	1
Unknown	1	0.9%	0	0.0%	1
Total	116	100%	60	100%	176

VI. Tongue Cancer

- Total Number (ICD 10: C01-02) : 167(30.5% in females and 69.4% in males)
- Tongue cancer is the fifth leading cancer among all
- 4th leading cancer among males
- Male to female ratio:1:0.4
- Peak age group: ≥ 75 years in females and 65-69 years in males
- Histology : Squamous cell Carcinoma: 81.0 % in males and 66.7% in females
- Method of diagnosis: Microscopic: 94.8% in males and 88.2% in females
- Detailed Microscopic diagnosis: Histology of Primary:90.5 % in males and 84.3 % in females
- Broad treatment group: Treatment only at RI : 61.2% in males and 51% in females
- Clinical extent of disease (Treatment Only at RI, no treatment): Regional: 89.4% in males and 77.8% in females
- Type of treatment (Treatment only at RI): Surgery: 30.8% in females and 40.8% in males
- Treatment status(Excluding cancer previously treated) : Received: 75.5% in males and 72% in females
- Intention to treat :Curative/Radical : 81.7% in males and 69.2% in females
- Marital status : Married: 90.5% in males and 66.7% in females
- Religion : Hindu: 70.7% in males and 68.6% in females.
- Education : Primary: 11.8% in females and 13.8% in males.

Table 92: Number and Relative Proportion of Tongue Cancer by five year age group

NHL					
Age	Male	%	Female	%	Total
25-29	1	0.9%	2	3.9%	3
30-34	3	2.6%	2	3.9%	5
35-39	7	6.0%	3	5.9%	10
40-44	12	10.3%	2	3.9%	14
45-49	15	12.9%	1	2.0%	16
50-54	14	12.1%	1	2.0%	15
55-59	7	6.0%	11	21.6%	18
60-64	19	16.4%	9	17.6%	28
65-69	19	16.4%	2	3.9%	21
70-74	13	11.2%	5	9.8%	18
≥ 75	6	5.2%	13	25.5%	19
Total	116	100%	51	100%	167

Table 93: Number and Relative Proportion of Tongue Cancer by method of diagnosis

TONGUE					
Method of diagnosis	Male	%	Female	%	Total
Clinical Only	2	1.7%	3	5.9%	5
Microscopic	110	94.8%	45	88.2%	155
X-Ray/Imaging Techniques	1	0.9%	0	0.0%	1
Others	3	2.6%	3	5.9%	6
Total	116	100%	51	100%	167

Table 94: Number and Relative Proportion of Tongue detailed Microscopic Diagnosis

TONGUE					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.9%	0	0.0%	1
Histology of Metastasis	4	3.4%	2	3.9%	6
Histology of Primary	105	90.5%	43	84.3%	148
Others	6	5.2%	6	11.8%	12
Total	116	100%	51	100%	167

Table 95: Number and Relative Proportion of Tongue Cancer by histology

TONGUE					
Morphology	Male	%	Female	%	total
Adenocystic Carcinoma	0	0.0%	1	2.0%	1
Carcinoma	1	0.9%	0	0.0%	1
Microinvasive Squamous Cell Carcinoma	7	6.0%	6	11.8%	13
Mucoepidermoid Carcinoma	1	0.9%	0	0.0%	1
Neoplasam Malignant	10	8.6%	8	15.7%	18
others	1	0.9%	0	0.0%	1
Sarcomatiod Carcinoma	1	0.9%	0	0.0%	1
Squamous Cell Carcinoma	94	81.0%	34	66.7%	128
Squamous Cell Carcinoma Keratinising	0	0.0%	1	2.0%	1
Verrcous Carcinoma	1	0.9%	1	2.0%	2
Total	116	100%	51	100%	167

Clinical Information

Table 96: Number and Relative Proportion of Tongue cancer by Broad Treatment Group

TONGUE					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	11	9.5	12	23.5	23
Prior & Treatment at RI	11	9.5	3	5.9	14
Treatment only at RI	71	61.2	26	51	97
No Treatment	23	19.8	10	19.6	33
Total	116	100	51	100	167

Table 97: Number and Relative Proportion of Tongue cancer by Clinical Extent of Disease

TONGUE					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	35	30.2%	17	33.3%	52
Direct Extension with Regional Nodes	52	44.8%	13	25.5%	65
Distant Metastasis	4	3.4%	5	9.8%	9
Localised	3	2.6%	1	2.0%	4
Not Palpable	1	0.9%	0	0.0%	1
Others (specify)	1	0.9%	0	0.0%	1
Recurrent	1	0.9%	1	2.0%	2
Too Advanced	3	2.6%	3	5.9%	6
Treated Elsewhere	16	13.8%	11	21.6%	27
Total	116	1	51	100%	167

Table 98: Number and Relative Proportion of Tongue cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

TONGUE					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	3	3.2	1	2.8	4
Regional	84	89.4	28	77.8	112
Distant	6	6.4	7	19.4	13
Others	1	1.1			1
Total	94	100	36	100	130

Table 99: Number and Proportion of Tongue cancers by type of treatment (Treatment Only at RI)

TONGUE					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery	29	40.8	8	30.8	37
R-Therapy	11	15.5	6	23.1	17
C-Therapy			1	3.8	1
S+R	21	29.6	10	38.5	31
R+C	2	2.8			2
S+R+C	8	11.3	1	3.8	9
Total	71	100	26	100	97

Table 100: Number and Relative Proportion of Tongue Cancer by any specific treatment (Treatment Only at RI)

TONGUE					
Any specific Treatment	Male	%	Female	%	Total
Any S	58	52.7	19	50	77
Any R	42	38.2	17	44.7	59
Any C	10	9.1	2	5.3	12
Total	110	100	38	100	148

Table 101: Number and Relative Proportion of Tongue Cancer by Treatment Status (Excluding the cancers previously treated)

TONGUE					
Treatment Status	Male	%	Female	%	Total
Received	71	75.5	26	72	97
Not Received	20	21.3	9	25	29
Incomplete	3	3.2	1	2.8	4
Total	94	100	36	100	130

Table 102: Number and Relative Proportion of Tongue Cancer intention to treat at MCC

TONGUE					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	58	81.7%	18	69.2%	76
Palliative	13	18.3%	8	30.8%	21
Total	71	100%	26	100%	97

Basic Demographic Parameters

Table 103: Number and Relative Proportion of Tongue Cancer by marital Status

TONGUE					
Marital Status	Male	%	Female	%	Total
Married	105	90.5%	34	66.7%	139
Unmarried	4	3.4%	1	2.0%	5
Widowed	3	2.6%	14	27.5%	17
Unknown	4	3.4%	2	3.9%	6
Total	116	100%	51	100%	167

Table 104: Number and Relative Proportion of Tonguecancer by Religion

TONGUE					
Religion	Male	%	Female	%	Total
Christian	12	10.3%	3	5.9%	15
Hindu	82	70.7%	35	68.6%	117
Muslim	22	19.0%	13	25.5%	35
Total	116	100%	51	100%	167

Table 105: Number and Relative Proportion of Tongue Cancer by Education

TONGUE					
Education	Male	%	Female	%	Total
Illiterate	5	4.3%	5	9.8%	10
Literate	5	4.3%	4	7.8%	9
Primary	16	13.8%	6	11.8%	22
Secondary	13	11.2%	0	0.0%	13
Middle	12	10.3%	2	3.9%	14
College and above	5	4.3%	0	0.0%	5
Technical-after matric	1	0.9%	1	2.0%	2
Unknown	59	50.9%	33	64.7%	92
Total	116	100%	51	100%	167

Table 106: Number and Relative Proportion of Tongue Cancer by mother Tongue

TONGUE					
Mother Tongue	Male	%	Female	%	Total
Malayalam	114	98.3%	51	100.0%	165
Oriya	1	0.9%	0	0.0%	1
Unknown	1	0.9%	0	0.0%	1
Total	116	100%	51	100%	167

VII. Rectum Cancer

- Total Number (ICD 10: C01-02) : 151 (43.04% in females and 56.9% in males)
- Rectum cancer is the seventh leading cancer among all
- 7th leading cancer among males
- Male to female ratio:1:0.7
- Average age at diagnosis is years. years
- Peak age group: ≥ 75years in females and 60-64 years in males
- Histology : Adenocarcinoma: 88.4% in males and 90.8% in females
- Method of diagnosis: Microscopic: 95.3% in males and 95.4% in females
- Detailed Microscopic diagnosis: Histology of Primary: 93.0% in males and 93.8% in females
- Broad treatment group: Treatment only at RI : 33.7% in males and 30.8% in females
- Clinical extent of disease (Treatment Only at RI, no treatment): Regional: 61.5% in males and 50% in females
- Type of treatment (Treatment only at RI): Surgery: 17.2% in males and 30% in females
- Treatment status (Excluding cancer previously treated) : Received: 55.8% in males and 56% in females
- Intention to treat : Curative/Radical : 89.7% in males and 70.0% in females
- Marital status : Married: 89.7% in males and 53.0% in females
- Religion : Hindu: 61.6% in males and 53.8% in females.
- Education : Primary: 17.4 % in males and 12.3% in females.

Table 107: Number and Relative Proportion of Rectum cancer by five year age group

TONGUE					
Age	Male	%	Female	%	Total
20-24	1	1.2%	0	0.0%	1
30-34	1	1.2%	0	0.0%	1
35-39	1	1.2%	4	6.2%	5
40-44	3	3.5%	3	4.6%	6
45-49	8	9.3%	5	7.7%	13
50-54	8	9.3%	9	13.8%	17
55-59	10	11.6%	8	12.3%	18
60-64	19	22.1%	7	10.8%	26
65-69	13	15.1%	11	16.9%	24
70-74	10	11.6%	5	7.7%	15
>=75	12	14.0%	13	20.0%	25
Total	86	100%	65	100%	151

Table 108: Number and Relative Proportion of Rectum Cancer by method of diagnosis

TONGUE					
Method of diagnosis	Male	%	Female	%	Total
Microscopic	82	95.3%	62	95.4%	144
X-Ray/Imaging Techniques	0	0.0%	2	3.1%	2
Others	4	4.7%	1	1.5%	5
Total	86	100%	65	100%	151

Table 109: Number and Relative Proportion of Rectum Cancer detailed Microscopic Diagnosis

TONGUE					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Endoscopy	0	0.0%	1	1.5%	1
Histology of Metastasis	2	2.3%	1	1.5%	3
Histology of Primary	80	93.0%	61	93.8%	141
Others	4	4.7%	2	3.1%	6
Total	86	100%	65	100%	151

Table 110: Number and Relative Proportion of Rectum cancer by histology

TONGUE					
Morphology	Male	%	Female	%	Total
Adenocarcinoma	76	88.4%	59	90.8%	135
Carcinoma	0	0.0%	1	1.5%	1
Mucin SecretingAdenoCarcinoma	2	2.3%	0	0.0%	2
MusinousAdenoCarcinoma	1	1.2%	0	0.0%	1
Neoplasam Malignant	6	7.0%	4	6.2%	10
Signet RingCell Carcinoma	1	1.2%	1	1.5%	2
Total	86	100%	65	100%	151

Clinical Information

Table 111: Number and Relative Proportion of Rectum Cancer by Broad Treatment Group

RECTUM					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	23	26.7	14	21.5	37
Prior & Treatment at RI	11	12.8	15	23.1	26
Treatment only at RI	29	33.7	20	30.8	49
No Treatment	23	26.7	16	24.6	39
Total	86	100	65	100	151

Table 112: Number and Relative Proportion of Rectum cancer by Clinical Extent of Disease (Prior & Treatment at RI)

RECTUM					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	19	22.1%	9	13.8%	28
Direct Extension with Regional Nodes	14	16.3%	13	20.0%	27
Distant Metastasis	10	11.6%	8	12.3%	18
Localised	1	1.2%	0	0.0%	1
Others (specify)	0	0.0%	3	4.6%	3
Recurrent	2	2.3%	3	4.6%	5
Too Advanced	11	12.8%	9	13.8%	20
Treated Elsewhere	29	33.7%	19	29.2%	48
Unknown	0	0.0%	1	1.5%	1
Total	86	100%	65	100%	151

Table 113: Number and Relative Proportion of Rectum cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

RECTUM					
Clinical Extent of Disease	Male	%	Female	%	Total
Localised	1	1.9			1
Regional	32	61.5	18	50	50
Distant	19	36.5	14	38.9	33
Others			3	8.3	3
Unknown			1	2.8	1
Total	52	100	36	100	88

**Table 114: Number and Proportion of Rectum cancers by type of treatment
(Treatment Only at RI)**

RECTUM					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery	5	17.2	6	30	11
R-Therapy	1	3.4	4	20	5
C-Therapy	2	6.9	2	10	4
S+R	1	3.4	1		2
S+C	5	17.2	2	10	7
R+C	3	10	2	10	5
S+R+C	12	41.4	4	20	16
Total	29	100	21	100	50

**Table 115: Number and Relative Proportion of Rectum Cancer by any specific treatment
(Treatment Only at RI)**

RECTUM					
Any specific Treatment	Male	%	Female	%	Total
Any S	23	37.1	12	37.5	35
Any R	17	27.4	10	31.2	27
Any C	22	35.5	10	31.2	32
Total	62	100	32	100	94

**Table 116: Number and Relative Proportion of Rectum Cancer by Treatment Status
(Excluding the cancers previously treated)**

RECTUM					
Treatment Status	Male	%	Female	%	Total
Received	29	55.8	20	56	49
Not Received	21	40.4	15	41.7	36
Incomplete	2	3.8	1	2.8	3
Total	52	100	36	100	88

Table 117: Number and Relative Proportion of Rectum Cancer intention to treat at MCC

RECTUM					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	26	89.7%	14	70.0%	40
Pallative	3	10.3%	6	30.0%	9
Total	29	100%	20	100%	49

Basic Demographic Parameters

Table 118: Number and Relative Proportion of Rectum cancer by marital Status

RECTUM					
Marital Status	Male	%	Female	%	Total
Married	78	89.7%	35	53.0%	113
Unmarried	1	1.1%	2	3.0%	3
Widowed	1	1.1%	23	34.8%	24
Divorced	0	0%	1	1.5%	1
Unknown	6	6.9%	4	6.1%	10
Total	86	100%	65	100%	151

Table 119: Number and Relative Proportion of Rectum cancer by Religion

RECTUM					
Religion	Male	%	Female	%	Total
Christian	10	11.6%	7	10.8%	17
Hindu	53	61.6%	35	53.8%	88
Muslim	21	24.4%	23	35.4%	44
Unknown	2	2.3%	0	0.0%	2
Total	86	100%	65	100%	151

Table 120: Number and Relative Proportion of Rectum cancer by Education

RECTUM					
Education	Male	%	Female	%	Total
Illiterate	3	3.5%	9	13.8%	12
LIterate	6	7.0%	2	3.1%	8
Primary	15	17.4%	8	12.3%	23
Secondary	11	12.8%	4	6.2%	15
Middle	11	12.8%	8	12.3%	19
College and above	2	2.3%	2	3.1%	4
Others	1	1.2%	0	0.0%	1
Unknown	37	43.0%	32	49.2%	69
Total	86	100%	65	100%	151

Table 121: Number and Relative Proportion of Rectum cancer by mother Tongue

RECTUM					
Mother Tongue	Male	%	Female	%	Total
Malayalam	86	100	65	100	151

VIII. Cervix Cancer

- Total Number (ICD 10: C53) :135
- Cervix cancer is the 9th leading cancer among all cancers
- 2nd leading cancer among females
- Average age at diagnosis is years: years
- Peak age group: 50-54years
- Histology : Squamous cell carcinoma: 29.6%
- Method of diagnosis: Microscopic: 88.9%
- Detailed Microscopic diagnosis: Histology of Primary : 88.7%
- Broad treatment group: Treatment only at RI : 45.2%
- Clinical extent of disease(Treatment only at RI, no treatment): Regional: 75.6%
- Type of treatment : R+C: 63.9%
- Treatment status(Excluding cancer previously treated) : Received: 71%
- Intention to treat : Curative/Radical : 78.7%
- Marital status : Married: 68.9%
- Religion : Hindu :73.3 %
- Education : Primary: 14.1%

Table 122: Number and Relative Proportion of Cervix cancer by five year age group

Cervix Uteri			
Age	Female	%	Total
30-34	1	0.7%	1
35-39	5	3.7%	5
40-44	14	10.4%	14
45-49	21	15.6%	21
50-54	27	20.0%	27
55-59	18	13.3%	18
60-64	14	10.4%	14
65-69	13	9.6%	13
70-74	8	5.9%	8
>=75	14	10.4%	14
Total	135	100%	135

Table 123: Number and Relative Proportion of Cervix Cancer by method of diagnosis

Cervix Uteri			
Method of diagnosis	Female	%	Total
Clinical Only	7	5.2%	7
Microscopic	120	88.9%	120
Others	8	5.9%	8
Total	135	100%	135

Table 124: Number and Relative Proportion of Cervix detailed Microscopic Diagnosis

Cervix Uteri			
Detailed Method of Diagnosis	Female	%	Total
Histology of Metastasis	2	1.5%	2
Histology of Primary	118	88.7%	118
Others	15	9.8%	15
Total	135	100%	135

Table 125: Number and Relative Proportion of Cervix cancer by histology

Cervix Uteri			
Morphology	Female	%	total
Adenocarcinoma	7	5.2%	7
Adenocystic Carcinoma	1	0.7%	1
AdenoSquamous Cell Carcinoma	1	0.7%	1
Carcino Sarcoma	1	0.7%	1
Carcinoma	1	0.7%	1
Endocervical Adenocarcinoma	4	3.0%	4
Microinvasive Squamous Cell Carcinoma	2	1.5%	2
Neoplasam Malignant	17	12.6%	17
Neuroendocrine Carcinoma	1	0.7%	1
others	5	3.7%	5
Papillary AdenoCarcinoma	1	0.7%	1
Serous CystadenoCarcinoma	1	0.7%	1
Squamous Cell Carcinoma	40	29.6%	40
Squamous Cell Carcinoma Keratinising	27	20.0%	27
Squamous Cell Carcinoma Non Keratinising	26	19.3%	26
Total	135	100%	135

Clinical Information

Table 126: Number and Relative Proportion of Cervix cancer by Broad Treatment Group

Cervix Uteri			
Broad Treatment group	Female	%	Total
Prior treatment only	28	20.7	28
Prior & Treatment at RI	21	15.6	21
Treatment only at RI	61	45.2	61
No Treatment	25	18.5	25
Total	135	100	135

Table 127: Number and Relative Proportion of Cervix cancer by Clinical Extent of Disease

Cervix Uteri			
Clinical Extent before Treatment	Female	%	Total
Direct Extension	66	48.9%	66
Direct Extension with Regional Nodes	8	5.9%	8
Distant Metastasis	11	8.1%	11
Localised	1	0.7%	1
Others (specify)	2	1.5%	2
Recurrent	5	3.7%	5
Regional Nodes	1	0.7%	1
Too Advanced	10	7.4%	10
Treated Elsewhere	31	23.0%	31
Total	135	100%	135

Table 128: Number and Relative Proportion of Cervix cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Cervix Uteri			
Clinical Extent of Disease	Female	%	Total
Localised	1	1.2	1
Regional	65	75.6	65
Distant	18	20.9	18
Others	2	2.3	2
Total	86	100	86

Table 129: Number and Proportion of Cervix cancers by type of treatment (Treatment Only at RI)

Cervix Uteri			
Clinical Extent of Disease	Female	%	Total
Surgery	3	4.9	3
R-Therapy	13	21.3	13
C-Therapy	1	1.6	1
S+R	4	6.6	4
R+C	39	63.9	39
S+R+C	1	1.6	1
Total	61	100	61

Table 130: Number and Relative Proportion of Cervix cancer by any specific treatment (Treatment Only at RI)

Cervix Uteri			
Any specific Treatment	Female	%	Total
Any S	8	7.5	8
Any R	57	53.8	57
Any C	41	38.7	41
Total	106	100	106

Table 131: Number and Relative Proportion of Cervix cancer by Treatment Status (Excluding the cancers previously treated)

Cervix Uteri			
Treatment Status	Female	%	Total
Received	61	71	61
Not Received	22	25.6	22
Not Accepted	1	1.2	1
Incomplete	2	2.3	2
Total	86	100	86

Table 132: Number and Relative Proportion of Cervix Cancer intention to treat at MCC

Cervix Uteri			
Intention to treat	Female	%	Total
Curative / Radical	48	78.7%	48
Pallative	13	21.3%	13
Total	61	100%	61

Basic Demographic Parameters

Table 133: Number and Relative Proportion of Cervix cancer by marital Status

Cervix Uteri			
Marital Status	Female	%	Total
Married	93	68.9%	93
Divorced	1	0.7%	1
Unmarried	1	0.7%	1
Widowed	37	27.4%	37
Other	1	0.7%	1
Unknown	2	1.5%	2
Total	135	100%	135

Table 134: Number and Relative Proportion of Cervix cancer by Religion

Cervix Uteri			
Religion	Female	%	Total
Christian	9	6.7%	9
Hindu	99	73.3%	99
Muslim	27	20.0%	27
Total	135	100%	135

Table 135: Number and Relative Proportion of Cervix cancer by Education

Cervix Uteri			
Education	Female	%	Total
Illiterate	11	8.1%	11
Literate	6	4.4%	6
Primary	19	14.1%	19
Secondary	6	4.4%	6
Middle	12	8.9%	12
College and above	2	1.5%	2
Others	1	0.7%	1
Unknown	78	57.8%	78
Total	135	100%	135

Table 136: Number and Relative Proportion of Cervix cancer by mother Tongue

Cervix Uteri			
Mother Tongue	Female	%	Total
Malayalam	135	100	135

IX. Oesophagus Cancer

- Total Number (ICD 10: C01-02) : 128 (36.7% in females and 63.3% in males)
- Oesophagus cancer is the 9th leading cancer among all
- 8th leading cancer among males
- Male to female ratio:1:0.6
- Peak age group: 65-69 years in females and ≥ 75 years in males
- Histology : Squamous cell Carcinoma: 74.1% in males and 76.6% in females
- Method of diagnosis: Microscopic: 91.4% in males and 89.4% in females
- Detailed Microscopic diagnosis: Histology of Primary: 90.1% in males and 87.2% in females
- Broad treatment group: Treatment only at RI : 44.4% in males and 40.4% in females
- Clinical extent of disease(Treatment Only at RI): Distant: 73.5% in males and 76.9% in females
- Type of treatment (Treatment only at RI): R-Therapy: 73.7% in females and 86.1% in males
- Treatment status(Excluding cancer previously treated) : Received:52.9 % in males and 49% in females
- Intention to treat :Palliative : 91.7% in males and 84.2% in females
- Marital status : Married: 91.4% in males and 46.8% in females
- Religion : Hindu: 71.6% in males and 61.7% in females.
- Education : Primary: 4.3% in females and 24.7% in males.

Table 137: Number and Relative Proportion of Oesophagus cancer by five year age group

Oesophagus					
Age	Male	%	Female	%	Total
25-29	1	1.2%	0	0.0%	1
30-34	0	0.0%	1	2.1%	1
40-44	1	1.2%	1	2.1%	2
45-49	6	7.4%	0	0.0%	6
50-54	7	8.6%	4	8.5%	11
55-59	13	16.0%	7	14.9%	20
60-64	16	19.8%	5	10.6%	21
65-69	10	12.3%	12	25.5%	22
70-74	9	11.1%	8	17.0%	17
≥ 75	18	22.2%	9	19.1%	27
Total	81	100%	47	100%	128

Table 138: Number and Relative Proportion of Oesophagus Cancer by method of diagnosis

Oesophagus					
Method of diagnosis	Male	%	Female	%	Total
Microscopic	74	91.4%	42	89.4%	116
X-Ray/Imaging Techniques	4	4.9%	3	6.4%	7
Others	3	3.7%	2	4.3%	5
Total	81	100%	47	100%	128

Table 139: Number and Relative Proportion of Oesophagus detailed Microscopic Diagnosis

Oesophagus					
Detailed Method of Diagnosis	Male	%	Female	%	Total
Endoscopy	2	2.5%	1	2.1%	3
Histology of Metastasis	1	1.2%	1	2.1%	2
Histology of Primary	73	90.1%	41	87.2%	114
Others	5	6.2%	4	8.5%	9
Total	81	100%	47	100%	128

Table 140: Number and Relative Proportion of Oesophagus cancer by histology

Oesophagus					
Morphology	Male	%	Female	%	total
Adenocarcinoma	7	8.6%	2	4.3%	9
Carcinoma	2	2.5%	1	2.1%	3
Microinvasive Squamous Cell Carcinoma	1	1.2%	1	2.1%	2
MusinousAdenoCarcinoma	0	0.0%	1	2.1%	1
Neoplasam Malignant	8	9.9%	6	12.8%	14
others	1	1.2%	0	0.0%	1
Signet RingCell Carcinoma	1	1.2%	0	0.0%	1
Squamous Cell Carcinoma	60	74.1%	36	76.6%	96
Squamous Cell Carcinoma Keratinising	1	1.2%	0	0.0%	1
Total	81	100%	47	100%	128

Clinical Information

Table 141: Number and Relative Proportion of Oesophagus cancer by Broad Treatment Group

Oesophagus					
Broad Treatment group	Male	%	Female	%	Total
Prior treatment only	10	12.3	6	12.8	16
Prior & Treatment at RI	3	3.7	2	4.3	5
Treatment only at RI	36	44.4	19	40.4	55
No Treatment	32	39.5	20	42.6	52
Total	81	100	47	100	128

Table 142: Number and Relative Proportion of Oesophagus cancer by Clinical Extent of Disease

Oesophagus					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	11	13.6%	7	14.9%	18
Direct Extension with Regional Nodes	8	9.9%	1	2.1%	9
Distant Metastasis	5	6.2%	5	10.6%	10
Others (specify)	1	1.2%	1	2.1%	2
Too Advanced	47	58.0%	28	59.6%	75
Treated Elsewhere	9	11.1%	5	10.6%	14
Total	81	100%	47	100%	128

Table 143: Number and Relative Proportion of Oesophagus Cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Oesophagus					
Clinical Extent of Disease	Male	%	Female	%	Total
Regional	17	25	8	20.5	25
Distant	50	73.5	30	76.9	80
Others	1	1.5	1	2.6	2
Total	68	100	39	100	107

Table 144: Number and Proportion of Oesophagus cancers by type of treatment (Treatment Only at RI)

Oesophagus					
Clinical Extent of Disease	Male	%	Female	%	Total
Surgery			1	5.3	1
R-Therapy	31	86.1	14	73.7	45
C-Therapy	1	2.8			1
S+R	2	5.6			2
R+C	2	5.6	4	21.1	6
Total	36	100	19	100	55

Table 145: Number and Relative Proportion of Oesophagus cancer by any specific treatment (Treatment Only at RI)

Oesophagus					
Any specific Treatment	Male	%	Female	%	Total
Any S	2	5	1	4.3	3
Any R	35	87.5	18	78.3	53
Any C	3	7.5	4	17.4	7
Total	40	100	23	100	63

Table 146: Number and Relative Proportion of Oesophagus cancer by Treatment Status (Excluding the cancers previously treated)

Oesophagus					
Treatment Status	Male	%	Female	%	Total
Received	36	52.9	19	49	55
Not Received	28	41.2	20	51.3	48
Incomplete	4	5.9			4
Total	68	100	39	100	107

Table 147: Number and Relative Proportion of Oesophagus Cancer intention to treat at MCC

Oesophagus					
Intention to treat	Male	%	Female	%	Total
Curative / Radical	3	8.3%	3	15.8%	6
Palliative	33	91.7%	16	84.2%	49
Total	36	100%	19	100%	55

Basic Demographic Parameters

Table 148: Number and Relative Proportion of Oesophagus cancer by marital Status

Oesophagus					
Marital Status	Male	%	Female	%	Total
Married	74	91.4%	22	46.8%	96
Unmarried	5	6.2%	5	10.6%	10
Widowed	1	1.2%	16	34.0%	17
Divorced	0	0.0%	1	2.1%	1
Unknown	1	1.2%	3	6.4%	4
Total	81	100%	47	100%	128

Table 149: Number and Relative Proportion of Oesophagus cancer by Religion

Oesophagus					
Religion	Male	%	Female	%	Total
Christian	8	9.9%	7	14.9%	15
Hindu	58	71.6%	29	61.7%	87
Muslim	15	18.5%	10	21.3%	25
Unknown	0	0.0%	1	2.1%	1
Total	81	100%	47	100%	128

Table 150: Number and Relative Proportion of Oesophagus cancer by Education

Oesophagus					
Education	Male	%	Female	%	Total
Illiterate	5	6.2%	11	23.4%	16
Literate	6	7.4%	4	8.5%	10
Primary	20	24.7%	2	4.3%	22
Secondary	4	4.9%	6	12.8%	10
Middle	15	18.5%	2	4.3%	17
Unknown	31	38.3%	22	46.8%	53
Total	81	100%	47	100%	128

Table 151: Number and Relative Proportion of Oesophagus cancer by mother Tongue

Oesophagus					
Mother Tongue	Male	%	Female	%	Total
Malayalam	80	98.8%	46	97.9%	126
Rajasthani	0	0.0%	1	2.1%	1
Tamil	1	1.2%	0	0.0%	1
Total	81	100%	47	100%	128

X. Ovary Cancer

- Total Number (ICD 10: C53) :128
- Ovary cancer is the 10th leading cancer among all cancers
- 3rd leading cancer among females
- Peak age group: 50-54 years
- Histology : Serous Cyst adenocarcinoma : 32.8%
- Method of diagnosis: Microscopic: 81.3%
- Detailed Microscopic diagnosis: Histology of Primary : 64.8%
- Broad treatment group: Treatment only at RI : 32%
- Clinical extent of disease(Treatment only at RI): Distant: 61%
- Type of treatment : R+C: 68%
- Treatment status(Excluding cancer previously treated) : Received: 53%
- Intention to treat : Curative/Radical : 92.7%
- Marital status : Married: 68.8%
- Religion : Hindu :60.9%
- Education : Primary : 19.5%

Table 152: Number and Relative Proportion of Ovary cancer by five year age group

Ovary			
Age	Female	%	Total
15-19	2	1.6%	2
20-24	2	1.6%	2
30-34	3	2.3%	3
35-39	11	8.6%	11
40-44	14	10.9%	14
45-49	18	14.1%	18
50-54	21	16.4%	21
55-59	18	14.1%	18
60-64	11	8.6%	11
65-69	6	4.7%	6
70-74	10	7.8%	10
>=75	12	9.4%	12
Total	128	100%	128

Table 153: Number and Relative Proportion of Ovary Cancer by method of diagnosis

Ovary			
Method of diagnosis	Female	%	Total
Microscopic	104	81.3%	104
X-Ray/Imaging Techniques	10	7.8%	10
Others	14	10.9%	14
Total	128	100%	128

Table 154: Number and Relative Proportion of Ovary detailed Microscopic Diagnosis

Ovary			
Detailed Method of Diagnosis	Female	%	Total
Histology of Metastasis	21	16.4%	21
Histology of Primary	83	64.8%	83
Others	19	14.8%	19
Specific Biochemical and/or immunological Tests	5	3.9%	5
Total	128	100%	128

Table 155: Number and Relative Proportion of Ovary cancer by histology

Ovary			
Morphology	Female	%	total
Adenocarcinoma	4	3.1%	4
Carcinoma	5	3.9%	5
Clear Cell Carcinoma	3	2.3%	3
Dysgerminoma	1	0.8%	1
Entometroid Carcinoma	4	3.1%	4
Granulosa Cell Tumor	1	0.8%	1
MusinousAdenoCarcinoma	4	3.1%	4
Neoplasam Malignant	45	35.2%	45
Neuroendocrine Carcinoma	1	0.8%	1
others	8	6.3%	8
Papillary AdenoCarcinoma	5	3.9%	5
Papillary Serous CystadennoCarcinoma	3	2.3%	3
Serous CystadenoCarcinoma	42	32.8%	42
Serous PaillaryCarcinoma	1	0.8%	1
Trancitional Cell Carcinoma	1	0.8%	1
Total	128	100%	128

Clinical Information

Table 156: Number and Relative Proportion of Ovary cancer by Broad Treatment Group

Ovary			
Method of diagnosis	Female	%	Total
Microscopic	104	81.3%	104
X-Ray/Imaging Techniques	10	7.8%	10
Others	14	10.9%	14
Total	128	100%	128

Table 157: Number and Relative Proportion of Ovary Cancer by Clinical Extent of Disease

Ovary			
Clinical Extent before Treatment	Female	%	Total
Direct Extension	13	10.2%	13
Direct Extension with Regional Nodes	6	4.7%	6
Distant Metastasis	45	35.2%	45
Localised	1	0.8%	1
Others (specify)	9	7.0%	9
Recurrent	9	7.0%	9
Too Advanced	9	7.0%	9
Treated Elsewhere	36	28.1%	36
Total	128	100%	128

Table 158: Number and Relative Proportion of Ovary cancer by Clinical Extent of Disease (Treatment only at RI, no treatment)

Ovary			
Clinical Extent of Disease	Female	%	Total
Localised	1	1.3	1
Regional	19	24.7	19
Distant	47	61	47
Others	10	13	10
Total	77	100	77

Table 159: Number and Proportion of Ovary cancers by type of treatment (Treatment Only at RI)

Ovary			
Clinical Extent of Disease	Female	%	Total
Surgery	4	9.8	4
C-Therapy	7	17.1	7
S+C	28	68	28
S+R+C	2	4.9	2
Total	41	100	41

Table 160: Number and Relative Proportion of Ovary cancer by any specific treatment (Treatment Only at RI)

Ovary			
Any specific Treatment	Female	%	Total
Any S	34	46.6	34
Any R	2	2.7	2
Any C	37	50.7	37
Total	73	100	73

Table 161: Number and Relative Proportion of Ovary Cancer by Treatment Status (Excluding the cancers previously treated)

Ovary			
Treatment Status	Female	%	Total
Received	41	53	41
Not Received	33	42.9	33
Incomplete	3	3.9	3
Total	77	100	77

Table 162: Number and Relative Proportion of Ovary Cancer intention to treat at MCC

Ovary			
Intention to treat	Female	%	Total
Curative / Radical	38	92.7%	38
Pallative	3	7.3%	3
Total	41	100%	41

Basic Demographic Parameters

Table 163: Number and Relative Proportion of Ovary cancer by marital Status

Ovary			
Marital Status	Female	%	Total
Divorced	1	0.8%	1
Married	88	68.8%	88
Unknown	7	5.5%	7
Unmarried	6	4.7%	6
Widowed	26	20.3%	26
Total	128	100%	128

Table 164: Number and Relative Proportion of Ovary cancer by Religion

Ovary			
Religion	Female	%	Total
Christian	11	8.6%	11
Hindu	78	60.9%	78
Muslim	39	30.5%	39
Total	128	100%	128

Table 165: Number and Relative Proportion of Ovary Cancer by Education

Ovary			
Education	Female	%	Total
Illiterate	7	5.5%	7
Literate	5	3.9%	5
Primary	25	19.5%	25
Secondary	15	11.7%	15
Middle	17	13.3%	17
College and above	6	4.7%	6
Others	1	0.8%	1
Unknown	52	40.6%	52
Total	128	100%	128

Table 166: Number and Relative Proportion of Ovary cancer by mother Tongue

Ovary			
Mother Tongue	Female	%	Total
Malayalam	124	96.9%	124
Hindi	1	0.8%	1
Kannada	2	1.6%	2
Unknown	1	0.8%	1
Total	128	100%	128

CHILDHOOD CANCERS

Table 167: Details of Childhood Cancers :Number (#) and Relative Proportion (%) of Broad Type of Cancers in Childhood (0-14 years)

Broad Type of Cancers in Childhood	Boys		Girls	
	#	%	#	%
LEUKAEMIAS	12	57.1	10	66.7
LYMPHOMAS & RETICULOENDOTHELIAL NEOP.	2	9.5	2	13.3
C.N.S & MISC. INTRACRANIAL &INTRASPINALNEOP.	2	9.5	1	6.7
SYMPATHETIC NERVOUS SYSTEM TUMOURS	1	4.8	-	-
RENAL TUMOURS	2	9.5	-	-
MALIGNANT BONE TUMOURS	2	9.5	1	6.7
SOFT-TISSUE(S-T) SARCOMAS(S)	-	-	1	6.7
ALL TYPES	21	100	15	100

Table 168: Number (#) and Relative Proportion (%) of Specific Type of Cancers in Childhood (0-14 years)

Specific Types of Cancers in Childhood	Boys		Girls	
	#	%	#	%
LEUKAEMIAS	12	57.1	10	66.7
LYMPHOID LEUKAEMIAS	8	38.1	9	60
ACUTE NON-LYMPHOCYTIC LEUKAEMIAS	2	9.5	1	6.7
Chronic Myeloid Leukaemias	1	4.8	-	-
UNSP. LEUKAEMIAS	1	4.8	-	-
LYMPHOMAS & RETICULOENDOTHELIAL NEOP.	2	9.5	2	13.3
Hodgkin"s Disease	1	4.8	1	6.7
NON-HODGKIN"S DISEASE	1	4.8	1	6.7
C.N.S & MISC. INTRACRANIAL & INTRASPINAL NEOP.	2	9.5	1	6.7
Primitive Neuroectodermal Tumours	1	4.8	-	-
UNSP. INTRACRANIAL AND INTRASPINAL NEOP.	1	4.8	1	6.7
SYMPATHETIC NERVOUS SYSTEM TUMOURS	1	4.8	-	-
NEUROBLASTOMA AND GANGLIONEUROBLASTOMA	1	4.8	-	-
RENAL TUMOURS	2	9.5	-	-
WILMS"STUMOUR, RHABDOID AND CLEAR CELL SARCOMA	2	9.5	-	-
MALIGNANT BONE TUMOURS	2	9.5	1	6.7
OSTEOSARCOMA	1	4.8	1	6.7
EWING"S SARCOMA	1	4.8	-	-
SOFT-TISSUE(S-T) SARCOMAS(S)	-	-	1	6.7
OTHER SPECIFIED SOFT TISSUE SARCOMA	-	-	1	6.7
ALL TYPES	21	100	15	100

MULTIPLE CANCERS

Table 169: Two Primary (Synchronous)

TWO PRIMARY (SYNCHRONOUS)												
Sl. No	Age of diagnosis	sex	Family History	Habits	Date of diagnosis	sequence	Primary site	Morphology	Date of Reg.	Date of last contact	Living / Expired	Treatment
1	49	F	No	Chronic	15/11/05	1	breast	IDC	15/5/15	1/6/2015	Unknown	No treatment
						2	breast	IDC				
2	50	M	Yes		19/10/15	1	Lung	SCC	19/10/15	28/3/16	Expired	Palliative
					28/01/16	2	Pancreas					
3	75	M	No	yes	9/9/2015	1	Lung	Unknown	15/09/15	9/11/2015	Expired	Palliative
					5/10/2015	2	Upper Alveolous	SCC-MD				
4	81	M	yes	yes	16/01/15	1	Prostate	Unknown	3/2/2015	9/2/2015	Unknown	Palliative
					30/01/15	2	Pancreas	Adeno Ca				
5	53	F	Yes	Chronic	21/2/15	1	Breast	IDC	23/2/15	26/4/16	Living	Radical
						2	breast	IDC				
6	80	M	No	Ex	7/3/2015	1	Caecum	Adeno Ca	7/3/2015	16/4/15	Unknown	Palliative
						2	Rectum	Adeno Ca				
7	51	F	Yes	Chronic	4/2/2015	1	breast	IDC	11/3/2015	15/7/15	Expired	Radical
						2	breast	IDC		19/7/15		
8	42	F	No	Chronic	21/1/15	1	breast	IDC	7/4/2015	1/8/2016	Living	Radical
						2	breast	IDC				
9	73	M	No	Chronic	1/4/2015	1	Bladder	Urothelial Ca	19/6/15	29/1/16	Unknown	Radical
					19/11/15	2	Prostate	Adeno Ca				

10	50		F		No	Chronic	23/4/15	1	Ovary	Neuro endocrine Ca	19/5/15	5/9/2016	Living	Palliative
								2	Ovary					
11	65		M	No	Yes		30/3/15	1	Oro-pharynx	SCC-WD 17/4/15	17/4/15	19/9/15	Expired	Radical
								2	Buccal Mucosa	SCC				
12	64		M	No			26/5/15	1	Stomach	Adeno Ca	8/6/2015	11/9/2015	Unknown	Palliative
							26/6/15	2	Lung	Adeno Ca				
13	63		M	No			29/04/15	1	Sigmoid colon	Adeno Ca	22/5/15	22/9/16	Living	Radical
							29/04/15	2	Anal Canal	Adeno Ca				
14	52		F	Yes	Chronic		21/4/15	1	Breast	IDC	13/5/15	13/8/16	Living	Radical
								2	Breast	IDC				
15	45		F	No	Chronic		23/6/15	1	Breast	IDC	8/7/2015	5/9/2016	Living	Radical
								2	Breast	IDC				
16	67		M	No	Yes		9/6/2015	1	Prostate	Adeno Ca	7/7/2015	6/4/2016	Unknown	Radical
							30/10/15	2	Oro-pharynx	SCC				
17	55		F	No	Chronic		16/9/15	1	Cervix	SCC	25/9/15	16/11/15	Unknown	Palliative
							16/10/15	2	Thyroid	Follicular Ca				
18	70		F	Yes	Chronic		4/9/2015	1	Breast	IDC	17/9/15	29/11/16	Living	Radical
							8/12/2015	2	Breast	IDC				
19	45		F	Yes	Chronic		14/11/15	1	Breast	IDC	16/11/15	27/1/17	Living	Radical
								2	Breast	IDC				

20	65	f	No	Chronic	17/11/15	1	Oro-pharynx	SCC-MD	18/11/15	10/2/2017	Living	Palliative
					27/11/15	2	Pancreas	Unknown				
21	39	F	No	Chronic	25/11/15	1	Breast	Mixed IDC	4/12/2015	10/1/2017	Living	Radical
						2	Thyroid	Papillary Ca				
22	51	M	Yes	Chronic	14/12/15	1	Oesophagus	SCC-MD	14/12/15	4/1/2016	Unknown	Palliative
					22/12/15	2	Vocal cord					
23	73	M	No	Yes	23/10/15	1	Buccal Mucosa	Ca-PD	26/10/15	12/11/2015	Unknown	Palliative
					6/11/2015	2	Lung	Unknown				

Table 170: Two Primary (Metachronous)

Two Primary (Metachronous)												
Sl. No	Age of diagnosis	sex	Family History	Habits	Date of diagnosis	sequence	Primary site	Morphology	Date of Reg.	Date of last contact	Living/Expired	Treatment
1	58	F	Yes	Chronic	12/6/2005	1	Tongue	Unknown	5/2/2016	13/3/15	Unknown	No treatment
	68				3/2/2015	2	Cervix	SCC				
2	54	M	Yes	Yes	5/6/2006	1	Pyriiform fossa	SCC-PD	5/2/2015	24/4/15	Unknown	No treatment
	60				15/12/2013	2		Ca-WD				
3	67	F	No	Chronic	15/06/04	1	Cervix	Unknown	5/2/2015	15/4/16	Living	Radical
	77				9/4/2015	2	Colon	Adeni ca-WD				
4	70	M	Yes	Yes	12/11/2013	1	Larynx	SCC-MD	23/02/15	5/1/2016	Unknown	No treatment
	72				16/2/15	2	Lung	SCC				
5	73	M	No	Yes	20/3/13	1	Prostate	Adeno Ca	20/02/15	20/02/15	Unknown	Unknown
	74				22/3/14	2	Tongue	SCC				
6	28	M	Yes	EX	13/02/15	1	Stomach	Adeno Ca	5/3/2015	11/3/2015	Unknown	Palliative
					13/02/15	2	Rectum	Adeno ca				
7	65	F	No	EX	9/2/2015	1	Buccal Muc-cosa	SCC	18/03/15	22/7/15	Unknown	Radical
					9/2/2015	2	Tongue	SCC				
8	49	F	Yes	Chronic	15/06/04	1	Breast	IDC	7/4/2015	6/9/2015	Unknown	Unknown
						2	Oesophagus	SCC				
9	79	M	No	Chronic	3/12/2010	1	Lower Lip	SCC	26/6/15	4/8/2016	Living	Radical
	83				26/6/15	2		SCC-WD				
10	51	F	Yes	Chronic	15/6/06	1	Breast	Unknown	21/4/15	9/9/2015	Unknown	Radical
					16/12/14	2	Oesophagus	SCC-MD				
11	33	M	No	Yes	1/5/2013	1	Hypopharynx	SCC-WD				
					29/10/14	2	Base of Tongue					

12	42	M	Yes	Chronic	17/6/15	1	Tongue	SCC-MD	17/8/15	17/8/15	Unknown	Unknown
13	66	F	Yes	Chronic	2/7/2015	2	Thyroid	Papillary Ca			Unknown	
	78				15/11/03	1	Cervix	SCC-WD	14/07/15	10/8/2015	Unknown	Unknown
14	29	F	No	Chronic	6/7/2015	2	Caecum	Unknown	6/5/2015	21/7/15	Unknown	Palliative
	61				15/6/12	1	Thyroid	SCC-LCNK				
15	38	F	No	Chronic	4/5/2015	2	Cervix	NHL	12/5/2015	19/7/16	Unknown	Radical
	39				6/5/2015	1	Bone Marrow	Adeno Ca				
16	53	M	No	Chronic	27/1/16	2	Rectum	NHL	14/05/15	20/5/15	Unknown	Unknown
	63				15/06/06	1	Lymphnode	SCC-PD				
17	55	M	No	Yes	23/04/15	2	Maxilla	SCC-WD	11/5/2015	1/10/2015	Living	Radical
	56				30/04/15	1	Lower Alveolous	SCC				
18	70	F	No	Yes	4/6/2016	2	Tonsil	Primary un-known	21/5/15	21/5/15	Unknown	Symptomatic
	74				5/9/2011	1	Tonsil	SCC				
19	56	M	No	Yes	18/3/15	2	Skin Toe	Adeno Ca	19/5/15	19/5/15	Unknown	Unknown
	61				9/9/2009	1	Stomach	Unknown				
20	56	M	No	Yes	11/8/2014	2	Colon	SCC-PD	10/6/2015	20/9/15	Living	Follow up
	67				15/6/04	1	Lung	Unknown				
21	34	F	No	Chronic	3/6/2015	2	Colon	SCC-PD	11/6/2015	11/6/2015	Unknown	Unknown
	65	M	No	Chronic	17/3/15	1	Endometrium	Adeno Ca				
22	75				2/6/2015	2	Stomach	Adeno Ca	25/5/15	1/8/2016	Living	Follow up
	63	M	No	Yes	15/12/05	1	Lymphnode	Follicular Lymph node				
23	64				6/5/2015	2	Tongue	SCC-WD	10/6/2015	26/9/16	Living	Radical
	67	F	No	Chronic	29/5/15	1	Lower lip	SCC-WD				
24	81				10/9/2016	2	G E Junction	Adeno Ca	7/6/2015	19/10/15	Unknown	Symptomatic
	43	F	No	Chronic	19/1/01	1	Breast	IDC	29/6/15	15/9/15	Unknown	Radical
25	47				18/06/15	2	Breast	IDC				

26	49				Chronic	25/8/14	1	Cervix	SCC		8/7/2015	8/3/2016	Unknown	Palliative
	51					23/1/16	2	Lung	SCC					
27	50	F	No	Chronic		18/6/98	1	Endometrium	Unknown		20/7/15	4/9/2015	Unknown	Symptomatic
						3/7/2015	2	Lung	Adeno Ca					
28	60	M	No	Yes		4/4/2008	1	Blood	Chronic Lymphoid Leukaemia		29/7/15	15/8/15	Unknown	Unknown
	67					18/7/15	2	Lung	SCC					
29	52	M	Yes	EX		24/07/01	1	Ascending colon	Adeno Ca		31/7/15	31/7/15	Unknown	Unknown
	62					15/9/11	2	Buccal Muc-cosa	SCC-WD					
30	50	F	No	Yes		15/6/95	1	Buccal Muc-cosa	scc		13/8/15	22/2/16	Unknown	Palliative
	70					8/8/2015	2	Hypopharynx	SCC-MD					
31	63	F	No	Chronic		3/8/2015	1	Lower Alvelous	SCC-MD		17/8/15	14/6/16	Living	Radical
	64					5/5/2016	2	Buccal Muc-cosa	SCC-WD					
32	61	F	No	Chronic		15/06/96	1	Breast	IDC		19/8/15	12/10/2015	Unknown	No treatment
	80					9/7/2015	2	Colon	Adeno Ca					
33	70	M	No	Chronic		15/06/12	1	Penis	Unknown		20/8/15	9/12/2016	Living	No treatment
	72					23/7/15	2	Urinary Bladder	Urothelial Ca					
34	65	M	No	EX		15/06/90	1	Bone Marrow	Multiple Myeloma		22/8/15	22/8/15	Unknown	No treatment
	85					7/08/2015	2	Urinary Bladder	SCC-MD					Symptomatic
35	46	M	No	EX		16/11/07	1	Oesophagus	Unknown		14/9/15	15/11/16	Living	No treatment
	54					14/09/15	2	Lung	Adeno Ca					
36	50	M	No	EX		28/08/07	1	Larynx	Unknown		12/10/2015	29/9/16	Unknown	No treatment
	58					30/9/15	2	Rectum	Adeno Ca					
37	55	F	No	Chronic		15/6/05	1	Breast	IDC		26/10/15	7/11/2016	Living	No treatment
						17/10/15	2	Lower Alvelous	SCC-MD				Living	Radical
38	36	M	No	Chronic		15/06/67	1	Base of Tongue	SCC-MD		27/10/15	2/12/2016	Living	No treatment
	84					27/10/15	2	Supraglottitis	SCC					Palliative

39	54		No	Occasional	29/10/15	1	Cervix	SCC-WD	24/05/06	5/12/2016	Living	No treatment
	63				4/11/2015	2	Vaginal	Adeno Ca				
40	60	M	No	Chronic	8/10/2007	1	Supraglottitis	Unknown	13/10/15	1/12/2016	Living	No treatment
	68				11/11/2015	2	Prostate	Adeno Ca				Palliative
41	59	M	No	EX	30/6/11	1	Hypopharynx	SCC-WD	7/12/2015	24/5/16	Unknown	No treatment
	63				30/11/15	2	Oesophagus	SCC-MD				
42	54	F	No	Chronic	16/12/15	1	Lower Alveolous	SCC-MD	22/12/15	6/12/2016	Living	Radical
	85				28/6/16	2	Tongue	SCC-MD				Palliative
43	30	M	No	Yes	15/6/85	1	Lower Alveolous	Unknown	30/12/15	31/5/16	Living	No treatment
	60				13/1/16	2	Tongue	SCC-MD				
44	63	M	No	EX	15/6/15	1	Rectum	Adeno Ca	31/7/15	29/3/17	Living	Radical
	64					2	Lung					
45	43	F	No	Chronic	15/06/07	1	Breast	IDC	30/03/15	28/3/17	Living	Palliative
	51				26/03/15	2	Breast	IDC				Palliative

Table 171: Three Primary Cases

SI No.	Age of diagnosis	sex	Family History	Habits	Date of diagnosis	sequence	Laterality	Primary site	Morphology	Date of Reg.	Date of last contact	Living/Expired	Treatment
1	44	F	2	2	5/9/1999	1	1	Breast	IDC	16/10/15	9/11/2015	Unknown	No treatment
	44				5/10/1999	2	2	Breast	Medullary Ca				No treatment
	60				12/10/2015	3	2	Breast	IDC				Radical - Not accepted
2	38	M	2	1	30/9/15	1	0	Pyloric Antrum	Adeno Ca	21/10/15	4/7/2016	Unknown	Palliative
	38				30/9/15	2	0	G E Junction	SCC-WD				
	38				30/9/15	3	0	Hypopharynx	SCC-MD				
3	65	F	2	2	2/5/2015	1	1	Breast	IDC	6/5/2015	1/11/2016		Radical
	65				13/5/15	2	2	Breast	IDC				Radical
	65				7/10/2015	3	0	Uterus	Carcino Sarcoma				Palliative

ABBREVIATION

C	Chemotherapy
ICD	International Classification of Disease
HBCR	Hospital Based Cancer Registry
ICMR	Indian Council of Medical Research
MCC	Malabar Cancer Centre
NCRP	National Cancer Registry Programme
NCCP	National Cancer Control Programme
NHL	Non-Hodgkin's Lymphoma
R	Radiation
RI	Reporting Institution
S	Surgery
TRC	Tobacco Related Cancers
#	Number
CNS	Central Nervous System
WD	Well Differentiated
U/UK	Unknown
SCC	Squamous Cell Carcinoma
IDC	Infiltrating Duct Carcinoma
CA	Carcinoma
R	Radical
P	Palliative

REFERENCES

1. Isabel dos Santos Silva (1999), Cancer Epidemiology, Principles and Methods IARC Publications, France.
2. Maclennan et al (1978) Cancer Registration and its Techniques IARC Scientific Publications No.21 France.
3. Young J.L (1991) Hospital Based Cancer Registry in Cancer Registration Principles and Methods IARC Publications France.
4. April Fritz, Constance Percy et al. International Classification of Disease for Oncology Third Edition, World Health Organization Geneva 2000.
5. John L. Young, Steven D. Roffers et al, seer summary staging manual 2000 codes and coding instruction.



Published by
Malabar Cancer Centre
(An autonomous centre under Government of Kerala)
Thalassery-670 103, Phone : (+91) 0490 2355881, Fax: 0490 2355880
E-mail: www.mcc.kerala.gov.in Website: www.mcc.kerala.gov.in